thalidomide has been researched along with bortezomib in 945 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 204 (21.59) | 29.6817 |
| 2010's | 649 (68.68) | 24.3611 |
| 2020's | 92 (9.74) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, W; Li, J; Liu, X; Shi, J; Zhang, Z; Zhao, L; Zhou, Y | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Hussein, MA | 1 |
| Anderson, KC | 6 |
| Barlogie, B; Shaughnessy, J; Tricot, G; Zangari, M | 1 |
| Anderson, KC; Mitsiades, CS; Mitsiades, N; Richardson, PG; Treon, SP | 1 |
| Mehta, J; Singhal, S | 1 |
| Hattori, Y | 1 |
| Gisslinger, H; Kees, M | 1 |
| Jäger, U | 1 |
| Barlogie, B | 1 |
| Kikuchi, S; Komatsu, N; Mori, M; Muroi, K; Noborio-Hatano, K; Ozawa, K; Takahashi, S; Takatoku, M | 1 |
| Chen, SL | 1 |
| Kaufman, J; Lonial, S | 1 |
| Kyle, RA; Rajkumar, SV | 1 |
| Duff, SB; Gupta, S; Mehta, J | 1 |
| Cardinale, G; Gervasi, F; Pagnucco, G | 1 |
| Davies, FE; Morgan, GJ | 1 |
| Jung, W; Schroers, R; Zettl, F | 1 |
| Crawford, CL | 1 |
| Carbonell, AL; del Giglio, A; Manhani, AR; Mitteldorf, CA; Weinschenker, P | 1 |
| Chou, T | 1 |
| Ahsan, MH; Purchio, AF; Sambucetti, LC; West, DB; Zhang, N; Zhu, L | 1 |
| Chng, WJ; Lau, LG; Mow, BM; Yusof, N | 1 |
| Jagannath, S | 1 |
| Nelson, JB; Smith, MR | 1 |
| Rajkumar, SV | 5 |
| Bruno, B; Gallamini, A; Mattei, D; Mordini, N; Rapezzi, D; Vigna Taglianti, R | 1 |
| Dimopoulos, MA; Rahemtulla, A; Terpos, E | 1 |
| Heinrich, B | 1 |
| Drach, J; Kaufmann, H; Seidl, S | 1 |
| Graeven, U; König, M; Schmiegel, W; Schmielau, J; Teschendorf, C | 1 |
| Chanan-Khan, A; Miller, KC | 1 |
| Balleari, E; Boccadoro, M; Bodenizza, C; Carella, AM; Cascavilla, N; Catalano, L; Cavallo, F; Dell'Olio, M; Falcone, A; Greco, MM; Guglielmelli, T; La Sala, A; Mantuano, S; Melillo, L; Merla, E; Musto, P; Nobile, M; Palumbo, A; Sanpaolo, G; Scalzulli, PR; Spriano, M; Zambello, R | 1 |
| Chaudhry, V; Umapathi, T | 1 |
| Glasmacher, A; von Lilienfeld-Toal, M | 1 |
| Richardson, P | 1 |
| Barlogie, B; Burns, MJ; Elice, F; Esseltine, D; Kang, SH; Lee, CK; Najarian, K; Richardson, P; Sonneveld, P; Tricot, G; Yaccoby, S; Zangari, M | 1 |
| Joshua, DE | 1 |
| Harousseau, JL; Moreau, P | 1 |
| Sonneveld, P; Wu, KL | 1 |
| Bosi, A; Ciolli, S; Gigli, F; Leoni, F; Rigacci, L | 1 |
| Greipp, P | 1 |
| Berrebi, A | 1 |
| Saunders, G | 1 |
| Murakami, H | 1 |
| Anderson, KC; Hideshima, T; Richardson, PG; Schlossman, R | 1 |
| Kaufman, JL; Lonial, S; Sinha, R | 1 |
| Coiteux, V; Facon, T; Leleu, X | 1 |
| Badros, A; Gahres, N | 1 |
| Kyle, RA; Vincent Rajkumar, S | 1 |
| Ferreri, AJ | 1 |
| Ayuk, FA; Corradini, P; Goldschmidt, H; Hegenbart, U; Kröger, N; Lokhorst, HM; Montefusco, V; Nagler, A; Perez-Simon, JA; Raymakers, RA; San Miguel, JF; van de Donk, NW; van Oers, MH; Verdonck, LF; Zijlmans, M | 1 |
| Handa, H; Murakami, H | 1 |
| Hess, U | 1 |
| Awada, A; de Castro, G | 1 |
| Bang, SM; Cho, KS; Jo, DY; Kim, CC; Kim, CS; Kim, K; Lee, JH; Lee, JJ; Lee, KH; Lee, NR; Min, CK; Min, YH; Park, S; Seong, CM; Sohn, SK; Suh, C; Yoon, HJ; Yoon, SS | 1 |
| Swieboda-Sadlej, A | 1 |
| Ambrosini, MT; Avonto, I; Boccadoro, M; Bringhen, S; Bruno, B; Cavallo, F; Falco, P; Falcone, A; Gay, F; Massaia, M; Musto, P; Palumbo, A; Rus, C; Scalzulli, PR | 1 |
| Hussein, MA; Kalmadi, SR | 1 |
| Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, A; Takayama, H | 2 |
| Orlowski, RZ; Voorhees, PM | 1 |
| Davies, MJ | 2 |
| Barrick, M | 1 |
| Harousseau, JL | 8 |
| Moreau, P | 1 |
| Bladé, J; Cibeira, MT; Esteve, J; Ramiro, L; Rosiñol, L; Torrebadell, M | 1 |
| Okamoto, S | 1 |
| McKenna, KE; Morris, TC; Ramadan, KM | 1 |
| Kenealy, M; Prince, HM | 1 |
| Avonto, I; Boccadoro, M; Bringhen, S; Magarotto, V; Palumbo, A | 1 |
| Ambrosini, MT; Avonto, I; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Caravita, T; Cavallo, F; Falco, P; Morabito, F; Musto, P; Palumbo, A; Pescosta, N; Pregno, P | 1 |
| Aggarwal, BB; Bhardwaj, A; Bueso-Ramos, C; Gaur, U; Nair, AS; Sethi, G; Shishodia, S; Takada, Y; Vadhan-Raj, S | 1 |
| Ribatti, D; Vacca, A | 1 |
| Akpek, G; Badros, A; Fenton, R; Goloubeva, O; Harris, C; Meisenberg, B; Rapoport, AP; Ruehle, K; Westphal, S | 1 |
| Boccadoro, M; Cavenagh, J; Dicato, M; Harousseau, JL; Ludwig, H; San Miguel, J; Sonneveld, P | 1 |
| Stadtmauer, EA; Stoopler, ET; Vogl, DT | 1 |
| Mileshkin, L; Prince, HM; Schenkel, B | 1 |
| Anderson, KC; Hideshima, T; Mitsiades, C; Richardson, PG | 1 |
| Anderson, KC; Ghobrial, IM; Hatjiharissi, E; Hideshima, T; Leleu, X; Mitsiades, C; Richardson, P; Schlossman, R | 1 |
| Iida, S | 4 |
| Strobeck, M | 1 |
| Alsayed, Y; Anaissie, E; Barlogie, B; Bolejack, V; Crowley, J; Epstein, J; Hollmig, K; Mohiuddin, A; Pineda-Roman, M; Shaughnessy, JD; Tricot, G; van Rhee, F; Woods, G; Zangari, M | 1 |
| Anagnostopoulos, A; Bamias, A; Barmparousi, D; Dimopoulos, MA; Gika, D; Grapsa, I; Kastritis, E; Matsouka, C; Psimenou, E; Roussou, M | 1 |
| Aggarwal, BB; Bhutani, M; Guha, S; Kunnumakkara, AB; Nair, AS; Pathak, AK; Sethi, G | 1 |
| Anderson, KC; Burger, P; Chauhan, D; Fulciniti, M; Ghobrial, IM; Hideshima, T; Leiba, M; Li, XF; Morrison, A; Munshi, NC; Podar, K; Richardson, P; Rumizen, M; Song, W; Tai, YT; Tassone, P | 1 |
| Alexanian, R; Delasalle, K; Giralt, S; Handy, B; Wang, M | 1 |
| Hulin, C | 1 |
| Alsayed, Y; Anaissie, E; Barlogie, B; Bolejack, V; Cottler-Fox, M; Crowley, J; Epstein, J; Gurley, J; Haessler, J; Hollmig, K; Jenkins, B; Mohiuddin, A; Petty, N; Pineda-Roman, M; Shaughnessy, JD; Steward, D; Sullivan, E; Tricot, G; van Rhee, F; Zangari, M | 1 |
| Anderson, K; Mitsiades, C; Munshi, N; Richardson, PG; Schlossman, R | 1 |
| Adena, M; Hertel, J; Prince, HM; Smith, DK | 1 |
| Akpek, G; Badros, A; Can, I; Dalal, JS; Fenton, RG; Goloubeva, O; Heyman, M; Rapoport, AP; Thompson, J | 1 |
| Fassas, AB; Tricot, G | 1 |
| Bensinger, W | 1 |
| Anderson, KC; Ghobrial, IM; Ghobrial, J; Hatjiharissi, E; Hideshima, T; Leleu, X; Mitsiades, C; Moreau, AS; Richardson, P; Roccaro, A; Schlossman, R | 1 |
| Anderson, KC; Breitkreutz, I; Raab, MS | 1 |
| Snively, A | 1 |
| Amen, K | 1 |
| McGee, L | 1 |
| Chim, CS | 2 |
| Anderson, KC; Hayden, PJ; Mitsiades, CS; Richardson, PG | 1 |
| Dytfeld, D; Komarnicki, M; Lewandowski, K; Matuszak, M | 1 |
| Ganser, A; Peest, D | 1 |
| Dammacco, F; Merchionne, F; Perosa, F | 1 |
| Dimopoulos, MA; Kastritis, E; Mitsiades, CS; Richardson, PG | 1 |
| Anderson, K; Chauhan, D; Ghobrial, I; Hideshima, T; Mitsiades, C; Munshi, N; Richardson, P; Schlossman, R | 1 |
| Faiman, B | 1 |
| Handa, H; Murakami, H; Saitoh, T | 1 |
| Ishida, T | 3 |
| Gotoh, A; Ohyashiki, K | 1 |
| Shimazaki, C | 1 |
| Takatoku, M | 1 |
| Miwa, A | 2 |
| Davies, FE; Morgan, GJ; Srikanth, M | 1 |
| Ambinder, RF; Barber, JP; Borrello, I; Brennan, S; Huff, CA; Jones, RJ; Lin, L; Matsui, W; McNiece, I; Peacock, C; Smith, BD; Wang, Q; Watkins, DN | 1 |
| Bladé, J; Cibeira, MT; Cid, MC; Filella, X; Lozano, E; Rosiñol, L; Rozman, M; Segarra, M | 1 |
| Gillmore, JD; Hawkins, PN; Lachmann, HJ; Offer, M; Wechalekar, AD | 1 |
| Lonial, S | 3 |
| Bladé, J; Hajek, R; Harousseau, JL; Nagler, A; Orlowski, RZ; Robak, T; Sonneveld, P; Spencer, A; Zhuang, SH | 1 |
| Kami, M; Tsubokura, M | 1 |
| Bosi, A; Breschi, C; Casini, C; Ciolli, S; Leoni, F; Santini, V | 1 |
| Anaissie, E; Barlogie, B; Crowley, J; Epstein, J; Hoering, A; Petty, N; Pineda-Roman, M; Shaughnessy, J; Szymonifka, J; van Rhee, F; Zangari, M | 1 |
| Gertz, MA | 2 |
| Gladney, SP; Kaufman, JL; Lonial, S | 1 |
| Dimopoulos, MA; Kastritis, E; Rajkumar, SV | 1 |
| Garderet, L; Gorin, NC; Isnard, F | 1 |
| Bladé, J; Dimopoulos, MA; Kastritis, E; Ludwig, H; Rosinol, L | 1 |
| Facon, T; Hulin, C; Moreau, P | 2 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Arpaci, F; Ataergin, S; Demiriz, M; Ozet, A | 1 |
| Asaoku, H; Katayama, Y; Kimura, A; Kubo, T; Kuroda, Y; Munemasa, S; Okikawa, Y; Sakai, A; Shimose, S | 1 |
| Anderson, KC; Breitkreutz, I; Chauhan, D; Hideshima, T; Mitsiades, C; Munshi, NC; Okawa, Y; Raab, MS; Raje, N; Richardson, PG; Vallet, S | 1 |
| Atkins, H; Belch, AR; Canning, LA; Kovacs, MJ; LeBlanc, R; Leitch, HA; Reece, DE; Voralia, M; White, D | 1 |
| Auran-Schleinitz, T; Blaise, D; Bouabdallah, R; Coso, D; de Collela, JM; de Lavallade, H; El-Cheikh, J; Gastaut, JA; Mohty, M; Stoppa, AM | 1 |
| Chen, YB; Fu, WJ; Hou, J; Wang, DX; Xi, H; Yuan, ZG | 1 |
| Berenson, JR; Yellin, O | 1 |
| Bamia, C; Bamias, A; Christoulas, D; Dimopoulos, MA; Eleftherakis-Papaiakovou, E; Gika, D; Kastritis, E; Melakopoulos, I; Migkou, M; Roussou, M; Terpos, E | 1 |
| Anagnostopoulos, N; Christoulas, D; Croucher, P; Dimopoulos, MA; Eleftherakis-Papaiakovou, E; Heath, D; Kastritis, E; Roussou, M; Terpos, E; Tsionos, K | 1 |
| Dimopoulos, MA; Kastritis, E | 1 |
| Czuczman, MS; O'Connor, OA | 1 |
| Boccadoro, M; Bringhen, S; Falco, P; Gay, F; Magarotto, V; Palumbo, A | 1 |
| Bladé, J; Rosiñol, L | 1 |
| Fonseca, R; Rajkumar, SV | 1 |
| Dahdaleh, FS; Musallam, KM; Shamseddine, AI; Taher, AT | 1 |
| Palumbo, A; Rajkumar, SV | 1 |
| Asaoku, H; Katayama, Y; Kimura, A; Kuroda, Y; Matsui, H; Mizuno, M; Munemasa, S; Nakaju, N; Nishisaka, T; Ogawa, K; Okikawa, Y; Sakai, A; Tanaka, H; Tsuyama, N | 1 |
| Coleman, M; Mark, T; Niesvizky, R | 1 |
| Deng, SH; Qiu, LG; Wang, Y; Wang, YF; Wu, T; Xu, Y; Zhao, YZ; Zou, DH | 1 |
| Dimopoulos, MA; Fermand, JP; Garcia-Sanz, R; Gertz, MA; Ghobrial, IM; Kastritis, E; Kimby, EK; Kyle, RA; Leblond, V; Merlini, G; Morel, P; Morra, E; Ocio, EM; Owen, R; Seymour, J; Treon, SP | 1 |
| Ambrus, JL; Islam, A | 1 |
| Hu, X; Huang, C; Lü, S; Ni, X; Qiu, H; Wang, J; Xu, X; Yang, J | 1 |
| Avvisati, G | 1 |
| Dmoszyńska, A | 1 |
| Borrello, I; Chaudhry, V; Cornblath, DR; Ferguson, A; Polydefkis, M | 1 |
| Higa, GM; Saad, AA; Sharma, M | 1 |
| Eby, C | 1 |
| Anagnostopoulos, N; Christoulas, D; Delimbassi, S; Dimopoulos, MA; Economopoulos, T; Gika, D; Kartasis, Z; Kastritis, E; Katodritou, E; Michali, E; Pouli, A; Roussou, M; Symeonidis, A; Terpos, E; Zervas, K; Zomas, A | 1 |
| Chen, SL; Hu, Y; Li, X; Zhang, JJ; Zhong, YP | 1 |
| Caravita, T; de Fabritiis, P; Del Poeta, G; Fratoni, S; Santeusanio, G; Siniscalchi, A | 1 |
| Baker, RD; Finkbiner, KL; Henry, DW; Kettle, JK; Klenke, SE; Williams, CB | 1 |
| Cavenagh, J; Lonial, S | 1 |
| Geffray, L | 1 |
| Aggarwal, BB; Anand, P; Guha, S; Kunnumakkara, AB; Sethi, G; Sung, B | 1 |
| Ailawadhi, S; Barcos, M; Bernstein, ZP; Chanan-Khan, A; Czuczman, MS; Iancu, D; Lee, K; Miller, KC; Mohr, A; Musial, L; Padmanabhan, S; Patel, M; Sher, T; Yu, J | 1 |
| Giralt, S; Krishnan, A; Mccarthy, P; Pasquini, MC; Somlo, G; Stadtmauer, E; Vesole, DH | 1 |
| Anderson, KC; Breitkreutz, I; Podar, K; Raab, MS; Richardson, PG | 1 |
| Anderson, KC; Bensinger, W; Bergsagel, L; Blade, J; Cavo, M; Comenzo, RL; Durie, BG; Einsele, H; Giralt, S; Harousseau, JL; Kumar, S; Lentzsch, S; Lonial, S; Ludwig, H; Munshi, N; Niesvizky, R; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Sonneveld, P; Stadtmauer, EA; Tosi, P; Vesole, D | 1 |
| Chen, SL; Zhong, YP | 1 |
| Bacovsky, J; Langova, K; Minarik, J; Ordeltova, M; Pika, T; Scudla, V | 1 |
| Brunetti, AE; Cafforio, P; Dammacco, F; De Matteo, M; Maiorano, E; Silvestris, F | 1 |
| Barbarousi, D; Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Grapsa, I; Kastritis, E; Matsouka, C; Migkou, M; Primenou, E; Roussou, M; Terpos, E; Zagouri, F | 1 |
| Anderson, KC; Boral, A; Facon, T; Harousseau, JL; Irwin, D; Neuwirth, R; Richardson, PG; Schuster, MW; Sonneveld, P; Stadtmauer, EA; Vogl, DT | 1 |
| Anderson, KC; Carreau, N; Ghobrial, IM; Hideshima, T; Laubach, JP; Mahindra, A; Mitsiades, CS; Munshi, NC; Richardson, PG; Schlossman, RL | 1 |
| Cai, Z; He, J; Huang, H; Huang, W; Li, L; Lin, M; Luo, Y; Shi, J; Wei, G; Wu, W; Xie, W; Xue, X; Ye, X; Zhang, J; Zheng, W | 1 |
| San Miguel, JF | 1 |
| Alsina, M; Anderson, KC; Avigan, DE; Dalton, W; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Knight, R; Lunde, LE; Mazumder, A; McKenney, M; Mitsiades, CS; Munshi, NC; Richardson, PG; Schlossman, RL; Warren, DL; Weller, E | 1 |
| Anderson, KC; Carreau, NA; Chauhan, D; Ghobrial, IM; Hideshima, T; Laubach, JP; Mahindra, A; Mitsiades, CS; Munshi, NC; Raje, N; Richardson, PG; Schlossman, RL | 1 |
| Chang, DZ; Chiang, J; Delasalle, K; Fang, W; Forman, A; Garcia, MK; Guo, Y; Lu, J; Romaguera, J; Wang, M; Yi, Q; Zhou, Y | 1 |
| Attal, M; Bourin, P; Laroche, M; Lemaire, O | 1 |
| Bacovsky, J; Langova, K; Minarik, J; Ordeltova, M; Pika, T; Scudla, V; Zemanova, M | 1 |
| Dereure, O; Guillot, B; Michot, C | 1 |
| Kanda, Y | 1 |
| Ozaki, S | 1 |
| Becker, P; Bensinger, WI; Camacho, E; Capo, G; Crowley, J; Durie, BG; Hilger, J; Irwin, D; Jagannath, S; Mazumder, A; McKinley, M; Potts, P; Vescio, R; Vesole, DH; Wolf, J | 1 |
| Ahn, JS; Kim, HJ; Kim, YK; Lee, JH; Lee, JJ; Moon, JH; Sohn, SK; Yang, DH | 1 |
| Baldini, L; Boccadoro, M; Bringhen, S; Callea, V; Casulli, AF; Catalano, L; Cavo, M; Ciolli, S; Di Raimondo, F; Galimberti, S; Gentile, M; Mannina, D; Mele, G; Morabito, F; Musto, P; Offidani, M; Palmieri, S; Palumbo, A; Petrucci, MT; Pinotti, G; Piro, E; Tosi, P | 1 |
| Aggarwal, BB; Pandey, MK; Sung, B | 1 |
| Adam, Z; Buchler, T; Hajek, R; Koza, V; Kralova, D; Krejci, M; Krivanova, A; Mayer, J; Pour, L; Sandecka, V; Schutzova, M; Scudla, V; Tothova, E; Vorlicek, J; Zahradova, L | 1 |
| Atadja, P; Crusoe, E; de Alava, E; Fernández-Lázaro, D; Garayoa, M; Hernández-Iglesias, T; Maiso, P; Ocio, EM; Pandiella, A; San-Miguel, JF; San-Segundo, L; Shao, W; Vilanova, D; Yao, YM | 1 |
| Mateos, MV; San-Miguel, JF | 1 |
| Gay, F; Palumbo, A | 2 |
| Stewart, AK | 1 |
| Ghobrial, IM; Stewart, AK | 1 |
| Chung, JS; Do, YR; Eom, HS; Jin, JY; Kim, CS; Kim, HJ; Kim, HY; Kim, K; Kim, YK; Lee, DS; Lee, JH; Oh, SJ; Seong, CM; Suh, C | 1 |
| Azaïs, I; Brault, R; Debiais, F | 1 |
| Bakan, CE; Benson, DM; Devine, SM; Elder, P; Hamadani, M; Hofmeister, CC; Krugh, D; O'Donnell, L; Panzner, K; Smith, MK | 1 |
| Kumiega, B; Skotnicki, AB; Wolska-Smoleń, T | 1 |
| Benevolo, G; Boccadoro, M; Bringhen, S; Caltagirone, S; Corradini, P; Crippa, C; Falco, P; Gay, F; Giuliani, N; Guglielmelli, T; Liberati, AM; Montefusco, V; Musto, P; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Petrucci, MT; Rossi, G; Rossini, F | 1 |
| Attal, M; Avet-Loiseau, H; Belhadj, K; Dorvaux, V; Fermand, JP; Garderet, L; Hulin, C; Minvielle, S; Moreau, P; Soulier, J; Yakoub-Agha, I | 1 |
| Bauer, F; Dasanu, CA; Reale, MA | 1 |
| Beksac, M; Bladé, J; Boccadoro, M; Cavenagh, J; Cavo, M; Dimopoulos, M; Drach, J; Einsele, H; Facon, T; Goldschmidt, H; Harousseau, JL; Hess, U; Ketterer, N; Kropff, M; Ludwig, H; Mendeleeva, L; Morgan, G; Palumbo, A; Plesner, T; San Miguel, J; Shpilberg, O; Sondergeld, P; Sonneveld, P; Zweegman, S | 1 |
| Lokhorst, HM; Minnema, MC; van de Donk, NW; van der Spek, E | 1 |
| Alsayed, Y; Anaissie, E; Barlogie, B; Crowley, J; Hoering, A; Nair, B; Shaughnessy, JD; Szymonifka, J; van Rhee, F; Waheed, S | 1 |
| Kulharya, A; Shah, R; Ustun, C; Yuan, J | 1 |
| El-Cheikh, J; Harousseau, JL; Mohty, B; Mohty, M; Moreau, P; Yakoub-Agha, I | 1 |
| Anderson, K; Laubach, JP; Mitsiades, C; Richardson, PG; Schlossman, RL | 1 |
| Richards, T; Weber, D | 1 |
| Boccadoro, M; Callea, V; Cangialosi, C; Caravita, T; Cavallo, F; Crippa, C; De Rosa, L; Drandi, D; Ferrero, S; Grasso, M; Guglielmelli, T; Ladetto, M; Liberati, AM; Musto, P; Pagliano, G; Palumbo, A; Passera, R; Pisani, F; Pregno, P; Santo, L | 1 |
| de Maat, MP; Leebeek, FW; Libourel, EJ; Sonneveld, P; van der Holt, B | 1 |
| Bang, SM; Chung, J; Do, YR; Jin, JY; Joo, YD; Kang, HJ; Kim, BS; Kim, HY; Kim, K; Lee, DS; Lee, GW; Lee, JH; Lee, JJ; Lee, MH; Lee, SS; Park, J; Ryoo, HM; Shim, H; Suh, C; Yoon, SS | 1 |
| Ludwig, H; Zojer, N | 2 |
| O'Connor, OA | 1 |
| Eeltink, CM; Huls, G; Kersten, MJ; Kneppers, E; Koedam, J; Lokhorst, HM; Minnema, MC; Raymakers, RA; Schaafsma, MR; Sonneveld, P; van Oers, MH; Vellenga, E; Wijermans, PW; Wittebol, S; Zweegman, S | 1 |
| Chang, J; Cho, SH; Kang, W; Kim, JS; Kim, SK; Park, MS | 1 |
| Adachi, T; Hayakawa, F; Iwasaki, T; Kurahashi, S; Narimatsu, H; Sawamoto, A; Sugimoto, T; Sugiura, I; Suzuki, H; Suzuki, K | 1 |
| Anderson, KC; Avigan, DE; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Jakubowiak, AJ; Joyce, R; Kaster, S; Kaufman, JL; Knight, R; Lonial, S; Lunde, LE; Mazumder, A; Mitsiades, CS; Munshi, NC; Raje, NS; Richardson, PG; Schlossman, RL; Vesole, DH; Warren, DL; Weller, E; Xie, W | 1 |
| Goldschmidt, H; Ho, AD; Schmitt, S | 1 |
| Adam, Z; Germáková, Z; Hájek, R; Kovárová, L; Krejcí, M; Kren, L; Krivanová, A; Mardová, J; Mayer, J; Moulis, M; Nedbálková, M; Pour, L; Stepánková, S; Svobodová, I; Veselý, K; Zahradová, L | 1 |
| Alexanian, R; Delasalle, K; Giralt, S; Wang, M | 1 |
| Kumar, S | 3 |
| Gleason, C; Kaufman, J; Lonial, S | 1 |
| Baldini, L; Boccadoro, M; Bringhen, S; Di Raimondo, F; Falco, P; Larocca, A; Magarotto, V; Palumbo, A | 1 |
| Chan, EY; Chan, SY; Cheung, SC; Chim, CS; Kwong, YL; Leung, YY; Liang, R; Lie, AK | 1 |
| Bargetzi, M; Betticher, D; Gmür, J; Gregor, M; Heim, D; Hess, U; Ketterer, N; Lerch, E; Matthes, T; Mey, U; Pabst, T; Renner, C; Taverna, C | 1 |
| Mateos, MV | 2 |
| Dimopoulos, MA; Jagannath, S; Lonial, S | 1 |
| Alsayed, Y; Anaissie, E; Barlogie, B; Crowley, J; Hoering, A; Nair, B; Petty, N; Shaughnessy, JD; Szymonifka, J; van Rhee, F; Waheed, S | 1 |
| Bhandari, M; Callander, N; Flinn, I; Gasparetto, C; Glass, J; Grosman, D; Hari, P; Krishnan, A; Kumar, SK; Noga, SJ; Rajkumar, SV; Richardson, PG; Rifkin, R; Sahovic, EA; Shi, H; Webb, IJ; Wolf, JL | 1 |
| Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Gika, D; Grapsa, I; Kastritis, E; Migkou, M; Psimenou, E; Roussou, M; Terpos, E | 1 |
| Destian, S; Hwang, BJ; Jagannath, S; Mazumder, A; Méndez, CE; Vesole, DH | 1 |
| Bergsagel, PL; Buadi, F; Dingli, DD; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Kapoor, P; Ketterling, RP; Kumar, S; Kyle, RA; Lacy, MQ; Rajkumar, SV; Sinha, S; Stewart, AK; Witzig, TE | 1 |
| Gleason, C; Heffner, LT; Kaufman, JL; Lonial, S; Nooka, A; Vrana, M | 1 |
| Chen, F; Chen, H; Guo, H; Jiang, Y; Lu, M; Mao, J; Qian, X; Shen, Y; Sun, C; Sun, H; Xia, J; Yang, G; Zhou, X; Zhuang, Y | 1 |
| Brodoefel, H; Claussen, CD; Fenchel, M; Horger, M; Konaktchieva, M; Kraus, S; Weisel, K | 1 |
| Fielding, K; Neeson, P; Quach, H; Ritchie, DS | 1 |
| Abildgaard, N; Andersen, NF; Gimsing, P; Gregersen, H; Klausen, TW; Rasmussen, HB; Søeby, K; Vangsted, AJ; Vogel, U; Werge, T | 1 |
| Chanan-Khan, A; Deeb, G; Lee, K; Miller, KC; Sher, T | 1 |
| Aggarwal, BB; Kannappan, R; Yadav, VR | 1 |
| Chen, SL; Gao, W; Jiang, B; Qiu, LG; Yu, L; Zhong, YP | 2 |
| Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; Cibeira, MT; de Arriba, F; de Paz, R; García-Laraña, J; García-Sanz, R; González, Y; Gutiérrez, N; Hernández, JM; Lahuerta, JJ; Martín, A; Martín-Mateos, ML; Martínez-López, J; Mateos, MV; Mediavilla, JD; Miguel, JF; Montalbán, MA; Oriol, A; Paiva, B; Palomera, L; Peñalver, FJ; Ramos, ML; Ribera, JM; Sureda, A; Teruel, AI; Vidriales, MB | 1 |
| Christoulas, D; Dimopoulos, MA; Efstathiou, E; Gavriatopoulou, M; Gkotzamanidou, M; Iakovaki, M; Kastritis, E; Matsouka, C; Migkou, M; Mparmparoussi, D; Roussou, M; Terpos, E | 1 |
| Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Cavalli, M; Cavo, M; De Rosa, L; Evangelista, A; Falcone, AP; Gaidano, G; Gentili, S; Genuardi, M; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Liberati, AM; Musto, P; Nozzoli, C; Palumbo, A; Patriarca, F; Ria, R; Rizzo, V; Rossi, D | 1 |
| Alba, L; Antinori, A; Bibas, M; Del Nonno, F; Grisetti, S; Picchi, G | 1 |
| Berno, T; Briani, C; Campagnolo, M; Zambello, R | 1 |
| Bocchia, M; Crupi, R; Defina, M; Gozzetti, A | 1 |
| Guo, H; Jiang, Y; Shen, Y; Sun, C; Tong, Y; Wang, J; Wang, Z; Yang, G; Zhou, X | 1 |
| Aschan, J; Dhawan, R; Hornberger, J; Liwing, J; Löthgren, M; Rickert, J | 1 |
| Rummel, M | 1 |
| Li, F; Rajendran, P; Sethi, G | 1 |
| Mey, UJ | 1 |
| Bladé, J; Delforge, M; Dimopoulos, MA; Facon, T; Kropff, M; Ludwig, H; Palumbo, A; San-Miguel, JF; Sonneveld, P; Van Damme, P | 1 |
| Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cavalli, M; Ciccone, G; Falcone, AP; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Leonardi, G; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rizzo, M; Rossi, D | 1 |
| Anderson, KC; Barlogie, B; Bladé, J; Cavo, M; Chanan-Khan, A; Comenzo, RL; Dimopoulos, MA; Durie, BG; Fermand, JP; Giralt, S; Harousseau, JL; Jagannath, S; Leung, N; Ludwig, H; Niesvizky, R; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Sonneveld, P; Terpos, E; Tosi, P | 1 |
| Palumbo, A | 1 |
| Ballanti, S; Corvatta, L; Gentili, S; Gozzetti, A; Leoni, P; Liberati, AM; Nozzoli, C; Offidani, M; Palumbo, A; Polloni, C; Pulini, S | 1 |
| Auwerda, JJ; Bertina, RM; de Maat, MP; Leebeek, FW; Osanto, S; Sonneveld, P; Yuana, Y | 1 |
| Aicher, B; Blau, IW; Busse, A; Dabrowski, R; Lohneis, P; Schmidt-Hieber, M; Thiel, E; Weimann, A | 1 |
| Liedtke, M; Medeiros, BC | 1 |
| Anderson, K; Laubach, J; Richardson, P | 1 |
| Djulbegovic, B; Hozo, I; Kumar, A; Wheatley, K | 1 |
| Morgan, G | 1 |
| Barnett, MJ; Broady, R; Connors, JM; Forrest, DL; Hamata, L; Hogge, DE; Mourad, YA; Nantel, SH; Narayanan, S; Nevill, TJ; Nitta, J; Power, MM; Shepherd, JD; Smith, CA; Song, KW; Sutherland, HJ; Toze, CL; Venner, CP | 1 |
| Richardson, PG | 1 |
| Baccarani, M; Caravita, T; Cavo, M; Cellini, C; Corradini, P; Crippa, C; Deliliers, GL; Di Raimondo, F; Galli, M; Ledda, A; Narni, F; Offidani, M; Palumbo, A; Pantani, L; Patriarca, F; Pescosta, N; Petrucci, MT; Spadano, A; Tacchetti, P; Tosi, P; Zamagni, E | 1 |
| Fukuhara, N; Harigae, H; Ichinohasama, R; Ishizawa, K; Ohba, R; Ohguchi, H; Okitsu, Y; Onishi, Y; Yamamoto, J | 1 |
| Alici, E; Gahrton, G; Jansson, M; Nahi, H; Sutlu, T | 1 |
| Ahn, KS; Chen, CY; Han, I; Jeong, SJ; Jung, JH; Kang, M; Kim, DK; Kim, SH; Kwon, TR; Lee, JW; Lee, SG; Yun, SM | 1 |
| Einsele, H; Knop, S; Kortüm, M | 1 |
| Buda, G; Galimberti, S; Orciuolo, E; Pelosini, M; Petrini, M | 1 |
| Farquhar-Smith, P | 1 |
| Armoiry, X; Aulagner, G; Benboubker, L; Facon, T; Fagnani, F; Fermand, JP; Hulin, C; Moreau, P | 1 |
| Borrello, I; Ferguson, A; Ghosh, N; Huff, CA; Ye, X | 1 |
| Candoni, A; De Muro, M; De Stefano, V; Ferrara, F; Fianchi, L; Galieni, P; Gozzetti, A; Leone, G; Musto, P; Pagano, L; Petrucci, MT; Pogliani, EM; Pulsoni, A; Specchia, G; Valentini, CG; Venditti, A; Visani, G; Visco, C | 1 |
| Anderson, KC; Laubach, JP; Mitsiades, CS; Richardson, PG; Schlossman, RL | 1 |
| Lacy, MQ; Tefferi, A | 1 |
| Mateos, MV; San-Miguel, J | 1 |
| Abildgaard, N; Andersen, NF; Gimsing, P; Gregersen, H; Klausen, TW; Nexø, BA; Vangsted, AJ; Vogel, U | 1 |
| Schots, R | 1 |
| Abraham, J; Awan, FT; Craig, M; Gibson, L; Hamadani, M; Jillella, A; Kochuparambil, ST; Osman, S; Remick, SC | 1 |
| Adam, Z; Buchler, T; Gregora, E; Hajek, R; Krejci, M; Krivanova, A; Mayer, J; Minarik, J; Pour, L; Scudla, V; Straub, J; Zahradova, L | 1 |
| Bosi, A; Maratea, D; Messori, A; Nozzoli, C | 1 |
| Attal, M; Palumbo, A; Roussel, M | 1 |
| Lonial, S; Mitsiades, CS; Richardson, PG | 1 |
| Blasi, N; Brunori, M; Caraffa, P; Catarini, M; Corvatta, L; Ferranti, M; Gentili, S; Leoni, P; Malerba, L; Mele, A; Offidani, M; Polloni, C; Rizzi, R; Samori, A | 1 |
| Arfons, LM; Ataergin, SA; Barr, PM; Cooper, BW; Creger, RJ; Fu, P; Gerson, SL; Kaplan, D; Kaye, NM; Kindwall-Keller, TL; Laughlin, MJ; Lazarus, HM; Liu, F; Sommers, SR | 1 |
| Beksac, M; Bladé, J; Cavenagh, J; Cavo, M; Delforge, M; Dimopoulos, M; Drach, J; Einsele, H; Facon, T; Goldschmidt, H; Harousseau, JL; Hess, U; Kropff, M; Leal da Costa, F; Louw, V; Ludwig, H; Magen-Nativ, H; Mendeleeva, L; Nahi, H; Palumbo, A; Plesner, T; San-Miguel, J; Sondergeld, P; Sonneveld, P; Udvardy, M | 1 |
| Brioli, A; Cavo, M; Pantani, L; Tacchetti, P; Zamagni, E; Zannetti, B | 1 |
| Abraham, J; Bridoux, F; Delbès, S; Desport, E; Fermand, JP; Jaccard, A; Lacotte-Thierry, L; Moumas, E; Touchard, G | 1 |
| Bringhen, S; Mateos, MV; Palumbo, A; San Miguel, JF | 1 |
| Akiba, T; Aotsuka, N; Matsuura, Y; Oguro, R; Satoh, M; Takada, K; Tani, Y; Wakita, H; Yamanaka, C | 1 |
| Kyle, RA; Steensma, DP | 1 |
| Attal, M; Facon, T; Harousseau, JL; Moreau, P; Roussel, M | 1 |
| Goldschmidt, H; Moehler, T | 1 |
| Gahrton, G | 1 |
| Abraham, J; Bridoux, F; Debiais, C; Delbès, S; Desport, E; Fermand, JP; Hanf, W; Jaccard, A; Lacotte-Thierry, L; Moumas, E; Touchard, G | 1 |
| Brugnatelli, S; Foli, A; Invernizzi, R; Lavatelli, F; Merlini, G; Milani, P; Nuvolone, M; Obici, L; Palladini, G; Russo, P | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Ailawadhi, S; Chanan-Khan, A; Czuczman, MS; Hernandez-Ilizaliturri, FJ; Hong, F; Iancu, D; Jamshed, S; Lawrence, W; Lee, K; Manfredi, D; Masood, A; Miller, KC; Sher, T; Soniwala, S; Sood, R; Tan, W; Wilding, G; Wood, M | 1 |
| Bao, L; Huang, XJ; Lai, YY; Lu, J; Lu, XJ; Zhang, XH; Zhu, HH | 1 |
| Fink, L; Tricot, G; Zangari, M; Zhan, F | 1 |
| Anderson, KC; Anderson, T; Barrickman, JC; Campagnaro, EL; Esseltine, DL; Griffith, KA; Harvey, CK; Hofmeister, CC; Jakubowiak, AJ; Kaminski, MS; Kelley, SL; Laubach, JP; Lonial, S; Mietzel, MA; Raje, NS; Reece, DE; Richardson, PG; Schlossman, RL; Tendler, CL; Wear, SM; Zimmerman, TM | 1 |
| Cheson, BD | 1 |
| Basak, GW; Jaksic, O; Koristek, Z; Labar, B; Masszi, T; Mayer, J; Mikala, G; Wiktor-Jedrzejczak, W | 1 |
| Allred, JB; Bergsagel, PL; Buadi, F; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, K; Lust, JA; Mandrekar, SJ; Mikhael, JR; Rajkumar, SV; Reeder, C; Roy, V; Russell, SJ; Short, KD; Stewart, AK; Zeldenrust, S | 1 |
| Ishak, J; Rodrigues, F | 1 |
| Anderson, KC; Chauhan, D; Kuhn, D; Orlowski, R; Raje, N; Richardson, P; Tian, Z; Zhou, B | 1 |
| Aicher, B; Blau, IW; Busse, A; Dabrowski, R; Lohneis, P; Reufi, B; Schmidt-Hieber, M; Thiel, E; Tietze-Buerger, C | 1 |
| Chung, JS; Eom, HS; Kang, HJ; Kim, CS; Kim, HJ; Kim, JS; Kim, K; Lee, DS; Lee, JH; Lee, JL; Lee, SJ; Park, JS; Seong, CM; Sohn, SK; Suh, C; Won, JH; Yoon, SS | 1 |
| Liu, L; Ran, X; Sheng, Z; Wang, B; Wang, L | 1 |
| Bosi, A; Bruno, B; Corradini, P; Einsele, H; Fanin, R; Festuccia, M; Isola, M; Morabito, F; Nozza, A; Nozzoli, C; Patriarca, F; Sperotto, A; Spina, F; Stuhler, G | 1 |
| Chang, H; Jiang, A; Reece, D | 1 |
| Bello, C; Cohen, A; Comenzo, RL; Drullinsky, P; Hassoun, H; Hoover, E; Jhanwar, S; Landau, H; Lendvai, N; Lesokhin, A; Nimer, SD; Pandit-Taskar, N; Riedel, E; Schulman, P | 1 |
| Araujo, C; Attal, M; Avet-Loiseau, H; Benboubker, L; Berthou, C; Caillot, D; Chaleteix, C; Decaux, O; Dib, M; Doyen, C; Escoffre, M; Facon, T; Fontan, J; Fuzibet, JG; Garderet, L; Harousseau, JL; Hulin, C; Kolb, B; Lenain, P; Lepeu, G; Lioure, B; Marit, G; Mathiot, C; Moreau, P; Pégourié, B; Randriamalala, E; Sebban, C; Stoppa, AM; Tiab, M; Traullé, C; Wetterwald, M | 1 |
| Adam, Z; Feit, J; Hájek, R; Klincová, M; Krejčí, M; Mayer, J; Pour, L; Szturz, P; Vašků, V; Zahradová, L | 1 |
| Bergsagel, PL; Bjorklund, CC; Braggio, E; Bruins, LA; Chang, XB; Fonseca, R; Orlowski, RZ; Schmidt, JE; Shi, CX; Stewart, AK; Van Wier, S; Zhu, YX | 1 |
| Falk, RH | 1 |
| Gao, J; Wang, X; Xiao, C; Xing, X; Xiong, C; Ye, S | 1 |
| Möller, J; Murthy, A; Nicklasson, L | 1 |
| Tokuhira, M | 1 |
| Ohmachi, K | 1 |
| Dimeski, G; Wood, P | 1 |
| Chongmei, H; Hui, C; Jianmin, Y; Shuqing, L; Wang, J | 1 |
| Cavo, M | 1 |
| Kuwabara, S | 1 |
| Alexander, MP; Méndez, GP; Nasr, SH; Rennke, HG; Watson, DC | 1 |
| Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Cascavilla, N; Cavo, M; Di Raimondo, F; Gentile, M; Grasso, M; Guglielmelli, T; Majolino, I; Marasca, R; Mazzone, C; Montefusco, V; Morabito, F; Musolino, C; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, I | 1 |
| Alsina, M; Nishihori, T | 1 |
| Doss, S; Hay, N; Sutcliffe, F | 1 |
| Benson, DM; Crawford, BS; Efebera, Y; Elder, P; Hofmeister, CC; Mori, S; Phillips, G; Roddy, JV | 1 |
| D'Arena, G; Di Renzo, N; Falcone, A; Ferrara, F; Guariglia, R; Mansueto, G; Martorelli, MC; Mastrullo, L; Musto, P; Onofrillo, D; Pagano, L; Palumbo, A; Pietrantuono, G; Semenzato, G; Specchia, G; Valentini, CG; Venditti, A; Villani, O | 1 |
| Benjamin, M; Gibbs, S | 1 |
| Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, P; Hayman, S; Keith Stewart, A; Khan, ML; Kumar, SK; Lacy, MQ; Laumann, KM; Leif Bergsagel, P; Lust, J; Mikhael, JR; Reece, DE; Reeder, CB; Russell, S; Vincent Rajkumar, S; Zeldenhurst, S | 1 |
| Cao, Y; Chen, RA; Liang, Y; Liu, L; Tu, Y | 1 |
| Dimopoulos, MA; Eleftherakis-Papapiakovou, E; Gkotzamanidou, M; Grapsa, I; Kastritis, E; Nikitas, N; Psimenou, E; Roussou, M; Terpos, E | 1 |
| Carney, DA; Gangatharan, SA; Harrison, SJ; Januszewicz, EH; Prince, HM; Ritchie, DS; Wolf, MM | 1 |
| Bryant, J; Clegg, AJ; Cooper, K; Picot, J | 1 |
| Reece, D; Scott, E | 1 |
| Appel, A | 1 |
| Anderson, KC; Avet-Loiseau, H; Beksac, M; Bladé, J; Cavo, M; Chng, WJ; Comenzo, R; Delforge, M; Dimopoulos, M; Durie, BG; Einsele, H; Harousseau, JL; Jagannath, S; Jongen, JL; Lahuerta, JJ; Lee, JH; Lonial, S; Mateos, MV; Mazumder, A; Merlini, G; Miguel, JS; Moreau, P; Morgan, G; Munshi, N; Niesvizky, R; Orlowski, R; Palumbo, A; Rajkumar, SV; Richardson, PG; Sezer, O; Siegel, D; Sonneveld, P; Terpos, E; Usmani, S; Vesole, D; Voorhees, P; Wen, P | 1 |
| Cai, JL; Duarte, L; Farol, L; Forman, SJ; Frankel, PH; Htut, M; Karanes, C; Kogut, NM; Krishnan, AY; Murata-Collins, JL; Parker, PM; Popplewell, LL; Reburiano, E; Ruel, C; Sahebi, F; Somlo, G; Spielberger, RT; Thomas, SH | 1 |
| Gil, L; Komarnicki, M; Rupa-Matysek, J | 1 |
| Anderson, KC; Gaballa, MR; Ghobrial, IM; Laubach, JP; Mitsiades, CS; Munshi, N; Noonan, K; Redman, K; Richardson, PG; Schlossman, RL | 1 |
| Airia, P; Cockwell, P; Cook, M; Grima, D; Heyne, N; Hutchison, CA; Schindler, R; Zickler, D | 1 |
| Abonour, R; Anderson, KC; Bengoudifa, BR; Bourquelot, PM; de Magalhaes-Silverman, M; Goldschmidt, H; Hazell, K; Lonial, S; Matous, J; Siegel, D; Vij, R; Wolf, JL | 1 |
| Bocchia, M; D'Arena, G; D'Auria, F; Defina, M; Gozzetti, A; Musto, P; Papini, G; Statuto, T; Steduto, T | 1 |
| Anderson, KC; Colson, K; Doss, D; Ghobrial, IM; Hideshima, T; Laubach, JP; Lunde, L; McKenney, M; Mitsiades, C; Munshi, NC; Noonan, K; Redman, KC; Richardson, PG; Schlossman, RL; Warren, D | 1 |
| Attal, M; Avet-Loiseau, H; Bourin, P; Cordelier, P; Corre, J; Espagnolle, N; Facon, T; Fournié, JJ; Gadelorge, M; Hébraud, B; Huynh, A; Klein, B; Labat, E; Moreau, P; Roussel, M | 1 |
| Ahn, JS; Bae, SY; Jung, SH; Kim, HJ; Kim, YK; Lee, JJ; Moon, JH; Park, HC; Sohn, SK; Yang, DH | 1 |
| Chanan-Khan, AA; Dimopoulos, MA; Jagannath, S; Ludwig, H; San Miguel, JF | 1 |
| Anderson, K; Laubach, J; Mahindra, A; Munshi, N; Raje, N; Richardson, PG | 1 |
| Bertsch, U; Goldschmidt, H; Hose, D; Schmitt, S | 1 |
| Berenson, JR; Bravin, E; Cartmell, A; Chen, CS; Flam, M; Hilger, JD; Kazamel, T; Nassir, Y; Swift, RA; Vescio, R; Woliver, T; Yellin, O | 1 |
| Choi, Y; Kang, YA; Kim, DY; Kim, SD; Lee, JH; Lee, KH; Seol, M | 1 |
| Ramchandren, R | 1 |
| Andersen, NF; Andréasson, B; Billström, R; Carlson, K; Carlsson, MS; Flogegård, M; Forsberg, K; Gimsing, P; Gulbrandsen, N; Hjertner, Ø; Hjorth, M; Holmberg, E; Karlsson, T; Knudsen, LM; Linder, O; Nahi, H; Othzén, A; Pedersen, PT; Swedin, A | 1 |
| Callander, N; Estevam, J; Flinn, I; Hari, P; Kumar, S; Mulligan, G; Noga, SJ; Rajkumar, SV; Richardson, PG; Rifkin, R; Shi, H; Stewart, AK; Turturro, F; Webb, IJ; Wolf, J | 1 |
| Kwong, YL; Loong, F; Yeung, CK | 1 |
| Domján, G; Gadó, K | 1 |
| Barosi, G; Billio, A; Boccadoro, M; Cavo, M; Corradini, P; Marchetti, M; Massaia, M; Merlini, G; Palumbo, A; Tosi, P; Tura, S | 1 |
| Dispenzieri, A; Gertz, MA | 1 |
| Ballanti, S; Baraldi, A; Boccadoro, M; Brioli, A; Califano, C; Callea, V; Carella, AM; Cavo, M; Crippa, C; De Stefano, V; Derudas, D; Dessanti, ML; Donnarumma, D; Falcone, A; Ferrara, F; Furlan, A; Grasso, M; Marcatti, M; Masini, L; Musto, P; Nozza, A; Nozzoli, C; Palumbo, A; Pantani, L; Patriarca, F; Perrone, G; Petrucci, MT; Pezzi, A; Zamagni, E; Zambello, R | 1 |
| Garcia-Sanz, R; Mateos, MV; Ocio, E; San Miguel, JF | 1 |
| Fonseca, R | 1 |
| Giralt, S | 1 |
| Kyle, RA | 1 |
| Adam, Z; Al-Sahmani, M; Antošová, L; Antošová, M; Buliková, A; Hájek, R; Kaisarová, B; Kissová, J; Penka, M; Trnavská, I | 1 |
| Bai, C; Hu, X; Liu, J; Song, X; Wang, J | 1 |
| Jimenez-Zepeda, VH; John, R; Trudel, S; Vajpeyi, R | 1 |
| Avet-Loiseau, H; Bladé, J; Boccadoro, M; Cavenagh, J; Cavo, M; Davies, F; de la Rubia, J; Delimpasi, S; Dimopoulos, M; Drach, J; Einsele, H; Facon, T; Goldschmidt, H; Hess, U; Ludwig, H; Mellqvist, UH; Moreau, P; Palumbo, A; San-Miguel, J; Sondergeld, P; Sonneveld, P; Udvardy, M | 1 |
| Cakana, A; Casassus, P; Chaleteix, C; de Witte, T; Dib, M; Doyen, C; Fontan, J; Gahrton, G; Garderet, L; Gorin, NC; Gratwohl, A; Hajek, R; Harousseau, JL; Hertenstein, B; Iacobelli, S; Ketterer, N; Koenecke, C; Kolb, B; Lafon, I; Ludwig, H; Masszi, T; Michallet, M; Milone, G; Mohty, M; Moreau, P; Morris, C; Niederwieser, D; Onida, F; Pegourie, B; van Os, M | 1 |
| Barrera, LN; Bowles, KM; MacEwan, DJ; Rushworth, SA | 1 |
| Barthelemy, M; Boulanger, F; Cossment, C; Facon, T; Fouquet, G; Le Ray, E; Leleu, X; Manier, S; Noel, MP; Prod'homme, C; Samarcq, P; Terriou, L | 1 |
| Ahmad, N; Al Sayed, Y; Atrash, S; Barlogie, B; Chauhan, N; Crowley, J; Heuck, CJ; Hoering, A; Nair, B; Petty, N; Sexton, R; Usmani, SZ; van Rhee, F; Waheed, S | 1 |
| Chan, EY; Chim, CS; Kwong, YL; Lau, CW; Liang, R; Lie, AK; Liu, HS; Ma, ES; Sim, J; Tse, E; Wan, TS; Yip, SF | 1 |
| Anderson, KC; Benajiba, L; Fennessy, F; Laubach, J; Richardson, PG; Saboo, SS | 1 |
| Charliński, G; Jedrzejczak, WW; Wiater, E | 1 |
| Goulston, C; Hanson, KE; Kim, JH; Lampas, M; Sanders, S; Tricot, G; Zangari, M | 1 |
| Dimopoulos, MA; Gkotzamanidou, M; Kastritis, E; Matsouka, C; Mparmparoussi, D; Nikitas, N; Psimenou, E; Roussou, M; Spyropoulou-Vlachou, M; Terpos, E | 1 |
| Fujiwara, S; Hata, H; Iyama, K; Izaki, M; Kawano, Y; Mitsuya, H; Okuno, Y; Sakai, A; Wada, N; Yamasaki, H; Yuki, H | 1 |
| Cai, X; Ding, K; Duan, Q; Han, Y; Liu, X; Sun, Z; Wang, A; Wu, J; Zhu, W | 1 |
| Takamatsu, Y | 1 |
| Alegre, A; Besalduch, J; Bladé, J; Cibeira, MT; de Arriba, F; de la Rubia, J; Díaz-Mediavilla, J; Etxebeste, MA; González, Y; Granell, M; Gutiérrez, NC; Hernández, D; Hernández, MT; Lahuerta, JJ; López-Jiménez, J; Martín-Ramos, ML; Martínez, J; Mateos, MV; Oriol, A; Palomera, L; Rosiñol, L; San Miguel, J; Teruel, AI | 1 |
| Bertsch, U; Blau, IW; Bos, GM; Broyl, A; Duehrsen, U; El Jarari, L; Goldschmidt, HM; Hose, D; Jauch, A; Kersten, MJ; Lindemann, W; Lokhorst, HM; Pfreundschuh, M; Raymakers, R; Salwender, H; Schaafsma, MR; Scheid, C; Schmidt-Wolf, IG; Sonneveld, P; Stevens-Kroef, M; van der Holt, B; van der Velde, H; van Marwijk-Kooy, M; Vellenga, E; Weisel, KC; Wijermans, PW; Wittebol, S; Zweegman, S | 1 |
| Chung, HM; Clark, WB; Hazlett, AF; Kmieciak, M; Manjili, MH; McCarty, JM; Payne, KK; Roberts, CH; Sabo, RT; Sanford, K; Toor, AA; Williams, DC | 1 |
| Gertz, M | 1 |
| Berenson, JR; Eshaghian, S | 1 |
| Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S | 2 |
| Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; de Arriba, F; García-Sanz, R; González, Y; Granell, M; Gutiérrez, N; Hernández, JM; Lahuerta, JJ; López de la Guía, A; López, J; Martín-Mateos, ML; Martínez-López, J; Mateos, MV; Oriol, A; Palomera, L; Peñalver, FJ; Pérez, M; Polo, M; Ribera, JM; San-Miguel, JF; Teruel, AI | 1 |
| Kimby, E | 1 |
| Cockwell, P; Cook, M; Stringer, S | 1 |
| Bladé, J; Dimopoulos, MA; Kastritis, E | 1 |
| Bashir, Q; Bayraktar, UD; Champlin, RE; Ciurea, SO; Qazilbash, M | 1 |
| Suzuki, K | 2 |
| Altun, M; Anderson, KC; Carrasco, R; Chauhan, D; Fulcinniti, M; Hideshima, T; Kessler, BM; Kingsbury, WD; Kodrasov, MP; Kumar, KG; Leach, CA; McDermott, JL; Minvielle, S; Munshi, N; Nicholson, B; Orlowski, R; Richardson, P; Shah, PK; Tian, Z; Weinstock, J; Zhou, B | 1 |
| Barrera, LN; Bowles, KM; MacEwan, DJ; Murray, MY; Rushworth, SA; Zaitseva, L | 1 |
| Bruce, JT; Devine, SM; Elder, P; Hofmeister, CC; Mastronarde, JG; Phillips, G; Tran, JM; Wood, KL | 1 |
| Arima, N; Kawada, H | 1 |
| Badros, A; Khan, RZ | 1 |
| Cakana, A; Dmoszynska, A; Enny, C; Esteves, G; Feng, H; Greil, R; Hajek, R; Harousseau, JL; Ludwig, H; Masszi, T; Paiva, B; Ricci, D; Robinson, D; Shpilberg, O; Spicka, I; Stoppa, AM; van de Velde, H; Vidriales, MB; Viterbo, L | 1 |
| Barley, K; Chari, A; Jagannath, S; Osman, K | 1 |
| Aisa, Y; Ito, C; Mihara, A; Nakazato, T | 1 |
| Giralt, S; Landau, H; Rosenzweig, M | 1 |
| Buda, G; Carulli, G; Cervetti, G; Galimberti, S; Ghio, F; Orciuolo, E; Pelosini, M; Petrini, M | 1 |
| Franken, MG; Gaultney, JG; Huijgens, PC; Redekop, WK; Sonneveld, P; Tan, SS; Uyl-de Groot, CA | 1 |
| Ogura, M | 1 |
| Bergsagel, PL; Gutierrez, NC; Mateos, MV; Rajkumar, SV; San Miguel, JF | 1 |
| Ludwig, H; Sonneveld, P | 1 |
| Chim, CS; Choi, PT; Lee, WK | 1 |
| Gertz, MA; Hayman, SR; Sher, T | 1 |
| Hildebrandt, GC; Panu, LD; Shahan, JL | 1 |
| Benson, DM; Byrd, JC; Devine, SM; Dunavin, NC; Efebera, YA; Elder, P; Greenfield, C; Heerema, N; Hofmeister, CC; Ketcham, J; Merritt, L; Penza, S; Phillips, GS; Rieser, G; Rose, KS; Wei, L | 1 |
| Chihara, D; Iwama, K; Matsue, K; Nishida, Y; Sugihara, H; Takeuchi, M; Tsuda, K; Ugai, T; Yamakura, M | 1 |
| Locke, FL; Morgan, GJ | 1 |
| Alsina, M; Anand, P; Anderson, KC; Baz, R; Bilotti, E; Chen, M; Doss, D; Ghobrial, IM; Jacques, C; Kelley, SL; Larkins, G; Laubach, J; Loughney, N; McBride, L; Munshi, NC; Nardelli, L; Richardson, PG; Schlossman, R; Siegel, D; Sullivan, D; Wear, S; Zaki, MH | 1 |
| Alexanian, R; Delasalle, K; Wang, M | 1 |
| Binder, G; Borrello, I; Durie, B; Hussein, M; Khan, Z; Pashos, C | 1 |
| Adam, Z; Almasi, M; Berankova, K; Frohlich, J; Greslikova, H; Hajek, R; Jarkovsky, J; Jurczyszyn, A; Kaisarova, P; Krejci, M; Kuglik, P; Kupska, R; Melicharova, H; Mikulasova, A; Nemec, P; Penka, M; Sandecka, V; Sevcikova, S; Smetana, J; Zahradova, L; Zaoralova, R | 1 |
| Allietta, N; Angermund, R; Bladé, J; Blau, IW; Broer, E; Corradini, P; Dimopoulos, MA; Drach, J; Giraldo, P; Mitchell, V; Petrucci, MT; Teixeira, A | 1 |
| Ba-Mancini, A; Henk, HJ; Huang, H; Teitelbaum, A | 1 |
| Ba-Mancini, A; Cakana, A; Chen, K; Corzo, D; Dhawan, R; Duh, MS; Garrison, LP; Huang, H; Korves, C; Shi, H; van de Velde, H; Wang, ST | 1 |
| Alsina, M; Anderson, KC; Bensinger, W; Biermann, JS; Cohen, AD; Devine, S; Djulbegovic, B; Faber, EA; Gasparetto, C; Hernandez-Illizaliturri, F; Huff, CA; Kassim, A; Krishnan, AY; Kumar, R; Liedtke, M; Meredith, R; Raje, N; Schriber, J; Shead, DA; Singhal, S; Somlo, G; Stockerl-Goldstein, K; Treon, SP; Weber, D; Yahalom, J; Yunus, F | 1 |
| Lonial, S; Miguel, JF | 1 |
| McCarthy, PL | 1 |
| Mina, R; Palumbo, A | 1 |
| Arnulf, B; Attal, M; Avet-Loiseau, H; Benboubker, L; Bréchignac, S; Caillot, D; Decaux, O; Escoffre-Barbe, M; Facon, T; Fermand, JP; Garderet, L; Hennache, B; Hulin, C; Kolb, B; Leleu, X; Macro, M; Marit, G; Mathiot, C; Meuleman, N; Michallet, M; Moreau, P; Pegourie, B; Petillon, MO; Roussel, M; Royer, B; Stoppa, AM; Thielemans, B; Traulle, C | 1 |
| Anderson, JL; Anderson, KC; Görgün, GT; Hideshima, T; Laubach, J; Maguire, C; Munshi, NC; Raje, N; Richardson, PG; Whitehill, G | 1 |
| Li, J; Zhou, DB | 1 |
| Adam, Z; Cermáková, Z; Král, Z; Krejčí, M; Pour, L; Sčudla, V | 1 |
| Lacy, MQ | 1 |
| Lu, H; Sheng, Z; Yu, J; Zou, Y | 1 |
| Abe, M; Fujii, S | 1 |
| Álvarez-Fernández, S; Burrows, FJ; Esparís-Ogando, A; Ocio, EM; Ortiz-Ruiz, MJ; Pandiella, A; Parrott, T; San Miguel, J; Zaknoen, S | 1 |
| Minvielle, S; Moreau, P | 1 |
| Arnulf, B; Attal, M; Benajiba, L; Caillot, D; Caulier, A; Chaleteix, C; Chrétien, ML; Facon, T; Fermand, JP; Fouquet, G; Garciaz, S; Garderet, L; Hebraud, B; Leleu, X; Loiseau, HA; Moreau, P; Pegourie, B; Regny, C; Roussel, M; Royer, B; Stoppa, AM; Szalat, R; Touzeau, C | 1 |
| Benner, A; Egerer, G; Goldschmidt, H; Heiss, C; Hillengass, J; Ho, AD; Hose, D; Lehners, N; Neben, K; Raab, MS; Sellner, L | 1 |
| Abidi, MH; Abrams, J; Al-Kadhimi, Z; Ayash, L; Bhutani, D; Deol, A; Lum, L; Ratanatharathorn, V; Tageja, N; Uberti, J; Valent, J; Zonder, J | 1 |
| Abdallah, AO; Bailey, C; Barlogie, B; Chauhan, N; Cottler-Fox, M; Crowley, J; Epstein, J; Heuck, CJ; Hoering, A; Johann, D; Muzaffar, J; Petty, N; Rosenthal, A; Sawyer, J; Sexton, R; Singh, Z; Usmani, SZ; van Rhee, F; Waheed, S; Yaccoby, S | 1 |
| Mahindra, A; Saini, N | 1 |
| Brandi, G; Dika, E; Maibach, H; Patrizi, A; Tacchetti, P; Venturi, M | 1 |
| Ahluwalia, R; Carson, KR; Cox, DP; Fiala, MA; Jaenicke, M; Moliske, CC; Stockerl-Goldstein, KE; Tomasson, MH; Trinkaus, KM; Vij, R; Wang, TF; Wildes, TM | 1 |
| Arakaki, H; Uchihara, JN | 1 |
| Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S | 1 |
| Cerrato, C; Palumbo, A | 2 |
| Alma, E; Cox, MC; Di Napoli, A; Naso, V; Pelliccia, S; Rebecchini, C | 1 |
| Arai, R; Fujimoto, K; Isozumi, Y; Koyama, T | 1 |
| Allietta, N; Angermund, R; Beksac, M; Benboubker, L; Broer, E; Couturier, C; Dimopoulos, MA; Facon, T; Mazier, MA; Roddie, H | 1 |
| Bernasconi, P; Cazzola, M; Cocito, F; Corso, A; Mangiacavalli, S; Pochintesta, L; Pompa, A | 1 |
| Ihara, K; Inomata, H; Kato, J; Kikuchi, S; Koyama, R; Muramatsu, H; Nagamachi, Y; Nishisato, T; Nozawa, E; Okamoto, T; Ono, K; Tanaka, S; Yamada, H; Yamauchi, N; Yano, T | 1 |
| Inui, Y; Kanakura, Y; Kataoka, S; Kawata, S; Kubo, M; Maeda, T; Matsunaga, H; Matsuura, N; Ueda, S | 1 |
| Gumulec, J; Hájek, R; Plonková, H | 1 |
| Awan, F; Chaudhary, L; Craig, M; Cumpston, A; Hamadani, M; Leadmon, S; Tse, W; Watkins, K | 1 |
| Chen, CI; Chu, CM; Cserti-Gazdewich, C; Jiang, H; Jimenez-Zepeda, VH; Kukreti, V; Masih-Khan, E; Rabea, A; Reece, DE; Tiedemann, R; Trudel, S; Tsang, R | 1 |
| Gibbs, SD; Gillmore, JD; Hawkins, PN; Lachmann, HJ; Pinney, JH; Roussel, M; Sachchithanantham, S; Venner, CP; Wechalekar, AD | 1 |
| Amrein, PC; Attar, EC; Ballen, KK; Deangelo, DJ; Fathi, AT; Foster, J; Fraser, JW; McAfee, S; Neuberg, D; Steensma, DP; Stone, RM; Wadleigh, M | 1 |
| Boccadoro, M; Cavallo, F; Corradini, P; Crippa, C; Ferrari, S; Gay, F; Giuliani, N; Guglielmelli, T; Liberati, AM; Magarotto, V; Montefusco, V; Offidani, M; Oliva, S; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Pescosta, N; Petrucci, MT; Pezzatti, S; Pietrantuono, G | 1 |
| Alsina, M; Baz, R; Dalton, WS; Djulbegovic, B; Ho, VQ; Miladinovic, B; Nishihori, T; Ochoa-Bayona, JL; Patel, A; Shain, KH; Sullivan, DM | 1 |
| Chng, WJ; Durie, BG; Eom, HS; Goh, YT; Kim, JS; Kim, K; Lee, JH; Ong, KH; Tan, D; Teoh, G | 1 |
| Kato, T; Miyao, K; Niimi, K; Ono, Y; Sakai, T; Sakemura, R; Sawa, M; Tsushita, N | 1 |
| Giannotta, A; Guaragna, G; Mele, G; Melpignano, A; Quarta, G; Spina, A | 1 |
| Forsberg, PA; Mark, TM | 1 |
| Adam, Z; Adamova, D; Bacovsky, J; Gregora, E; Gumulec, J; Hajek, R; Jarkovsky, J; Maisnar, V; Melicharova, H; Minarik, J; Pavlicek, P; Pika, T; Plonkova, H; Pour, L; Radocha, J; Sandecka, V; Scudla, V; Spicka, I; Starostka, D; Straub, J; Walterova, L; Wrobel, M | 1 |
| Bao, L; Huang, X; Jiang, Q; Lai, Y; Liu, Y; Lu, J; Lu, X; Qin, Y; Zhao, X | 1 |
| El Azeeim, HA; El Husseiny, NM; Kasem, N; Mattar, MW | 1 |
| Attal, M; Bladé, J; Cakana, A; Cavo, M; Desai, A; Esseltine, DL; Goldschmidt, H; Lahuerta, JJ; Liu, K; Lokhorst, HM; Moreau, P; Rosiñol, L; Sonneveld, P; Tacchetti, P; van de Velde, H; Zamagni, E | 1 |
| Cırak, MY; Emmez, H; Oner, AY; Pamukçuoğlu, M; Senol, E; Sucak, GT; Tunçcan, OG | 1 |
| Klánová, M; Špička, I | 1 |
| Ise, M; Kumagai, K; Sakai, C | 1 |
| Morgan, GJ | 1 |
| Mark, TM; Meadows, JP | 1 |
| Cavenagh, J; Ingram, W; Quinn, J; Smith, D; Stevens, J; Yong, K | 1 |
| Wang, L; Xu, YL; Zhang, XQ | 1 |
| Cicero, S; Drach, J; Fu, T; Goy, A; Kalayoglu Besisik, S; Ramchandren, R; Sinha, R; Williams, ME; Witzig, TE; Zhang, L | 1 |
| Eom, HS; Jo, DY; Jun, HJ; Kim, JS; Kim, K; Kim, KH; Kim, SH; Kim, SJ; Kim, YS; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Min, CK; Moon, JH; Mun, YC; Park, SK; Ryoo, HM; Suh, C; Voelter, V; Yoon, SS | 1 |
| Christoulas, D; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Gkotzamanidou, M; Kanellias, N; Kastritis, E; Manios, E; Migkou, M; Papadimitriou, C; Roussou, M; Terpos, E | 1 |
| Lin, M; Niu, S; Sheng, Z; Zou, Y | 1 |
| Drach, J; Drach-Schauer, B; Eder, S; Lamm, W | 1 |
| Ballester, G; Ballester, O; Yaqub, S | 1 |
| Cho, BS; Cho, SG; Eom, KS; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Shin, SH; Yoon, JH | 1 |
| Bačovský, J; Látalová, P; Lochman, P; Metelka, R; Minařík, J; Pika, T; Ščudla, V; Vymětal, J; Zapletalová, J | 1 |
| Atanackovic, D; Schilling, G | 1 |
| Moreau, P; Touzeau, C | 1 |
| Liu, H; McCarthy, P | 1 |
| Brioli, A; Cavo, M; Mancuso, K; Tacchetti, P; Zamagni, E; Zannetti, BA | 1 |
| Lentzsch, S; Schecter, J | 1 |
| Aróstegui, JI; Bladé, J; Cibeira, MT; Elena, M; Fernández de Larrea, C; Filella, X; Pedrosa, F; Rosiñol, L; Tovar, N; Yagüe, J | 1 |
| Boise, LH; Casbourne, D; Gleason, C; Heffner, LT; Kaufman, JL; Langston, A; Lonial, S; Muppidi, S; Nooka, AK; Saxe, D | 1 |
| Akhtar, S; Ansell, SM; Carr, J; Chanan-Khan, A; Chitta, K; Dispenzieri, A; Foran, J; Kumar, S; Mikhael, JR; Miller, KC; Paulus, A; Personett, D; Reeder, CB; Rivera, CE; Roy, V; Thompson, KJ | 1 |
| Aljama, P; Alonso, C; Alvarez-Lara, MA; Caballero-Villarraso, J; Carracedo, J; Martín-Malo, A; Ojeda-López, R; Pendón-Ruiz de Mier, MV | 1 |
| Caba-Molina, M; Claver-Ferré, C; García-Marcos, SA; Gómez-Morales, M; Martín-Gómez, MA; Palacios-Gómez, ME | 1 |
| Beksac, M; Boccadoro, M; Bringhen, S; Catalano, L; Cavalli, M; Cavo, M; Cerrato, C; Gentile, M; Gimsing, P; Gottardi, D; Isabel Turel, A; José Lahuerta, J; Juliusson, G; Larocca, A; Magarotto, V; Marina Liberati, A; Mazzone, C; Morabito, F; Musto, P; Offidani, M; Omedè, P; Oriol, A; Palumbo, A; Passera, R; Rossi, D; Rosso, S; San Miguel, J; Schaafsma, M; Sonneveld, P; Victoria Mateos, M; Waage, A; Wijermans, P; Zambello, R; Zweegman, S | 1 |
| Ahn, KS; Bae, EK; Choi, JH; Jung, WJ; Lee, C; Park, J; Yoon, SS | 1 |
| Cavallo, F; Cerrato, C; Mina, R; Palumbo, A | 1 |
| An, G; Deng, S; Meng, H; Qiu, L; Shi, L; Sui, W; Wang, J; Xu, Y; Zhan, F; Zhu, G; Zou, D | 1 |
| Angelucci, E; Annese, T; Berardi, S; Caivano, A; Catacchio, I; Dammacco, F; De Luisi, A; Derudas, D; Ditonno, P; Frassanito, MA; Guarini, A; Minoia, C; Moschetta, M; Nico, B; Piccoli, C; Ria, R; Ribatti, D; Ruggieri, S; Ruggieri, V; Vacca, A | 1 |
| Aldrin, A; Alici, E; Aschan, J; Blimark, C; Carlson, K; Enestig, J; Flogegård, M; Forsberg, K; Gahrton, G; Gruber, A; Haglöf Kviele, H; Johansson, P; Lauri, B; Liwing, J; Lund, J; Mellqvist, UH; Nahi, H; Näsman, P; Svensson, M; Swedin, A; Uttervall, K | 1 |
| Alexanian, R; Delasalle, K; Handy, B; Qazilbash, M; Wang, M; Wang, S; Weber, D | 1 |
| Hahn, T; McCarthy, PL | 1 |
| Munemoto, S; Murata, R; Nakajima, K; Nakao, S; Takamatsu, H; Terasaki, Y | 1 |
| Delimpasi, S; Dimopoulos, MA; Gika, D; Kartasis, Z; Kastritis, E; Katodritou, E; Konstantopoulos, K; Kyrtsonis, MC; Michael, M; Michalis, E; Parcharidou, A; Pouli, A; Repousis, P; Symeonidis, A; Terpos, E; Vassou, A | 1 |
| Devine, E; Krause, B; Krieter, DH; Lemke, HD; Storr, M; Wanner, C | 1 |
| Anderson, KC; Bahlis, N; Baz, R; Belch, A; Chen, C; Chen, M; Hofmeister, CC; Jacques, C; Jagannath, S; Jakubowiak, A; Lacy, M; Lentzsch, S; Lonial, S; Matous, J; Mikhael, J; Raje, N; Richardson, PG; Shustik, C; Siegel, DS; Song, K; Vesole, D; Vij, R; Yu, Z; Zaki, MH | 1 |
| Alsina, M; Anderson, KC; Colson, K; Esseltine, DL; Feather, J; Francis, D; Ghobrial, IM; Hideshima, T; Jagannath, S; Jakubowiak, A; Kaufman, JL; Knight, R; Lonial, S; Lunde, LE; Maglio, ME; Mazumder, A; McKenney, M; Mitsiades, CS; Munshi, NC; Raje, NS; Richardson, PG; Schlossman, RL; Vesole, DH; Warren, D; Weller, E; Xie, W | 1 |
| Liu, G; Liu, L; Wang, SX; Wang, Y; Yao, Y; Zhang, YK | 1 |
| Blanco Cid, N; Dacal Quintas, R; Santalla Martínez, M | 1 |
| Benevolo, G; Boccadoro, M; Bringhen, S; Cavo, M; Di Raimondo, F; Falcone, AP; Franceschini, L; Gaidano, G; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Magarotto, V; Marasca, R; Mina, R; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, ID; Zambello, R | 1 |
| Bryant, J; Clegg, A; Cooper, K; Picot, J | 1 |
| Attal, M; Einsele, H; Giralt, S; McCarthy, PL | 1 |
| Collins, DJ; Davies, FE; deSouza, NM; Giles, SL; Messiou, C; Morgan, GJ; Morgan, VA; Simpkin, CJ; West, S | 1 |
| Anderson, KC; Chauhan, D; Coffman, RL; Das, DS; Ray, A; Richardson, P; Tian, Z | 1 |
| Blum, KA; Maddocks, K | 1 |
| Bonnet, A; Bourcier, J; Chauvin, C; Lok, A; Mahé, B; Mocquard, J; Moreau, P; Redelsperger, L; Thomaré, P; Touzeau, C | 1 |
| Dondero, R; Francis, SM; Liu, Z; Tang, T; Taylor, CA; Thompson, JE; Zheng, Q | 1 |
| Cavallo, F; Genadieva-Stavric, S; Palumbo, A | 1 |
| Fuchida, S; Hino, M; Ishii, K; Kanakura, Y; Kaneko, H; Kobayashi, M; Kosugi, S; Kuroda, J; Matsumura, I; Nomura, S; Ohta, K; Shibayama, H; Shimazaki, C; Shimura, Y; Takaori-Kondo, A; Tanaka, H; Taniwaki, M; Tsudo, M; Uoshima, N | 1 |
| Abar, F; Dibb, J; Dibb, W; Frires, R; Heitner, SB; Kovacsovics, T; Maziarz, RT; Meyers, G; Perez-Avraham, G; Scott, EC; Smith, SD; Stentz, A | 1 |
| Asaoku, H; Chou, T; Harada, T; Hayashi, K; Itagaki, M; Kuroda, Y; Mina, R; Murakami, H; Ozaki, S; Palumbo, A; Saitoh, T; Shimazaki, C; Shimizu, K; Suzuki, K; Yoshiki, Y | 1 |
| Bird, J; Bowcock, S; Cook, G; Davies, F; Lai, M; Low, E; Morgan, G; Owen, R; Pratt, G; Rabin, N; Snowden, J; Wechalaker, A; Yong, K | 1 |
| Chen, CY; Chen, YC; Chou, SJ; Chou, WC; Hou, HA; Huang, SY; Lin, CW; Lin, HH; Lu, HY; Tang, JL; Tien, HF; Tsay, W; Wu, SJ; Yao, M | 1 |
| Balsas, P; Campo, E; Colomer, D; Martínez, A; Montraveta, A; Moros, A; Normant, E; Pérez-Galán, P; Rodríguez, V; Roué, G; Saborit-Villarroya, I; Sandy, P; Wiestner, A | 1 |
| Chuang, WH; Hsu, LF; Huang, SY; Hwang, SM; Liao, YH; Lin, HH; Sheen, YS; Wu, SJ | 1 |
| Ahn, SY; Choi, CW; Joo, YD; Jung, SH; Kim, K; Kim, SJ; Lee, JJ; Lee, SM; Lee, WS | 1 |
| Chang, WJ; Kang, ES; Kim, DW; Kim, K; Kim, SH; Kim, SJ; Lee, ST | 1 |
| Bringhen, S; Donato, F; Gay, F; Palumbo, A; Troia, R | 1 |
| Choquet, S; Leblond, V; Nguyen, S; Souchet-Cömpain, L | 1 |
| Abildgaard, N; Hansen, CT; Nielsen, LC; Pedersen, PT | 1 |
| Abe, Y; Hamano, A; Hattori, Y; Miyazaki, K; Nakagawa, Y; Sekine, R; Shingaki, S; Suzuki, K; Tsukada, N | 1 |
| Avigdor, A; Duek, A; Freidman, T; Kedmi, M; Leiba, M; Leiba, R; Nagler, A; Weiss, M | 1 |
| Fujimoto, T; Koyama, A; Kurihara, T; Nishikawa, A; Okamoto, Y; Shiotani, C; Tamura, S | 1 |
| Alexanian, R; Badillo, M; Chen, Y; Chiang, J; Cohen, L; Delasalle, K; Garcia, MK; Green, V; Guo, Y; Lee, R; Orlowski, RZ; Romaguera, J; Shah, J; Thomas, S; Wang, M; Weber, D; Wei, Q; You, B; Zhang, L; Zhou, Y | 1 |
| Anderson, KC; Bianchi, G; Richardson, PG | 1 |
| El-Shentenawy, A; Mohammed, AA | 1 |
| Akashi, K; Aoki, T; Ito, Y; Iwasaki, H; Kadowaki, M; Kamimura, T; Kato, K; Miyamoto, T; Muta, T; Shima, T; Shiratsuchi, M; Takase, K; Takashima, S; Takenaka, K; Teshima, T; Yoshimoto, G | 1 |
| Foard, D; Gibbs, SD; Gillmore, JD; Hawkins, PN; Lachmann, HJ; Lane, T; Mahmood, S; Pinney, JH; Rannigan, L; Sachchithanantham, S; Venner, CP; Wechalekar, AD; Whelan, CJ | 2 |
| de Zoysa, JR; Hutchison, CA; Lam-Po-Tang, M; Tan, J | 1 |
| Dytfeld, D; Gil, L; Kaźmierczak, M; Komarnicki, M; Nowicki, A; Rupa-Matysek, J; Wojtasińska, E | 1 |
| Chung, DJ; Devlin, S; Giralt, SA; Hassoun, H; Hilden, P; Koehne, G; Landau, H; Lendvai, N; Lesokhin, AM; Redling, K; Schaffer, WL; Tsakos, I | 1 |
| Hahn-Ast, C; Kanz, L; Oehrlein, K; Rendl, C; Weisel, K; Zago, M | 1 |
| Hu, H; Jia, Y; Peng, J; Wang, L; Xu, H | 1 |
| Bartlett, NL; Blum, KA; Cheson, BD; Johnson, J; Jung, SH; LaCasce, A; Morrison, VA; Pitcher, BN | 1 |
| Ali, SM; Chmielecki, J; Miller, VA; Morosini, D; Palmer, GA; Ross, JS; Sharman, JP; Stafl, J; Stephens, PJ | 1 |
| Ise, M; Kumagai, K; Sakai, C; Tsujimura, H | 1 |
| Attal, M; Avet-Loiseau, H; Benboubker, L; Caillot, D; Chretien, ML; Corre, J; Facon, T; Fruchart, C; Gentil, C; Hebraud, B; Hulin, C; Huynh, A; Lauwers-Cances, V; Leleu, X; Marit, G; Moreau, P; Pegourie, B; Robillard, N; Roussel, M; Stoppa, AM; Wuilleme, S | 1 |
| Boccadoro, M; Callea, V; Caltagirone, S; Cangialosi, C; Carovita, T; Cavallo, F; Crippa, C; De Rosa, L; Drandi, D; Falcone, AP; Ferrero, S; Genuardi, E; Grasso, M; Guglielmelli, T; Ladetto, M; Liberati, AM; Musto, P; Oliva, S; Palumbo, A; Passera, R; Pisani, F; Pregno, P; Rossini, F; Terragna, C; Urbano, M | 1 |
| Cheng, J; Lamy, T; Loughran, TP; Malysz, J; Ochmann, M; Talamo, G | 1 |
| Joks, M; Jurczyszyn, A; Komarnicki, M; Machaczka, M; Skotnicki, AB | 1 |
| Fu, W; Hou, J; Huang, H; Peng, L; Zhang, C; Zhou, L | 1 |
| Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; de Arriba, F; González, Y; Granell, M; Hernández, JM; Lahuerta, JJ; López de la Guía, A; López, J; Martín-Mateos, ML; Martínez, R; Martínez-López, J; Mateos, MV; Montalbán, MA; Oriol, A; Paiva, B; Palomera, L; Peñalver, FJ; Pérez, M; San-Miguel, JF; Teruel, AI | 1 |
| Huang, L; Liu, W; Liu, Z; Luo, L; Mao, X; Meng, F; Qin, S; Sun, H; Zeng, W; Zheng, M; Zhou, J | 1 |
| Cerase, A; Gozzetti, A | 1 |
| Aljijakli, A; Arakelyan, N; Bouallegue, S; Chaoui, D; Genet, P; Sutton, L | 1 |
| Baldini, L; Cavaletti, G; Cavo, M; Elice, F; Galli, M; Gozzetti, A; Lazzaro, A; Martello, M; Montefusco, V; Palumbo, A; Pantani, L; Peccatori, J; Petrucci, MT; Pezzi, A; Rocchi, S; Ruggieri, M; Tacchetti, P; Terragna, C; Tosi, P; Zamagni, E | 1 |
| Hamdy, AA; Neemat, K; Rania, K; Tarek, M | 1 |
| Mateos, MV; Miguel, JF | 1 |
| Vij, R | 1 |
| Awai, K; Date, S; Kaichi, Y; Kiguchi, M; Kuroda, Y; Sakai, A; Sakoda, Y; Takasu, M; Tani, C | 1 |
| Dakhil, C; Haideri, N; Kumar, AK; Teeka Satyan, M | 1 |
| Hummers, LK | 1 |
| Vincent Rajkumar, S | 1 |
| Cao, C; Kai, S; Liu, T; Wang, L; Xiang, B; Zhu, H | 1 |
| Koeppen, S | 1 |
| Chu, SH; Cleeland, CS; Geng, Y; Lee, ES; Lee, YJ; Wang, XS | 1 |
| Bories, C; Facon, T; Fouquet, G; Guidez, S; Herbaux, C; Javed, S; Leleu, X; Renaud, L | 1 |
| Hobeika, L; Self, SE; Velez, JC | 1 |
| Fabbro, SK; Kaffenberger, BH | 1 |
| Dimopoulos, MA; Dispenzieri, A; Gertz, MA; Kastritis, E; Kumar, S; Orlowski, R; Shah, J; Shah, RA; Terpos, E | 1 |
| Shibayama, H | 1 |
| Nakaseko, C | 1 |
| Tsurumi, H | 1 |
| Bátorová, A; Mistrík, M; Roziaková, L | 1 |
| Basnayake, K; Talbot, B; Wright, D | 1 |
| Izumi, H; Komatsu, N; Nakamura, N; Noguchi, M; Ohta, Y; Sawada, T; Sekiguchi, Y; Shimada, A; Sugimoto, K; Tomita, S; Wakabayashi, M | 1 |
| Aitchison, R; Blesing, N; Lau, IJ; Peniket, A; Rabin, N; Ramasamy, K; Roberts, P; Smith, D; Yong, K | 1 |
| Bari, A; Civallero, M; Cosenza, M; Marcheselli, L; Pozzi, S; Sacchi, S | 1 |
| Bakker, J; de Jong-Korlaar, R; Groen, RW; Lokhorst, HM; Martens, AC; Mutis, T; Nijhof, IS; Noort, WA; Parren, PW; van Bueren, JJ; van de Donk, NW; van Kessel, B | 1 |
| Bay, JO; Ravinet, A; Tournilhac, O | 1 |
| Anderson, KC; Dimopoulos, MA; Moreau, P; Richardson, PG | 1 |
| Acharya, C; An, G; Cheng, T; Deng, S; Feng, X; Hao, M; Li, Z; Qi, J; Qin, X; Qiu, L; Ru, K; Shi, L; Sui, W; Tai, YT; Wang, J; Xu, Y; Yi, S; Zang, M; Zhao, Y; Zou, D | 1 |
| Harrison, SJ; Slavin, MA; Teh, BW; Thursky, KA; Worth, LJ | 2 |
| Anderson, KC; Ghobrial, IM; Glavey, S; Görgün, GT; Kawano, Y; Manier, S; Moschetta, M; Roccaro, AM | 1 |
| Gooding, S; King, AJ; Ramasamy, K | 1 |
| Dimopoulos, MA; Gavriatopoulou, M; Kalapanida, D; Kaldara, E; Kastritis, E; Migkou, M; Ntalianis, A; Pamboucas, C; Psimenou, E; Roussou, M; Tasidou, A; Terpos, E; Toumanidis, ST | 1 |
| Guglielmelli, T; Palumbo, A | 1 |
| Nakaseko, C; Sakaida, E; Takeda, Y | 1 |
| Gozzetti, A | 1 |
| Ballerini, F; Boccadoro, M; Brioli, A; Catalano, L; Cavo, M; Davies, FE; Liberati, AM; Mancuso, K; Morgan, GJ; Motta, MR; Nobile, F; Palumbo, A; Patriarca, F; Perrone, G; Pezzi, A; Rizzi, S; Ronconi, S; Tacchetti, P; Volpe, S; Zamagni, E; Zannetti, BA | 1 |
| Liu, G; Sheng, Z | 1 |
| Colson, K | 1 |
| Acharya, C; An, G; Anderson, KC; Cheng, T; Deng, S; Feng, X; Hao, M; Li, C; Li, Q; Li, Z; Qi, J; Qin, X; Qiu, L; Ru, K; Shi, L; Sui, W; Tai, YT; Wang, J; Xu, Y; Yi, S; Zang, M; Zhao, J; Zhao, Y; Zou, D | 1 |
| Camarero, J; Flores, B; Gisselbrecht, C; Hanaizi, Z; Hemmings, R; Laane, E; Pignatti, F; Salmonson, T; Sancho-Lopez, A | 1 |
| Shen, Q; Zhuang, Y | 1 |
| Arikian, SR; Binder, G; Corvino, FA; Gibson, CJ; Hu, XH; Hussein, M; Milentijevic, D; Nagarwala, Y; Surinach, A; Usmani, SZ | 1 |
| Chai, X; Fang, B; Huang, H; Li, Y; Lin, Q; Song, Y; Xia, Q; Yu, F; Zhang, Y; Zhou, J | 1 |
| Hoskote, SS; Onigkeit, JA; Reddy, DR | 1 |
| Gandhi, V; He, J; Orlowski, RZ; Shentu, S; Stellrecht, CM; Yang, J; Zaman, S | 1 |
| Oza, A; Rajkumar, SV | 1 |
| Adler, AI; Burke, MJ; George, E | 1 |
| Alonge, MM; Dytfeld, D; Jakubowiak, AJ; Jasielec, J; Kandarpa, M; Mayampurath, A; Mellacheruvu, D; Nesvizhskii, AI; Ngoka, L; Richardson, PG; Rosebeck, S; Sreekumar, A; Volchenboum, S | 1 |
| Avivi, I; Ballan-Haj, M; Chubar, E; Cohen, Y; Dally, N; Gatt, ME; Hardan, I; Jakubinsky, J; Magen, H; Muchtar, E; Patachenco, P; Shevetz, O; Suriu, C; Tadmor, T; Trestman, S; Yeganeh, S | 1 |
| Chung, JS; Lee, GW; Lee, IS; Lee, JH; Lee, JJ; Lee, SM; Shin, DY; Song, IC; Song, MK | 1 |
| Bay, JO | 1 |
| Laubach, JP; Richardson, PG | 1 |
| Blommestein, HM; de Groot, S; Huijgens, PC; Sonneveld, P; Uyl-de Groot, CA; Verelst, SG | 1 |
| Champlin, RE; Pingali, SR | 1 |
| Alrajeh, A; Hanbali, A; Rasheed, W | 1 |
| Anderson, KC; Ghobrial, IM; Laubach, J; Maglio, ME; Mitsiades, CS; Munshi, NC; O'Donnell, EK; Paba-Prada, C; Raje, N; Richardson, PG; Schlossman, R; Varga, C; Warren, D; Weinstock, M; Weller, E; Xie, W | 1 |
| Gong, J; Mita, M; Rimel, B; Sachdev, E | 1 |
| Charu, V; Clowney, B; Elliott, J; Essell, J; Esseltine, DL; Flinn, IW; Gabrail, N; Gaffar, Y; Neuwirth, R; Niculescu, L; Niesvizky, R; Reeves, J; Rifkin, R; Warr, T; Zhu, Y | 1 |
| Lee, J; Rabin, N; Smith, D; Tobias, J; Yong, K | 1 |
| Bladé, J; García-Sanz, R; Lahuerta, JJ; Martínez-López, J; Mateos, MV; Ocio, EM; Paiva, B; Rosiñol, L; San Miguel, JF | 1 |
| Alsina, M; Baz, RC; Fulp, W; Griffin, PT; Ho, VQ; Nishihori, T; Shain, KH | 1 |
| Amatya, R; Belch, A; Dimopoulos, M; Gibson, CJ; Jacques, C; Moreau, P; Palumbo, A; San Miguel, J; Schey, S; Song, KW; Sonneveld, P; Sternas, L; Weisel, K; Yu, X; Zaki, M | 1 |
| Ataman, O; Chaturvedi, S; Dmoszynska, A; Enny, C; Esteves, G; Feng, H; Greil, R; Hajek, R; Ludwig, H; Masszi, T; Paiva, B; Robinson, D; Shpilberg, O; Spicka, I; Stoppa, AM; van de Velde, H; Vidriales, MB; Viterbo, L | 1 |
| Arnulf, B; Bridoux, F; Caulier, A; Chevret, S; Cohen, C; El Karoui, K; Fermand, JP; Jaccard, A; Javaugue, V; Knebelmann, B; Royer, B; Szalat, R; Touchard, G | 1 |
| Kadowaki, M; Kohno, K; Okamura, S; Takase, K; Yamasaki, S | 1 |
| Fowler, N; Gribben, JG; Morschhauser, F | 1 |
| Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Go, RS; Hayman, SR; Hwa, L; Kapoor, P; Kumar, SK; Kyle, RA; Lacy, MQ; Lust, JA; Majithia, N; Russell, SJ; Vincent Rajkumar, S | 1 |
| Ailawadhi, S; Bartlett, B; Durie, B; Fredette, S; Hoering, A; Lipe, B; Orlowski, RZ; Rosenzweig, M; Sexton, R; Shah, JJ; Usmani, SZ; Valent, J; Zonder, JA | 1 |
| Buadi, FK; Cheng, WY; Dea, K; Dispenzieri, A; Duh, MS; Engebretson, AE; Kumar, SK; Lacy, MQ; Lafeuille, MH; Lefebvre, P; Ma, E; Niculescu, L; Patt, D; Quick, M; Rajkumar, SV; Rembert, D | 1 |
| Boise, LH; Kaufman, J; Lonial, S | 1 |
| Buonanno, M; Ingrosso, C; Mazza, P; Minoia, C; Palazzo, G; Pisapia, G; Pricolo, G; Prudenzano, A; Spinosa, C | 1 |
| Benevolo, G; Boccadifuoco, L; Boccadoro, M; Caravita, T; Cavallo, F; Cavo, M; Cerrato, C; Ciccone, G; Corradini, P; Delforge, M; Di Raimondo, F; Dimopoulos, MA; Donato, F; Gay, F; Guglielmelli, T; Hajek, R; Hardan, I; Jacques, C; Larocca, A; Musto, P; Nagler, A; Nozzoli, C; Palumbo, A; Patriarca, F; Petrucci, MT; Pezzatti, S; Vincelli, D; Yu, Z | 1 |
| Bullement, A; Dickens, E; Elvidge, J; Gooding, S; Lau, IJ; Lee, D; Ramasamy, K; Roberts, P; Sheikh, M; Wong, J | 1 |
| Hazlehurst, L; Lynch, CC; Shay, G | 1 |
| Cai, X; Chen, S; Chen, Y; Lin, B; Shi, Y; Wu, S; Zheng, C | 1 |
| Brioli, A; Cavo, M; Di Raimondo, F; Galli, M; Gamberi, B; Marzocchi, G; Montefusco, V; Palumbo, A; Pantani, L; Patriarca, F; Petrucci, MT; Pezzi, A; Sonneveld, P; Tacchetti, P; Zamagni, E | 1 |
| Ichikawa, K; Izumi, H; Komatsu, N; Nakamura, N; Noguchi, M; Ohta, Y; Sawada, T; Sekiguchi, Y; Sugimoto, K; Tomita, S; Wakabayashi, M | 1 |
| Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Go, RS; Hayman, SR; Hwa, YL; Kapoor, P; Kaufman, GP; Kumar, SK; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Russell, S | 1 |
| Cong, Z; Song, X; Wilson, K | 1 |
| Bargay, J; Bengoechea, E; Bladé, J; Cabrera, C; Cedena, MT; Encinas, C; Gironella, M; González, Y; Gutiérrez, NC; Hernández, MT; Lahuerta, JJ; Martín Ramos, ML; Martín, J; Martínez, R; Martínez-López, J; Mateos, MV; Ocio, EM; Oriol, A; Paiva, B; Pérez de Oteyza, J; Puig, N; Rosiñol, L; San-Miguel, J; Teruel, AI | 1 |
| Basu, S; Belch, AR; Berger, A; Binder, G; Cavenagh, JD; Ervin-Haynes, A; Facon, T; Gibson, CJ; Guo, S; Hulin, C; Nagarwala, Y; Nooka, A; Pelligra, CG; Usmani, SZ; White, D; Yiu, W | 1 |
| Cai, XY; Guo, XF; Guo, XL; Guo, XN; Ren, JH; Yang, DY; Zhang, JN | 1 |
| Choe, PG; Kim, BS; Kim, I; Kim, JW; Koh, Y; Kwon, JH; Min, CK; Mun, YC; Nam, SH; Park, WB; Park, Y | 1 |
| Bagratuni, T; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Kalapanida, D; Kastritis, E; Liacos, CI; Matsouka, C; Migkou, M; Mparmparousi, D; Tasidou, A; Terpos, E | 1 |
| Borsi, E; Brioli, A; Cangialosi, C; Castellani, G; Cavo, M; Ciambelli, F; De Sabbata, G; Dico, FA; Levi, G; Martello, M; Martinelli, G; Marzocchi, G; Offidani, M; Palumbo, A; Pantani, L; Patriarca, F; Pezzi, A; Proserpio, I; Remondini, D; Santacroce, B; Tacchetti, P; Terragna, C; Viganò, CV; Zamagni, E | 1 |
| Berardi, M; Biagioli, T; Bosi, A; Brogi, M; Caldini, A; Nozzoli, C; Staderini, M; Terreni, A | 1 |
| Brioli, A; Cavo, M; Mancuso, K; Martello, M; Pantani, L; Rizzello, I; Rocchi, S; Tacchetti, P; Terragna, C; Zamagni, E; Zannetti, BA | 1 |
| Attal, M; Avet-Loiseau, H; Dejoie, T; Harousseau, JL; Moreau, P | 1 |
| Duvic, M | 1 |
| Chen, W; Du, J; Fu, W; Hou, J; Huang, X; Liu, A; Lu, J | 1 |
| Cohen, A; Iakobishvili, Z; Itchaki, G; Kornowski, R; Magen, H; Muchtar, E; Raanani, P; Rosenfeld, R; Shochat, T | 1 |
| Alemayehu, WG; Bos, GM; Broijl, A; Cornelisse, PB; de Weerdt, O; Kersten, MJ; Levin, MD; Lokhorst, H; Meijer, E; Sonneveld, P; Stevens-Kroef, M; Tanis, BC; Vellenga, E; Wijermans, PW; Wittebol, S | 1 |
| Hellmich, M; Kuhr, K; Lehmacher, W; Srivastava, K; Wirth, D | 1 |
| Hagiwara, S; Iida, S; Ishida, T; Ito, A; Kanamori, T; Kato, C; Kinoshita, S; Komatsu, H; Kusumoto, S; Masuda, A; Murakami, S; Nakashima, T; Narita, T; Ri, M; Suzuki, N; Totani, H; Yoshida, T | 1 |
| Bouchnita, A; Eymard, N; Koury, MJ; Moyo, TK; Volpert, V | 1 |
| Cheah, CY; Seymour, JF; Wang, ML | 1 |
| Alignani, D; Barcena, P; Barlogie, B; Blade, J; Burgos, L; Corchete, LA; De Arriba, F; Echeveste, MA; Epstein, J; García-Sanz, R; Gironella, M; Gonzalez, Y; Hernandez, MT; Johnson, SK; Lahuerta, JJ; Maiso, P; Mateos, MV; Ocio, EM; Orfao, A; Oriol, A; Paiva, B; Palomera, L; Puig, N; Rodriguez, I; San Miguel, JF; Sanchez, ML; Vidriales, MB | 1 |
| Arai, N; Fujiwara, S; Homma, M; Kabasawa, N; Kawaguchi, Y; Kobayashi, K; Nakamaki, T; Okino, K; Shiozawa, E; Takimoto, M; Tate, G; Tazawa, S; Yamochi, T | 1 |
| Arnulf, B; Attal, M; Avet-Loiseau, H; Banos, A; Benbouker, L; Brechiniac, S; Caillot, D; Decaux, O; Escoffre-Barbe, M; Facon, T; Fermand, JP; Fouquet, G; Garderet, L; Hulin, C; Karlin, L; Kolb, B; Leleu, X; Macro, M; Marit, G; Mathiot, C; Moreau, P; Pegourie, B; Petillon, MO; Richez, V; Rodon, P; Roussel, M; Royer, B; Stoppa, AM; Wetterwald, M | 1 |
| Berkova, Z; Champlin, RE; Cleeland, C; Feng, L; Mendoza, TR; Orlowski, RZ; Qazilbash, MH; Shah, JJ; Thomas, SK; Wang, M; Weber, DM | 1 |
| Chang, H; Du, J; Fan, J; Fu, W; He, H; Hou, J; Jiang, H; Jin, L; Xi, H; Zeng, T; Zhang, C; Zhou, L | 1 |
| Berenson, JR; Bravin, E; Ibrahim, E; Masri, M; Spektor, TM; Swift, RA; Treisman, J; Udd, KA; Vidisheva, A; Wang, J | 1 |
| Rochau, U; Siebert, U; Weger, R; Willenbacher, E; Willenbacher, W | 1 |
| Li, Y; Wang, X; Yan, X | 1 |
| Berno, T; Cortelazzo, S; DE March, E; Marabese, A; Meneghini, V; Mian, M; Mondello, P; Patriarca, F; Pescosta, N; Pizzolo, G; Semenzato, G; Tinelli, M; Turri, G; Zambello, R | 1 |
| Hamid, G; Mojtahedi, K; Musavi, A; Soleimani, A; Soleymanian, T | 1 |
| Gentile, M; Martino, M; Morabito, F; Morabito, L; Recchia, AG; Vigna, E | 1 |
| Anderson, KC; Attal, M; Avet-Loiseau, H; Bladé, J; Caers, J; Chng, WJ; Durie, BG; Einsele, H; Goldschmidt, H; Hillengass, J; Kyle, RA; Lonial, S; Mateos, MV; Moreau, P; Orlowski, R; Palumbo, A; San Miguel, J; Siegel, D; Sonneveld, P; Usmani, S; van de Donk, NW | 1 |
| Allangba, O; Araujo, C; Attal, M; Avet-Loiseau, H; Belhadj, K; Biron, L; Brechignac, S; Caillon, H; Caillot, D; Chaleteix, C; Chaoui, D; Dejoie, T; Dib, M; Dorvaux, V; Eisenmann, JC; Escoffre, M; Facon, T; Fermand, JP; Fontan, J; Garderet, L; Glaisner, S; Godmer, P; Hulin, C; Jaccard, A; Kolb, B; Laribi, K; Lenain, P; Luycx, O; Macro, M; Malfuson, JV; Marit, G; Moreau, P; Pegourie, B; Planche, L; Puyade, M; Rodon, P; Roussel, M; Royer, B; Slama, B; Stoppa, AM; Tiab, M; Wetterwald, M | 1 |
| Jung, CK; Jung, Y; Kang, SW; Kim, BG; Kim, TH; Lee, SE; Lim, JY; Min, CK; Park, E; Park, J; Won, KA | 1 |
| Adami, F; Angelini, A; Cacciavillani, L; Cianci, A; De Lazzari, M; Fedrigo, M; Giorgi, B; Iliceto, S; Migliore, F; Perazzolo Marra, M; Tarantini, G; Thiene, G; Valente, M | 1 |
| Aagre, S; Anand, A; Madabhavi, I; Panchal, H; Parikh, S; Patel, A | 1 |
| Anderson, KC; Chauhan, D; Das, A; Das, DS; Oronsky, B; Ray, A; Richardson, P; Scicinski, J; Song, Y; Tian, Z | 1 |
| Borg, S; Elvidge, J; Hansson, M; Lee, D; Nahi, H; Persson, U | 1 |
| Chen, M; Dong, B; Dong, T; Guan, P; Li, J; Liu, T; Ma, H; Niu, T; Pan, L; Shuai, X; Valencia, CA; Wang, F; Wu, Y; Xiang, B; Xie, L; Zhang, L; Zhu, H; Zou, X | 1 |
| Chinen, Y; Fushiki, S; Horiike, S; Kiyota, M; Kobayashi, T; Kuroda, J; Maegawa, S; Mizutani, S; Nagoshi, H; Sasaki, N; Shimura, Y; Tando, S; Taniwaki, M; Tatekawa, S; Tsukamoto, T | 1 |
| An, N; Huang, ZX; Jiang, XX; Li, X; Shen, M; Zhang, JJ | 1 |
| Christoulas, D; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Fotiou, D; Gavriatopoulou, M; Iakovaki, M; Kanellias, N; Kastritis, E; Migkou, M; Panagiotidis, I; Terpos, E; Ziogas, DC | 1 |
| Atalla, A; Castro, TB; Hallack Neto, AE; Ribeiro, LC | 1 |
| Montefusco, V; Musto, P | 1 |
| Nagy, Z | 1 |
| Bostrom, B; Vundamati, D | 1 |
| Chen, W; Gao, S; Huang, L; Shu, C; Xia, T; Zeng, T; Zhang, F | 1 |
| Hollmann, S; LeBlanc, R; Tay, J | 1 |
| Ahn, JS; Cho, MS; Choi, HJ; Hwang, EC; Jung, SH; Jung, TY; Kim, HJ; Kim, YK; Lee, JJ; Lee, SS; Shin, MG; Yang, DH | 1 |
| Gotoh, N; Handa, H; Ino, R; Kasamatsu, T; Matsumoto, M; Mitsui, T; Murakami, H; Saitoh, T; Sawamura, M; Shimizu, H; Tsukamoto, N; Yokohama, A | 1 |
| Moreau, P; Rajkumar, SV | 1 |
| Hogan, JJ; Weiss, BM | 1 |
| Callander, NS; Dreosti, LM; Fonseca, R; Jacobus, SJ; Lacy, MQ; Rajkumar, SV; Stadtmauer, EA; Stewart, AK; Weiss, M | 1 |
| Alapat, D; Avery, D; Bailey, C; Barlogie, B; Crowley, J; Epstein, J; Heuck, CJ; Hoering, A; Jethava, Y; Khan, R; Mitchell, A; Morgan, G; Petty, N; Sawyer, J; Schinke, C; Smith, R; Stein, C; Steward, D; Thanendrarajan, S; Tian, E; van Rhee, F; Waheed, S; Yaccoby, S; Zangari, M | 1 |
| Iqbal, N; Majid, H; Shaikh, MU; Tariq, MU | 1 |
| Buadi, FK; Chakraborty, R; Dingli, D; Dispenzieri, A; Gertz, MA; Hayman, SR; Hogan, WJ; Kapoor, P; Kumar, S; Lacy, MQ; Leung, N; Muchtar, E | 1 |
| Gray, E; Krishna, A; Majer, I; Polanyi, Z; Roy, A; van de Wetering, G | 1 |
| Delforge, M; Kint, N | 1 |
| Lee, HS; Min, CK | 1 |
| Alcoceba, M; Barrio, S; Blanchard, MJ; Chillon, MC; Corchete, LA; de la Rubia, J; García-Álvarez, M; García-Sanz, R; González Díaz, M; Jiménez, C; Lahuerta, JJ; Martínez, R; Martínez-López, J; Mateos, MV; Oriol, A; Prieto, I; Puig, N; Rapado, I; San Miguel, JF; Sarasquete, ME | 1 |
| Dimopoulos, MA; Gavriatopoulou, M; Kastritis, E; Terpos, E | 2 |
| Abudayyeh, A; Doshi, M; Edeani, A; Glezerman, IG; Jhaveri, KD; Monga, D; Rosner, M; Wanchoo, R | 1 |
| Aghemo, E; Corvatta, L; Gay, F; Gentili, S; Maracci, L; Offidani, M; Palumbo, A | 1 |
| An, N; Chen, SL; Huang, ZX; Li, X; Shen, M | 1 |
| Fujimi, A; Hashimoto, A; Hirayama, Y; Horiguchi, H; Ibata, S; Iyama, S; Kamihara, Y; Kato, J; Kobune, M; Konuma, Y; Kuroda, H; Miyanishi, K; Murase, K; Nagamachi, Y; Ono, K; Sato, T; Takada, K; Tatekoshi, A; Yoshida, M | 1 |
| Cartia, CS; Cazzola, M; Cocito, F; Corso, A; Ferretti, V; Klersy, C; Mangiacavalli, S; Pompa, A; Varettoni, M | 1 |
| Lipe, B; Mikhael, J; Vukas, R | 1 |
| Asante, D; Buadi, FK; Herrmann, J; Lerman, A; Reneau, JC; Sangaralingham, LR; van Houten, H | 1 |
| Bier, G; Fritz, J; Horger, M; Ioanoviciu, SD; Kum, S; Schabel, C; Weisel, K | 1 |
| Brown, SR; Cavenagh, J; Cook, G; Flanagan, L; Gregory, W; Hall, A; Kishore, B; Low, E; Oakervee, H; Popat, R; Streetly, M; Yong, K | 2 |
| Chao, NJ; Gasparetto, C; Green, MM; Horwitz, ME; Kang, Y; Li, Z; Long, GD; Lopez, RD; Rizzieri, DA; Sarantopoulos, S; Sivaraj, D; Sullivan, KM; Sung, AD | 1 |
| Akashi, K; Aoki, T; Ito, Y; Iwasaki, H; Kamezaki, K; Kamimura, T; Kato, K; Kikushige, Y; Miyamoto, T; Mori, Y; Shima, T; Takenaka, K; Tochigi, T; Yamauchi, T; Yoshimoto, G | 1 |
| Boccadoro, M; Bringhen, S; Corvatta, L; Gay, F; Gentili, S; Larocca, A; Leoni, P; Maracci, L; Offidani, M; Troia, R | 1 |
| Cavo, M; Mancuso, K; Pantani, L; Pezzi, A; Rizzello, I; Rocchi, S; Tacchetti, P; Zamagni, E; Zannetti, BA | 1 |
| Berenson, A; Berenson, JR; David, M; Eades, B; Eshaghian, S; Gottlieb, J; Halleluyan, R; Harutyunyan, NM; Nassir, Y; Spektor, TM; Swift, R; Udd, KA; Vardanyan, S; Wang, J | 2 |
| Boyd, KD; Cairns, DA; Collett, C; Cook, G; Davies, FE; Drayson, MT; Gregory, WM; Henderson, R; Jackson, GH; Jenner, M; Jones, JR; Kaiser, MF; Kishore, B; Lindsay, J; Morgan, GJ; Owen, RG; Pawlyn, C; Pratt, G; Russell, NH; Sigsworth, R; Striha, A; Williams, C | 1 |
| Agarwal, A; Bhutani, M; Chow, E; Friend, R; Usmani, SZ; Voorhees, PM | 1 |
| Bringhen, S; Di Raimondo, F; Gay, F; Gentile, M; Grazia Recchia, A; Greco, R; Larocca, A; Magarotto, V; Morabito, F; Musto, P; Offidani, M; Palumbo, A; Petrungaro, A; Ria, R; Teresa Petrucci, M; Tripepi, G; Uccello, G; Vigna, E | 1 |
| Rajan, AM; Rajkumar, SV | 1 |
| Bello, A; Dodge, R; Gibiansky, L; Gupta, M; Mora, J; Passey, C; Roy, A; Sheng, J | 1 |
| Deng, M; Lin, Q; Mei, Z; Song, Y; Yang, J; Yin, Q; Zhu, X; Zuo, W | 1 |
| Barilà, G; Bonaldi, L; Cabrelle, A; Carrino, M; Costacurta, M; Gianesin, K; Macaccaro, P; Manni, S; Manzoni, M; Martines, A; Neri, A; Nunes, SC; Piazza, F; Semenzato, G; Taiana, E; Trentin, L; Tubi, LQ; Zambello, R | 1 |
| Boudreault, JS; Moreau, P; Touzeau, C | 1 |
| Alegre, A; Bladé, J; Blanchard, M; Cibeira, M; de Arriba, F; de la Guía, AL; de la Rubia, J; Etxebeste, M; González, Y; Granell, M; Hernández, MT; Lahuerta, JJ; Martínez-López, J; Martínez-Martínez, R; Mateos, M; Oriol, A; Palomera, L; Rosiñol, L; Sampol, M; San Miguel, J; Teruel, AI | 1 |
| Basset, M; Foli, A; Merlini, G; Milani, P; Palladini, G; Perlini, S; Russo, F | 2 |
| Blommestein, HM; Franken, MG; Sonneveld, P; Uyl-de Groot, CA; van Beurden-Tan, CHY | 1 |
| Abderrahim, K; Amina, BB; Asma, A; Bechir, A; Emna, B; Haifa, R; Mondher, K; Mrabet, S; Nesrine, BS; Senda, M; Yosra, BY | 1 |
| Arnould, B; Bacon, P; Gilet, H; Kyriakou, C; Leleu, X; Lewis, P; Murphy, P; Petrucci, MT; Vande Broek, I | 1 |
| Banerjee, D; Bhattacharyya, M; Kalantri, SA; Nath, UK | 1 |
| Garderet, L; Malard, F; Mohty, M; Savani, BN; Sengsayadeth, S | 1 |
| Carrasco, V; Cases, E; Gómez Gonzalez, C; Lázaro Sierra, J | 1 |
| Anderson, KC; Arnulf, B; Attal, M; Avet-Loiseau, H; Belhadj, K; Caillot, D; Escoffre, M; Facon, T; Fermand, JP; Garderet, L; Harousseau, JL; Hulin, C; Lauwers-Cances, V; Leleu, X; Macro, M; Maglio, ME; Mathiot, C; Meuleman, N; Moreau, P; Munshi, N; Payen, C; Richardson, PG; Rollet, S; Roussel, M; Weller, EA; Zeytoonjian, AA | 1 |
| Goldschmidt, H; Kellermann, L; Knauf, W; Kohnke, J; Merz, M; Poenisch, W; Tischler, HJ | 1 |
| Abe, N; Bohgaki, M; Kasahara, H; Koike, T; Tomita, T | 1 |
| Aguiar, PM; Colleoni, GWB; de Mendonça Lima, T; Storpirtis, S | 1 |
| Guan, HM; Wang, S | 1 |
| Chen, JF; Li, YX; Meng, XY; Xiao, LF; Zeng, ZH; Zhang, R | 1 |
| Davidoff, AJ; Dusetzina, SB; Eaton, CB; Olszewski, AJ; Trivedi, AN | 1 |
| de Wit, E; Moreau, P | 1 |
| Cao, Z; Tian, C; Yang, H; Zhang, Q; Zhang, Y; Zhu, L | 1 |
| Bouscary, D; Chavarot, N; Karras, A; Lebbe, C; Thervet, E | 1 |
| Cook, M; Denman, J; Manavi, K | 1 |
| Bittencourt, RI; Pilger, DA; Silla, L; Vigolo, S; Zuckermann, J | 1 |
| Braga, WMT; Colleoni, GWB; Davies, FE; de Carvalho, MF; de Oliveira, MB; Eugenio, AIP; Fernando, RC; Fook-Alves, VL; Sanson, LFG | 1 |
| Abildgaard, N; Christian Frølund, U; Frost Andersen, N; Gimsing, P; Helleberg, C; Helm-Petersen, S; Juul Vangsted, A; Kjeldsen, E; Klarskov Andersen, M; Klausen, T; Pedersen, P; Preiss, B; Svirskaite, A; Thidemann Andersen, K | 1 |
| Bertsch, U; Blau, IW; Bos, GMJ; Broijl, A; Brossart, P; Croockewit, S; Duehrsen, U; Goldschmidt, H; Hielscher, T; Hillengass, J; Hose, D; Jarari, L; Jauch, A; Kersten, MJ; Lindemann, HW; Lokhorst, HM; Mai, EK; Pfreundschuh, M; Potamianou, A; Raab, MS; Raymakers, R; Salwender, HJ; Schaafsma, RM; Scheid, C; Sonneveld, P; Stevens-Kroef, M; van der Holt, B; van Marwijk Kooy, M; Vellenga, E; Weisel, KC; Ypma, P; Zweegman, S | 1 |
| Chan, W; Chen, Y; Du, XL; Lairson, DR | 1 |
| Cho, H; Do, YR; Eom, HS; Jo, JC; Kang, HJ; Kim, JS; Kim, K; Kim, SY; Lee, HS; Lee, JB; Lee, JH; Lee, JJ; Lee, WS; Min, CK; Moon, JH; Mun, YC; Park, Y; Shin, HJ; Suh, C; Yoon, DH | 1 |
| Bhatnagar, V; Farrell, AT; Goldberg, KB; Gormley, NJ; Luo, L; Ma, L; McKee, AE; Pazdur, R; Shen, G; Shen, YL; Shord, S; Sridhara, R; Subramaniam, S | 1 |
| Al, MJ; Albuquerque de Almeida, F; Armstrong, N; Büyükkaramikli, NC; de Groot, S; Fayter, D; Kleijnen, J; Stirk, L; Wolff, R; Worthy, G | 1 |
| Advani, P; Ailawadhi, S; Chanan-Khan, AA; Colibaseanu, DT; Colon-Otero, G; Frank, RD; Hashmi, SK; Hodge, DO; Kakar, TS; Khera, N; Meghji, Z; Menghani, R; Paulus, A; Paulus, S; Roy, V; Sharma, M; Swaika, A; Temkit, M; Vizzini, MR | 1 |
| Blair, HA | 1 |
| Belch, A; Diels, J; Ito, T; Oriol, A; Van Sanden, S; Vogel, M | 1 |
| Avivi, I; Cohen, Y; Duek, A; Gatt, ME; Leiba, M; Shaulov, A | 1 |
| Ding, JY; Huang, QC | 1 |
| Bennani, B; Berrady, R; Khammar, Z; Ouazzani, M; Oubelkacem, N | 1 |
| Blaedel, J; DeCosta, L; Goldschmidt, H; Leleu, X; Mateos, MV; Mikhael, J; Obreja, M; San-Miguel, J; Szabo, Z; Zhou, L | 1 |
| Hoshino, K; Imai, G; Kojima, M; Ooi, A; Takemori, N | 1 |
| Arredondo-Campos, D; Cantú-Rodríguez, O; Gómez-Almaguer, D; Gómez-De León, A; Gutiérrez-Aguirre, CH; Jaime-Pérez, JC; Martínez-González, O; Martínez-Pacheco, V; Ramírez-López, A; Tarín-Arzaga, L | 1 |
| Ando, K; Asai, H; Hanamura, I; Iida, S; Inoue, Y; Kikukawa, Y; Kobayashi, M; Kuroda, J; Kusumoto, S; Maruyama, D; Masaki, Y; Miyamoto, K; Nagai, H; Shimada, K; Takatsuka, Y; Tobinai, K; Tsukamoto, N; Tsukasaki, K; Wakabayashi, M; Yamamoto, K | 1 |
| Baaj, ME; Doghmi, K; Eddou, H; Maaroufi, HE; Mikdame, M; Moudden, MK; Zinebi, A | 1 |
| Bourquard, P; Chevallier, T; Cousin, C; Dubois, F; Favier, M; Favier-Archinard, C; Le Gall, T; Leguelinel-Blache, G; Passemard, N; Rey, A; Rossi, M; Tora, S | 1 |
| Abraham, I; Anwer, F; Iftikhar, A; Kapoor, V; Latif, A; McBride, A; Mushtaq, A; Riaz, IB; Zahid, U | 1 |
| Guo, HM; Liu, XJ; Luo, JM; Nie, ZY; Sun, L; Yang, L | 1 |
| Alani, M; Laribi, K; Lemaire, P | 1 |
| Dimopoulos, MA; Gavriatopoulou, M; Migkou, M; Terpos, E | 1 |
| Bouwmeester, W; Campioni, M; DeCosta, L; Fraňková, H; Gonzalez-McQuire, S; Gregora, E; Hájek, R; Jarkovsky, J; Kessler, P; Maisnar, V; Minařík, J; Pour, L; Špička, I; Sýkora, M; Treur, M | 1 |
| Litwinska, Z; Luczkowska, K; Machalinski, B; Paczkowska, E | 1 |
| Lai, T; Li, F; Mei, JG; Song, P; Wang, LP; Zhai, YP; Zhao, Q; Zhou, XG | 1 |
| Fu, LP; Ji, Y; Li, CS; Zhang, WP | 1 |
| Nohgawa, M; Oka, S; Ono, K | 1 |
| Anderson, DF; Karmiris, E; Turnbull, AMJ | 1 |
| Abadi, U; Bekadja, MA; Beksac, M; Berthou, C; Boccadoro, M; Borbényi, Z; Cavo, M; Černelč, P; Corso, A; Couturier, C; De Stefano, V; Dimopoulos, M; Durán, MS; Feys, C; Kochkareva, Y; Laane, E; Legiec, W; Lejniece, S; Louw, V; Masliak, Z; Mateos, MV; Mohty, M; Nemet, D; Pečeliūnas, V; Pedersen, RS; Potamianou, A; Salwender, H; Silva, J; Stankovic, S; Terpos, E; Thoret-Bauchet, F; Willenbacher, W | 1 |
| Chen, X; Feng, J; Gao, G; Shen, H; Tang, H; Xu, L; Zhang, N; Zheng, Y | 1 |
| Tomlinson, R | 1 |
| Chehab, S; Gleason, C; Lonial, S; Nooka, AK; Panjic, EH | 1 |
| Aitini, E; Andriani, A; Angelucci, E; Annibali, O; Baraldi, A; Bernardini, A; Boccadoro, M; Bringhen, S; Centurioni, R; De Stefano, V; Di Renzo, N; Evangelista, A; Ferrando, P; Grammatico, S; Larocca, A; Marcatti, M; Meneghini, V; Musto, P; Offidani, M; Palmas, A; Palmieri, S; Palumbo, A; Pisani, F; Rizzi, R; Rocco, S; Siniscalchi, A; Spada, S; Storti, S; Vallone, R | 1 |
| Korubo, KI; Madu, AJ; Nwogoh, B; Okoye, HC | 1 |
| Balayssac, D; Chaleteix, C; Collin, A; Condé, S; Guastella, V; Kerckhove, N; Pezet, D | 1 |
| Boise, LH; Dhodapkar, MV; Gleason, C; Gupta, VA; Heffner, LT; Hofmeister, CC; Joseph, NS; Kaufman, JL; Lonial, S; Mina, R; Nooka, AK | 1 |
| Adami, F; Angelini, A; Berno, T; Calò, LA; Riva, M; Vertolli, U | 1 |
| Belch, A; Capra, M; Clemens, PL; Dimopoulos, MA; Gomez, D; Ho, PJ; Iida, S; Jansson, R; Leiba, M; Medvedova, E; Min, CK; Schecter, J; Sonneveld, P; Sun, YN; Xu, XS; Zhang, L | 1 |
| Ganly, P; Hock, BD; MacPherson, SA; McKenzie, JL; Mulholland, KS; Pearson, JF | 1 |
| Bailly, S; Croizier, C | 1 |
| Badiali, S; Billio, A; Cappelletto, PC; Cortelazzo, S; Luminari, S; Marabese, A; Marcheselli, L; Mian, M; Mondello, P; Pascarella, A; Patriarca, F; Pescosta, N; Tagariello, G; Zambello, R | 1 |
| Wang, CY; Wang, L; Wang, XF; Wang, YF; Xia, B; Xu, YJ; Yang, HL; Yu, Y; Zhang, YZ; Zhao, HF | 1 |
| Breitkreutz, I; Goldschmidt, H; Raab, M | 1 |
| Chen, W; Huang, X; Ren, G; Zuo, K | 1 |
| Nougawa, M; Oka, S; Shimazu, Y; Shiragami, H; Takeuchi, S | 1 |
| Blommestein, HM; Franken, MG; Sonneveld, P; Uyl-de Groot, CA; van Beurden-Tan, CHY; Zweegman, S | 1 |
| Gertz, M; Vaxman, I | 1 |
| Chen, HM; Chen, XL; Peng, R; Shi, HT; Wei, W; Wu, LX; Zhou, F; Zhou, N | 1 |
| Antunes, L; Bento, MJ; Chacim, S; Lefèvre, C; Pereira, M; Pereira, S; Rocha-Gonçalves, F; Zagorska, A | 1 |
| An, G; Deng, SH; Feng, XY; Li, ZJ; Liu, LT; Lv, R; Ma, YP; Qin, XQ; Qin, Y; Qiu, LG; Sui, WW; Wang, TY; Xu, Y; Yang, LH; Yang, WJ; Yi, SH; Zang, MR; Zhang, YR; Zhao, YZ; Zou, DH | 1 |
| Roussel, M; Royer, B; Talbot, A | 1 |
| Adachi, Y; Akashi, K; Choi, I; Fuchida, SI; Fujishima, N; Harada, M; Kiguchi, T; Kuroda, Y; Maeda, A; Matsumoto, M; Miyamoto, T; Nagafuji, K; Nakazato, T; Omoto, E; Sunami, K; Suzumiya, J; Takamatsu, H; Takamatsu, Y; Yamamura, R; Yujiri, T | 1 |
| Li, S; Mengzhen, L; Ren, L; Wang, S; Wang, X; Xia, B; Yang, K; Yang, R; Zhang, Y | 1 |
| Dingli, D; Mishra, AK | 1 |
| Dispenzieri, A | 1 |
| Boise, LH; Gleason, C; Gupta, VA; Heffner, LT; Joseph, NS; Kaufman, JL; Lonial, S; Nooka, AK | 1 |
| Gay, F; Mina, R | 1 |
| Abdul-Hay, M; Naymagon, L | 1 |
| Cao, Y; Jiang, J; Liang, Z; Lin, T; Wan, N; Wang, S; Xie, J; Zhang, T | 1 |
| Hofmeister, CC; Kaufman, JL; Lonial, S; Nooka, A | 1 |
| Ahmadi, T; Arnulf, B; Attal, M; Avet-Loiseau, H; Belhadj, K; Benboubker, L; Béné, MC; Broijl, A; Caillon, H; Caillot, D; Chiu, C; Corre, J; de Boer, C; Dejoie, T; Delforge, M; Deraedt, W; Doyen, C; Escoffre-Barbe, M; Eveillard, JR; Facon, T; Fermand, JP; Fontan, J; Garderet, L; Garidi, R; Hulin, C; Jie, KS; Kampfenkel, T; Karlin, L; Klein, SK; Kolb, B; Kuhnowski, F; Lambert, J; Leleu, X; Lenain, P; Levin, MD; Macro, M; Marolleau, JP; Mathiot, C; Meuleman, N; Moreau, P; Orsini-Piocelle, F; Pei, L; Perrot, A; Roussel, M; Schecter, J; Smith, E; Sonneveld, P; Sonntag, C; Stoppa, AM; Tiab, M; Touzeau, C; van de Donk, NW; Vekemans, MC; Vermeulen, J; Westerman, M; Wuilleme, S; Zhuang, S; Zweegman, S | 1 |
| Killock, D | 1 |
| Chen, W; Lu, J | 1 |
| Alfaro, V; Banh, RH; Cannell, P; Carella, AM; D'Rozario, JM; Dimopoulos, MA; Extremera, S; Greil, R; Hájek, R; Huang, SY; Kahatt, C; Ludwig, H; Martínez, S; Mateos, MV; Meuleman, N; Min, CK; Oakervee, HE; Ocio, EM; Sonneveld, P; Spicka, I; Symeonidis, A | 1 |
| Chai, K; Chan, H; Chen, K; Jackson, S; Lewsey, R; McDiarmid, B; Shih, S; Simpson, D | 1 |
| Huang, J; Su, H; Sun, C; Xiong, J; Zhang, C | 1 |
| Bae, SH; Jo, JC; Jung, SH; Kim, K; Kim, MK; Kim, SJ; Lee, HS; Lee, JH; Lee, JJ; Lee, WS; Lee, YJ; Min, CK; Moon, JH; Shin, HJ; Sohn, SK | 1 |
| Ammann, EM; Barreyro, P; Cao, C; Chen, YW; Cugliari, MS; de Moraes Hungria, VT; Duarte, FB; Fernandez, M; Grings, M; Lin, JH; Machnicki, G; Martínez-Baños, DM; Miguel, CE; Peñafiel, CR; Remaggi, G; Santos, T; Vela-Ojeda, J; Wong, YN | 1 |
| Giuliani, N; Malavasi, F | 1 |
| An, Z; Guo, X; Li, F; Li, H; Mei, J; Shao, J; Song, P; Wang, X; Zhai, Y; Zhao, Q; Zhou, X | 1 |
| Das, BP; Das, S; Jena, RK; Panda, T; Rout, SB | 1 |
| Falcetta, FS; Manica, D; Morais, VD; Pithan, CDF; Ribeiro, MR; Ribeiro, RA; Salazar, AP; Sekine, L; Sosnoski, M; Ziegelmann, PK | 1 |
| Cavo, M; Dimopoulos, MA; Facon, T; Gebregergish, SB; Heeg, B; Lam, A; Mateos, MV; Nair, S; Pisini, M; Slavcev, M; van Beekhuizen, S | 1 |
| Buchanan, V; D'Souza, VK; Dhanasiri, S; Ramasamy, K; Robinson, S; Thom, H; Weisel, K | 1 |
| Kimball, A; Klippel, Z; Tekle, C | 1 |
| Adams, A; Estcourt, LJ; Jakob, T; Kuhr, K; Langer, P; Monsef, I; Ocheni, S; Piechotta, V; Scheckel, B; Scheid, C; Skoetz, N; Theurich, S | 1 |
| Jin, J; Li, F; Lin, P; Liu, L; Lou, Y; Meng, H; Wang, H; Wang, J; Xu, H; Yang, M; Zhou, Y | 1 |
| Eom, HS; Jung, KS; Kim, HJ; Kim, JS; Kim, K; Kim, SH; Lee, JJ; Lee, JO; Min, CK; Shin, HJ | 1 |
| Adam, Z; Boichuk, I; Brozova, L; Krejci, M; Pour, L; Sandecká, V; Sevcikova, S; Stork, M | 1 |
| Barlogie, B; Mouhieddine, TH; Teruya-Feldstein, J | 1 |
| Choi, CW; Eom, HS; Kang, HJ; Kim, I; Kim, JS; Kim, K; Kim, MK; Kim, SJ; Lee, HS; Lee, JJ; Lim, SN; Min, CK; Mun, YC; Shin, HJ; Suh, C; Yoon, DH; Yoon, SS | 1 |
| Boggio, E; Bruna, R; Crisà, E; De Paoli, L; Dianzani, U; Gaidano, G; Gigliotti, L; Margiotta Casaluci, G; Moia, R; Patriarca, A; Rolla, R | 1 |
| Gau, YC; Hsiao, HH; Liu, YC; Yeh, TJ | 1 |
| Bernhard, H; Bertsch, U; Blau, IW; Brossart, P; Dürig, J; Elmaagacli, A; Fuhrmann, S; Giesen, N; Goerner, M; Goldschmidt, H; Hänel, M; Hielscher, T; Hillengass, J; Hoffmann, M; Hose, D; Hügle-Dörr, B; Huhn, S; Jauch, A; Kunz, C; Lindemann, HW; Luntz, S; Mai, EK; Merz, M; Munder, M; Raab, MS; Rabold, B; Salwender, HJ; Scheid, C; Seckinger, A; Tichy, D; Weisel, KC | 1 |
| Cantero-Fortiz, Y; Cruz-Mora, A; García-Navarrete, YI; León-Peña, A; Murrieta-Álvarez, I; Olivares-Gazca, JC; Olivares-Gazca, M; Ruiz-Argüelles, A; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ; Steensma, DP | 1 |
| Djebbari, F; Eyre, TA; Kothari, J; McLain-Smith, S; Moore, S; Ramasamy, K; Sharpley, FA; Vallance, G | 1 |
| Chung, DJ; Diamond, B; Lesokhin, AM; Maclachlan, K; Ola Landgren, C | 1 |
| Lesokhin, AM; Wills, B; Wudhikarn, K | 1 |
| Diamond, B; Hillengass, J; Kazandjian, D; Landgren, CO; Maclachlan, K; Maura, F; Turesson, I | 1 |
| Lu, SX | 1 |
| Aryal, M; Chhabra, S; D'Souza, A; Dhakal, B; Ghose, S; Giri, S; Hamadani, M; Hari, PN; Janz, S; Narra, RK; Pathak, LK; Smunt, TL; Szabo, A | 1 |
| Kassir, N; Li, Y; Palmisano, M; Wang, X; Zhou, S | 1 |
| Daguenet, E; Fouillet, L; Guyotat, D; Laurent, B; Le Jeune, C; Sapet, M | 1 |
| Corzo, A; Duarte, P; Fantl, D; Fernández, V; García, CA; Lopresti, S; Ochoa, P; Orlando, S; Quiroga, L; Remaggi, G; Schütz, NP; Shanley, C; Verri, V; Yantorno, S; Zabaljauregui, S | 1 |
| Aoki, G; Notsumata, K; Okafuji, K; Sawazaki, A; Toya, D; Ushiogi, Y | 1 |
| Anttila, P; Basu, S; Ben-Yehuda, D; Biyukov, T; Byeff, P; Cascavilla, N; Dhanasiri, S; Dimopoulos, M; Grote, L; Guo, S; Hayden, PJ; Hus, M; Johnson, P; Kanate, AS; Krauth, MT; Larocca, A; Lucio, P; Mendeleeva, L; Moreau, P; Muelduer, E; Richardson, P; Rodríguez-Otero, P; Vural, F; Weisel, K; Yagci, M; Yu, X | 1 |
| Biyukov, T; Matsue, K; Peluso, T; Richardson, P; Sakurai, S; Shinagawa, A; Sunami, K; Suzuki, K; Takezako, N; Tamakoshi, H | 1 |
| Bachour, J; El Gemayel, M; Haber, R | 1 |
| Arnall, JR; Janes, A; Moore, DC; Pineda-Roman, M | 1 |
| Tsukada, N | 1 |
| Hagiwara, S; Hirai, R; Miwa, A; Nakamura, M; Sekine, R; Takeshita, M; Tanimura, A; Togano, T | 1 |
| Chen, Y; Cutter, D; Loh, Y; Master, Z; Mikhaeel, G; Nagarajan, C; Thitsar, SM; Tin, KM; Yeoh, KW | 1 |
| Ii, Y; Ishikawa, H; Kawada, N; Matsuura, K; Matsuyama, H; Mizutani, M; Sakano, S; Shindo, A; Tomimoto, H | 1 |
| Bonferroni, M; Castellino, A; Castellino, C; Celeghini, I; Drandi, D; Elba, S; Foglietta, M; Fraternali Orcioni, G; Giordano, F; Grasso, M; Massaia, M; Mattei, D; Mordini, N; Rapezzi, D; Soriasio, R; Strola, G | 1 |
| Bury-Kamińska, M; Homa-Mlak, I; Hus, M; Krawczyk, J; Kuśmierczuk, K; Mazurek, M; Małecka-Massalska, T; Mielnik, M; Mlak, R; Podgajna, M; Szczyrek, M; Szudy-Szczyrek, A | 1 |
| Iftikhar, R; Mahmood, SK; Rehman, JU; Satti, TM; Shamshad, GU; Toor, SH | 1 |
| Einsele, H; Grathwohl, D; Kortüm, KM; Krummenast, F; Leicht, HB; Meckel, K; Nickel, K; Rasche, L; Steinhardt, MJ; Zhou, X | 1 |
| Cairns, DA; Collett, C; Cook, G; Davies, FE; Drayson, MT; Garg, M; Gregory, WM; Jackson, GH; Jenner, MW; Jones, JR; Kaiser, MF; Karunanithi, K; Kishore, B; Lindsay, J; Morgan, GJ; Owen, RG; Pawlyn, C; Russell, NH; Striha, A; Taylor, C; Waterhouse, A; Williams, CD; Wilson, J | 1 |
| Kasinathan, G | 1 |
| Antier, C; Blin, N; Chevallier, P; Cormier, N; Dubruille, V; Dupuis, P; Fronteau, C; Garnier, A; Gastinne, T; Godmer, P; Guillaume, T; Laurent, V; Le Bourgeois, A; Le Gouill, S; Loirat, M; Lok, A; Mahé, B; Moreau, P; Peterlin, P; Sadot, S; Tessoulin, B; Tiab, M; Touzeau, C; Trebouet, A; Vantyghem, S | 1 |
| Hou, HA; Liu, Y; Qiu, H; Tang, CH | 1 |
| Anderson, LD; Biyukov, T; Casal, E; Corso, A; Dimopoulos, M; Dürig, J; Engelhardt, M; Jenner, M; Moreau, P; Nguyen, TV; Pavic, M; Peluso, T; Richardson, P; Salomo, M; San-Miguel, J; Sonneveld, P; Srinivasan, S; Weisel, K; White, D; Yu, X | 1 |
| Lamb, YN | 1 |
| Dourado, C; Gupta, S; Swaminathan, N | 1 |
| Ahmed, Z; Anwer, F; Ashraf, A; Ehsan, H; Faisal, MS; Khakwani, M; Khan, A; Mushtaq, K; Rafae, A; Rehan, T; Shah, Z; Wahab, A | 1 |
| Gagelmann, N; Kröger, N | 1 |
| Bai, M; Liu, B; Ning, X; Sun, S; Wang, D; Wang, Y; Zhao, J; Zhou, M | 1 |
| Berenson, JR; Eades, B; Emamy-Sadr, M; Regidor, B; Spektor, TM; Swift, R; Tarhini, F | 1 |
| van de Donk, NWJC; Zweegman, S | 1 |
| Barbato, S; Boccadoro, M; Cangialosi, C; Catalano, L; Cavo, M; Cellini, C; Ciambelli, F; Crippa, C; De Sabbata, G; Di Raimondo, F; Dozza, L; Elice, F; Galieni, P; Galli, M; Gobbi, M; Lazzaro, A; Marzocchi, G; Montefusco, V; Musto, P; Narni, F; Pantani, L; Patriarca, F; Pescosta, N; Petrucci, MT; Ronconi, S; Spadano, A; Tacchetti, P; Terragna, C; Testoni, N; Tosi, P; Zamagni, E | 1 |
| Broijl, A; de Boer, C; Dib, M; Dorvaux, V; Fastenau, J; Frenzel, L; Gries, KS; Hebraud, B; Jaccard, A; Jie, KS; Kampfenkel, T; Klein, SK; Laribi, K; Moreau, P; Roussel, M; Royer, B; Slama, B; Sonneveld, P; Vanquickelberghe, V; Wang, J; Zweegman, S | 1 |
| Abildgaard, N; Axelsson, P; Blimark, C; Hansson, M; Haukas, E; Hieu Do, T; Klein, SK; Klostergaard, A; Knut-Bojanowska, D; Levin, MD; Leys, RBL; Mellqvist, UH; Poddighe, PJ; Salomo, M; Schjesvold, FH; Sonneveld, P; Stege, CAM; Stevens-Kroef, M; Svirskaite, A; Szatkowski, D; van de Donk, NWCJ; van der Holt, B; van der Spek, E; Waage, A; Ypma, PF; Zweegman, S | 1 |
| van de Donk, NWCJ | 1 |
| Korst, CLBM; van de Donk, NWCJ | 1 |
| Baker, B; Chan, H; Chien, N; Goodman, H; Romeril, K | 1 |
| Bal, S; Costa, LJ; Giri, S; Godby, KN | 1 |
| Hou, HA; Liu, Y; Qiu, H; Siggins, S; Tang, CH | 1 |
| Barchnicka, A; Bednarczyk, M; Grosicka, O; Grosicki, S | 1 |
| Andriani, A; Annibali, O; Antolino, G; Cantonetti, M; Cimino, G; Coppetelli, U; De Rosa, L; De Stefano, V; di Toritto, TC; La Verde, G; Petrucci, MT; Piciocchi, A; Rizzo, M; Siniscalchi, A; Vozella, F; Za, T | 1 |
| Belhadj, K; Benboubker, L; Caillot, D; De Boer, C; Facon, T; Garderet, L; Hulin, C; Jie, KS; Kampfenkel, T; Kolb, B; Kuhnowski, F; Lambert, J; Moreau, P; Offner, F; Pei, L; Roussel, M; Sonneveld, P; Stoppa, AM; Tiab, M; Van de Donk, NWCJ; Vanquickelberghe, V; Vermeulen, J; Westerman, M | 1 |
| Gómez-Almaguer, D; Ruiz-Argüelles, GJ | 1 |
| Delforge, M; Kint, N; Vlayen, S | 1 |
| Cheng, CN; Huang, ST; Huang, SY; Lien, PW; Lin, FJ | 1 |
| Aslam, M; Atenafu, EG; Cherniawsky, H; Gul, E; Jimenez-Zepeda, VH; Kotb, R; LeBlanc, R; Louzada, ML; Masih-Khan, E; McCurdy, A; Reece, DE; Reiman, A; Sebag, M; Song, K; Stakiw, J; Venner, CP; White, D | 1 |
| Brožová, L; Hájek, R; Heindorfer, A; Jelínek, T; Jungová, A; Kessler, P; Maisnar, V; Minařík, J; Pavlíček, P; Pika, T; Pour, L; Radocha, J; Sandecká, V; Ševčíková, S; Špička, I; Starostka, D; Stejskal, L; Štork, M; Straub, J; Sýkora, M; Ullrychová, J; Wróbel, M | 1 |
| Aliaga, K; Casanova, L; Quintana, S; Ruiz, R; Valencia, F; Vasquez, J; Vidaurre, T; Villena, M | 1 |
| Aisa, Y; Fujisawa, S; Hagihara, M; Higashihara, M; Hua, J; Inoue, M; Irie, S; Ishii, R; Kobayashi, T; Miyazaki, K; Nakazato, T; Sahara, N; Sakai, R; Tajika, K; Tamai, Y; Tamaki, S; Tanaka, E; Wake, A | 1 |
| Anderson, LD; Beksac, M; Corso, A; Dimopoulos, M; Dürig, J; Engelhardt, M; Galli, M; Grote, L; Jenner, M; Jiang, R; Kanate, AS; Larocca, A; Liberati, AM; Lindsay, J; Moreau, P; Oriol, A; Pavic, M; Peluso, T; Richardson, PG; Robak, P; Rodriguez-Otero, P; Salomo, M; Schjesvold, F; Sonneveld, P; Vural, F; Weisel, K; White, D; Yagci, M | 1 |
| Ahmadi, T; Arnulf, B; Avet-Loiseau, H; Belhadj, K; Benboubker, L; Béné, MC; Broijl, A; Caillon, H; Caillot, D; Corre, J; de Boer, C; Dejoie, T; Delforge, M; Doyen, C; Escoffre-Barbe, M; Eveillard, JR; Facon, T; Fontan, J; Garidi, R; Hulin, C; Jie, KS; Kampfenkel, T; Karlin, L; Klein, SK; Krevvata, M; Kuhnowski, F; Lambert, J; Leleu, X; Levin, MD; Macro, M; Marolleau, JP; Meuleman, N; Mohty, M; Moreau, P; Offner, F; Orsini-Piocelle, F; Perrot, A; Roussel, M; Sonneveld, P; Sonntag, C; Stoppa, AM; Tiab, M; Touzeau, C; van de Donk, NWCJ; Vanquickelberghe, V; Vara, S; Vekemans, MC; Vermeulen, J; Westerman, M; Wuillème, S; Zhang, K; Zweegman, S | 1 |
| Fang, YH; Wei, KC; Yu, MS | 1 |
| Bassermann, F; Bertsch, U; Eichner, R; Emde-Rajaratnam, M; Goldschmidt, H; Heider, M; Hose, D; Keller, U; Rudelius, M; Salwender, H; Scheid, C; Schick, M; Seckinger, A; Slawska, J; Stroh, J; Weisel, K | 1 |
| Costa, NL; de Pádua, CAM; Drummond, PLM; Machado, CJ; Malta, JS; Reis, AMM; Santos, RMMD; Silveira, LP | 1 |
| Al Hamed, R; Bazarbachi, A; Bazarbachi, AH; Harousseau, JL; Malard, F; Mohty, M | 1 |
| Andoh, S; Hagiwara, S; Hirai, R; Itoi, S; Komuro, M; Mitsui, Y; Miwa, A; Nakamura, M; Sekine, R; Takeshita, M; Tanimura, A; Togano, T | 1 |
| Ashizawa, M; Fujiwara, SI; Fukui, Y; Hatano, K; Ikeda, T; Ito, S; Kanda, Y; Kawaguchi, SI; Koyama, S; Matsuoka, S; Minakata, D; Morita, K; Murahashi, R; Nagayama, T; Nakano, H; Nakashima, H; Ohmine, K; Sato, K; Sekiguchi, K; Toda, Y; Ueda, M; Umino, K; Yamamoto, C; Yamasaki, R | 1 |
| Buzoianu, AD; Ciechanover, A; Dima, D; Drula, R; Ghiaur, G; Gulei, D; Iluta, S; Iuga, C; Tomuleasa, C | 1 |
| Akahoshi, Y; Gomyo, A; Kako, S; Kameda, K; Kanda, Y; Kawamura, M; Kawamura, S; Kimura, SI; Kusuda, M; Matsumi, S; Misaki, Y; Nakamura, Y; Nakasone, H; Okada, Y; Takeshita, J; Tamaki, M; Tanihara, A; Yoshimura, K; Yoshino, N | 1 |
| Abeyaratne, S; Arseculeratne, G; Balawardena, J; De Silva, C; Deshapriya, S; Ekanayake, L; Faiz, M; Fernando, J; Galagoda, G; Gunasena, P; Harischandra, M; Hewamana, S; Jayasinghe, C; Jayawardena, P; Kariyawasam, C; Lin, TT; Mawathakubura, S; Mowlana, A; Munasinghe, N; Munasinghe, S; Paranawithane, S; Peiris, N; Perera, C; Perera, E; Perera, N; Skandarajah, T; Somasundaram, G; Somiah, S; Srinivasan, V; Wadanamby, R; Wickramarathna, C; Wijesiriwardena, B; Wijewickrama, A | 1 |
| Bathija, S; Berringer, H; Dwarakanathan, HR; He, J; Heeg, B; Johnston, S; Kampfenkel, T; Lam, A; Mackay, E; Mendes, J; Ruan, H | 1 |
| Afari, J; Berenson, JR; Bessudo, A; Cohen, A; Eades, BM; Eshaghian, S; Gabrail, N; Jhangiani, H; Kim, C; Kim, S; Kubba, S; Neidhart, JD; Spektor, TM; Swift, RA; Turner, C; Vescio, R | 1 |
| Bao, S; Chai, G; Chen, X; Liu, C; Mao, J; Zhi, Y; Zhu, J | 1 |
| Borsi, E; Bratosin, F; Cerbu, B; Costachescu, D; Negrean, RA; Potre, C; Potre, O; Samfireag, M; Secosan, C | 1 |
| Alihodzic, D; Bokemeyer, C; Ghandili, S; Leypoldt, LB; Weisel, K; Wiessner, C | 1 |
| Akhtar, S; Brouwer, R; Drayson, M; Dunn, J; Iqbal, G; Lindsay, J; Ramasamy, K; Schey, S; Stalker, V; Varghese, S | 1 |
| Anagnostopoulos, A; Arcese, W; Beksac, M; Bolaman, AZ; Bulabois, CE; Bunjes, D; Deconinck, E; Delforge, M; Eikema, DJ; Fenk, R; Gagelmann, N; Hayden, PJ; Itälä-Remes, M; Koster, L; Labussière-Wallet, H; Lund, J; McDonald, A; Nabil, Y; Netelenbos, T; Reményi, P; Schönland, S; Stoppa, AM; Thurner, L; van Gorkom, G; Yakoub-Agha, I | 1 |
| Brazauskas, R; D'Souza, A; Dong, J; Dwinell, MB; Giralt, S; Janz, S; Krishnan, A; Landau, H; Mohan, M; Pasquini, MC; Stadtmauer, E; Teng, BQ; Yun, G | 1 |
| Costa, IHFD; Drummond, PLM; Malta, JS; Menezes de Pádua, CA; Reis, AMM; Santos, RMMD; Silveira, LP | 1 |
| Bardin, C; Hulin, C; Madelaine, I; Moreau, P; Rioufol, C; Slimano, F; Tournamille, JF | 1 |
| Ichikawa, D; Inoue, K; Ito, T; Kuroda, J; Midorikawa, S; Suzuki, K; Uno, S | 1 |
| Horvath, N; Kalff, A; Kerridge, I; Khong, T; Lee, E; Morris, E; Quach, H; Reynolds, J; Spencer, A; Turner, R | 1 |
| Cao, Y; Dhodapkar, M; Hall, KH; Harvey, RD; Hofmeister, CC; Joseph, NS; Kaufman, JL; Liu, Y; Lonial, S; Maples, KT; Nooka, AK; Sun, LF | 1 |
| Anderson, LD; Bumma, N; Chari, A; Cortoos, A; Costa, LJ; Costello, C; Cowan, AJ; Dinner, S; Efebera, YA; Holstein, SA; Jakubowiak, A; Kaufman, JL; Laubach, J; Lin, TS; Nathwani, N; Orlowski, RZ; Patel, S; Pei, H; Reeves, B; Richardson, PG; Rodriguez, C; Sborov, DW; Shah, N; Shain, KH; Silbermann, R; Usmani, SZ; Voorhees, PM; Wildes, TM | 1 |
| An, G; Deng, S; Du, C; Fan, H; Hao, M; Li, C; Li, L; Liu, J; Mao, X; Qiu, L; Sui, W; Xu, Y; Yi, S; Zhao, J; Zhao, Y; Zou, D | 1 |
| Chu, XX; Wang, J; Wang, W; Xu, H | 1 |
311 review(s) available for thalidomide and bortezomib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
A review on the treatment of multiple myeloma with small molecular agents in the past five years.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Deubiquitinating Enzymes; Drug Development; Drug Resistance; Histone Deacetylases; Humans; Ikaros Transcription Factor; Immunomodulating Agents; Models, Molecular; Morpholines; Multiple Myeloma; Phthalimides; Piperidones; Proteasome Inhibitors; Treatment Outcome; Ubiquitin-Protein Ligases | 2022 |
Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Adhesion Molecules; Cytokines; Humans; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Pyrazines; Thalidomide; Treatment Outcome | 2002 |
Moving disease biology from the laboratory to the clinic.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion Molecules; Clinical Trials as Topic; Cytokines; Endothelial Growth Factors; Humans; Intercellular Adhesion Molecule-1; Intercellular Signaling Peptides and Proteins; Interferons; Killer Cells, Natural; Lymphokines; Multiple Myeloma; Protease Inhibitors; Pyrazines; Signal Transduction; Stem Cell Transplantation; Thalidomide; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
High-dose therapy and immunomodulatory drugs in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Gene Expression Profiling; Humans; Interferons; Lenalidomide; Melphalan; Multiple Myeloma; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide | 2002 |
Novel biologically based therapies for Waldenstrom's macroglobulinemia.
Topics: Adjuvants, Immunologic; Anti-Bacterial Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Enzyme Inhibitors; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Protease Inhibitors; Pyrazines; Thalidomide; Thiazoles; Waldenstrom Macroglobulinemia | 2003 |
Novel therapies in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2003 |
[Thalidomide treatment in multiple myeloma].
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cysteine Endopeptidases; Dexamethasone; Drug Therapy, Combination; Enzyme Inhibitors; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multienzyme Complexes; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Recurrence; Thalidomide | 2003 |
Therapy strategies for multiple myeloma: current status.
Topics: Adjuvants, Immunologic; Aged; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Diphosphonates; Drug Therapy, Combination; Erythropoietin; Glucocorticoids; Growth Inhibitors; Humans; Immunosuppressive Agents; Middle Aged; Multiple Myeloma; Oxides; Peripheral Blood Stem Cell Transplantation; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Transplantation, Homologous | 2003 |
Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.
Topics: Adjuvants, Immunologic; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arkansas; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Protease Inhibitors; Pyrazines; Salvage Therapy; Stem Cell Transplantation; Survival Analysis; Thalidomide; Treatment Outcome; Universities | 2003 |
Multiple myeloma: the role of transplant and novel treatment strategies.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Oxides; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Humans; Lenalidomide; Multiple Myeloma; Paraproteinemias; Protease Inhibitors; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide | 2004 |
Targeting multiple myeloma cells and their bone marrow microenvironment.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cytokines; Disease Progression; Disease-Free Survival; Humans; Ligands; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Protease Inhibitors; Pyrazines; Signal Transduction; Thalidomide | 2004 |
Evolving treatment strategies for myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide | 2005 |
[Multiple myeloma--recent advances in diagnosis and treatment].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Multiple Myeloma; Neoplasm Staging; Pamidronate; Protease Inhibitors; Pyrazines; Thalidomide; Zoledronic Acid | 2005 |
Clinical update: novel targets in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide | 2004 |
Targeted therapy in multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; DNA, Antisense; Drug Delivery Systems; Farnesyltranstransferase; Humans; Immunosuppressive Agents; Lovastatin; Multiple Myeloma; Oxides; Protease Inhibitors; Pyrazines; Thalidomide | 2005 |
Treatment of myeloma in patients not eligible for transplantation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Pyrazines; Salvage Therapy; Thalidomide | 2005 |
Future therapies in hormone-refractory prostate cancer.
Topics: Antibodies, Monoclonal; Atrasentan; Boronic Acids; Bortezomib; Diphosphonates; DNA, Antisense; Forecasting; Humans; Immunotherapy; Male; Prostatic Neoplasms; Pyrazines; Pyrrolidines; Receptors, Growth Factor; Thalidomide | 2005 |
Novel approaches to the management of myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide | 2005 |
Current treatment options for myeloma.
Topics: Age Factors; Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Doxorubicin; Humans; Melphalan; Multiple Myeloma; Osteolysis; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Stem Cell Transplantation; Survival Analysis; Thalidomide; Transplantation, Autologous; Vincristine | 2005 |
Treatment of mantle cell lymphoma: targeting the microenvironment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Clinical Trials as Topic; Humans; Immunosuppressive Agents; Lymphoma, Mantle-Cell; Prognosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Rituximab; Thalidomide | 2005 |
Toxic neuropathy.
Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Epothilones; Genetic Therapy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoxazoles; Leflunomide; Neuritis; Neuroprotective Agents; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Pyrazines; Pyridoxine; Thalidomide | 2005 |
The current status of thalidomide in the management of multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Tumor Necrosis Factor-alpha | 2005 |
Evolving role of stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Disease-Free Survival; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2005 |
Induction therapy before transplantation in multiple myeloma: new strategies to achieve complete response.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Humans; Immunosuppressive Agents; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Treatment Outcome; Vincristine | 2005 |
Treatment paradigms for the newly diagnosed patient with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide | 2005 |
Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunologic Factors; Interleukin-6; Lenalidomide; Models, Immunological; Multiple Myeloma; Pyrazines; Signal Transduction; Thalidomide | 2005 |
Overview of drug therapy for multiple myeloma.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Myeloma Proteins; Oxides; Pyrazines; Thalidomide | 2005 |
[New strategy for the treatment of multiple myeloma].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Dexamethasone; Drug Design; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Oxides; Prognosis; Protease Inhibitors; Purines; Pyrazines; Roscovitine; Thalidomide; Transplantation Conditioning | 2005 |
New treatments for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2005 |
Novel treatment approaches for patients with multiple myeloma.
Topics: Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Cell Proliferation; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Delivery Systems; Drug Design; Heat-Shock Proteins; Histones; Humans; Lenalidomide; Multiple Myeloma; Oncogene Protein v-akt; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Recurrence; Remission Induction; Signal Transduction; Thalidomide | 2006 |
[Prognostic factors and new treatments of multiple myeloma].
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2006 |
Treatment of multiple myeloma: an emphasis on new developments.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2006 |
[New treatment strategy of multiple myeloma for cure].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Medical Oncology; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide | 2006 |
[The plasma cell myeloma--molecular pathogenesis and target therapies].
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Communication; Chromosome Aberrations; Gene Expression; Glycoproteins; Growth Inhibitors; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Osteoporosis; Osteoprotegerin; Oxides; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Thalidomide; Time Factors | 2006 |
Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies).
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Design; Farnesyltranstransferase; Humans; Immunologic Factors; Lenalidomide; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; Pyrazines; Receptors, Vascular Endothelial Growth Factor; Thalidomide | 2006 |
[Current therapy for multiple myeloma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Thalidomide | 2005 |
The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; History, 18th Century; History, 20th Century; History, 21st Century; History, Ancient; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2006 |
Emerging role of novel combinations for induction therapy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Thalidomide; Treatment Outcome | 2006 |
Advancing access to myeloma treatment: administration, side effects, and implications for survival.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Health Services Accessibility; Humans; Immunosuppressive Agents; Information Services; Lenalidomide; Multiple Myeloma; Nurse's Role; Oncology Nursing; Patient Education as Topic; Protease Inhibitors; Pyrazines; Radiotherapy, Adjuvant; Stem Cell Transplantation; Survival Rate; Thalidomide | 2006 |
Advances in the treatment of multiple myeloma: a nursing perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Nurse's Role; Oncology Nursing; Practice Guidelines as Topic; Protease Inhibitors; Pyrazines; Quality of Life; Stem Cell Transplantation; Survival Rate; Thalidomide; Treatment Outcome | 2006 |
[New drugs for myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2006 |
[Recent progress in diagnosis of and therapy for multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Thalidomide | 2006 |
Current status of new drugs for the treatment of patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2006 |
Investigational treatments for multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Design; Drug Resistance, Neoplasm; Drugs, Investigational; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Remission Induction; Risk Factors; Salvage Therapy; Thalidomide; Treatment Outcome | 2006 |
Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Administration Schedule; Hemoglobins; Humans; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Quality of Life; Thalidomide | 2006 |
The emerging role of novel therapies for the treatment of relapsed myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence; Thalidomide | 2007 |
Emerging drugs in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2007 |
[Recent progress in the treatment of multiple myeloma].
Topics: Age Factors; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Diphosphonates; Drug Design; Football; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Reference Standards; Thalidomide | 2007 |
[New treatment of multiple myeloma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide | 2007 |
New drugs for myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide; Treatment Outcome | 2007 |
Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison.
Topics: Animals; Blood Proteins; Boronic Acids; Bortezomib; Cell Transplantation; Humans; Immunoglobulins; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2007 |
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2007 |
Tandem transplants in the treatment of multiple myeloma. Pro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Remission Induction; Reoperation; Survival Rate; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2004 |
Initial Therapy of Multiple Myeloma in Patients who are Candidates for Stem Cell Transplantation.
Topics: Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide | 2007 |
Novel therapeutic avenues in myeloma: changing the treatment paradigm.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Signal Transduction; Thalidomide | 2007 |
Targeted treatments to improve stem cell outcome: old and new drugs.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Delivery Systems; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2007 |
Management of novel therapeutics' side effects: a nurse-centric model.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lenalidomide; Models, Nursing; Neoplasms; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Advocacy; Patient Education as Topic; Pyrazines; Thalidomide | 2007 |
Novel therapies in myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2007 |
[Therapy of multiple myeloma: indications and options].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Remission Induction; Thalidomide; Tumor Burden | 2007 |
New therapies in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2007 |
Management of relapsed and relapsed refractory myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2007 |
The treatment of relapsed and refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2007 |
Clinical updates and nursing considerations for patients with multiple myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Disease Progression; Doxorubicin; Drug Administration Schedule; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Nurse's Role; Oncology Nursing; Patient Compliance; Patient Education as Topic; Practice Guidelines as Topic; Prednisone; Pyrazines; Quality of Life; Survival Rate; Thalidomide; Treatment Outcome | 2007 |
[Diagnosis and management guideline for multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Japan; Lenalidomide; Multiple Myeloma; Practice Guidelines as Topic; Pyrazines; Reference Standards; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2007 |
[Chemotherapy for multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Humans; Melphalan; Meta-Analysis as Topic; Multiple Myeloma; Prednisolone; Pulse Therapy, Drug; Pyrazines; Thalidomide; Vincristine | 2007 |
[Role of bortezomib in the treatment of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Doxorubicin; Humans; Liposomes; Melphalan; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Thalidomide | 2007 |
[Role of stem cell transplantation in treatment of multiple myeloma].
Topics: Age Factors; Aged; Boronic Acids; Bortezomib; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Meta-Analysis as Topic; Middle Aged; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Survival Rate; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Heterologous | 2007 |
[Molecular targeting therapy for multiple myeloma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Oxides; Protease Inhibitors; Pyrazines; Thalidomide; TNF-Related Apoptosis-Inducing Ligand; Vascular Endothelial Growth Factor A | 2007 |
[Advances in therapeutic strategies for multiple myeloma].
Topics: Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Communication; Humans; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Signal Transduction; Thalidomide | 2007 |
An update on drug combinations for treatment of myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Treatment Outcome | 2008 |
[Molecular-targeted therapy for prostate cancer].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Male; Neoplasms, Hormone-Dependent; NF-kappa B; Prostatic Neoplasms; Pyrazines; Thalidomide | 2008 |
Multiple myeloma: novel approaches for relapsed disease.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2007 |
Current therapy of myeloma induced renal failure.
Topics: Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide | 2008 |
Treatment of plasma cell dyscrasias with lenalidomide.
Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Paraproteinemias; Pyrazines; Renal Insufficiency; Thalidomide; Thromboembolism; Waldenstrom Macroglobulinemia | 2008 |
Maintenance treatment in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Stem Cell Transplantation; Survival Analysis; Thalidomide | 2008 |
Pathogenesis and treatment of renal failure in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide | 2008 |
Frontline treatment of multiple myeloma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Health Services for the Aged; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate; Thalidomide | 2008 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Treatment of relapsed and refractory myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Salvage Therapy; Thalidomide; Treatment Outcome | 2008 |
New drugs in multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2008 |
The role of novel drugs in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2008 |
Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Non-Hodgkin; Protease Inhibitors; Pyrazines; Thalidomide | 2008 |
[Treatment for multiple myeloma: current status and future strategy in Japan].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Immunologic Factors; Japan; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Recurrence; Thalidomide; Time Factors; Transplantation, Autologous | 2008 |
Advances in therapy of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous; Treatment Outcome | 2008 |
Practical considerations for multiple myeloma: an overview of recent data and current options.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Pyrazines; Remission Induction; Salvage Therapy; Thalidomide | 2008 |
Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
Topics: Arsenic Trioxide; Arsenicals; Aspirin; Boronic Acids; Bortezomib; Heparin, Low-Molecular-Weight; Humans; Incidence; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide; Venous Thromboembolism | 2009 |
Treatment of newly diagnosed myeloma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Deletion; Clinical Trials as Topic; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prognosis; Pyrazines; Risk; Thalidomide; Translocation, Genetic; Transplantation Conditioning | 2009 |
Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Boronic Acids; Bortezomib; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Pyrazines; Rituximab; Thalidomide; Transplantation, Autologous; Transplantation, Homologous; Waldenstrom Macroglobulinemia | 2009 |
Diagnosis and the current trends in multiple myeloma therapy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Protease Inhibitors; Pyrazines; Remission Induction; Thalidomide | 2008 |
Treatment of multiple myeloma in the targeted therapy era.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Drug Delivery Systems; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Salvage Therapy; Thalidomide; Transplantation Conditioning | 2009 |
Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias.
Topics: Blood Coagulation Disorders; Blood Platelet Disorders; Boronic Acids; Bortezomib; Hemorrhage; Humans; Immunosuppressive Agents; Paraproteinemias; Protease Inhibitors; Pyrazines; Retrospective Studies; Thalidomide; Thrombosis | 2009 |
Initial therapy in multiple myeloma: investigating the new treatment paradigm.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Comorbidity; Evidence-Based Medicine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous | 2009 |
Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide | 2009 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Genetic Predisposition to Disease; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Protease Inhibitors; Pyrazines; Remission Induction; Stem Cell Transplantation; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
The use of novel agents in the treatment of relapsed and refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Pyrazines; Salvage Therapy; Thalidomide; Treatment Outcome | 2009 |
Novel therapies in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide | 2009 |
Multiple myeloma, painful neuropathy, acupuncture?
Topics: Acupuncture Therapy; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pain; Pain Management; Peripheral Nervous System Diseases; Pyrazines; Thalidomide | 2009 |
[Hematopoietic stem cell transplantation for multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Doxorubicin; Drug Discovery; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Interferons; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vincristine | 2009 |
[New treatment strategies for multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Diagnosis, Differential; Doxorubicin; Drug Discovery; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisolone; Pyrazines; Remission Induction; Salvage Therapy; Thalidomide; Vincristine | 2009 |
How to treat a newly diagnosed young patient with multiple myeloma.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Disease Management; Doxorubicin; Endpoint Determination; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Middle Aged; Molecular Diagnostic Techniques; Multicenter Studies as Topic; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide; Transplantation Conditioning | 2009 |
How to treat elderly patients with multiple myeloma: combination of therapy or sequencing.
Topics: Acute Kidney Injury; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Comorbidity; Disease Management; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Myeloablative Agonists; Peripheral Nervous System Diseases; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide; Transplantation Conditioning; Venous Thrombosis | 2009 |
Novel therapies for relapsed myeloma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Drug Screening Assays, Antitumor; Drugs, Investigational; Heat-Shock Proteins; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Mice; Mice, Transgenic; Multiple Myeloma; Neoplasm Proteins; Nitrogen Mustard Compounds; Oligopeptides; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Salvage Therapy; Thalidomide | 2009 |
ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Evidence-Based Medicine; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Interferon-alpha; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Practice Guidelines as Topic; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide | 2009 |
New treatments for myeloma.
Topics: Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Neoplasm Staging; Prednisone; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide | 2010 |
Current multiple myeloma treatment strategies with novel agents: a European perspective.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Clinical Trials as Topic; Decision Making; Decision Trees; Humans; Kidney Failure, Chronic; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous | 2010 |
New developments in the treatment of patients with multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Recurrence; Thalidomide | 2010 |
Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide | 2010 |
Advances in treatment for relapses and refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pyrazines; Recurrence; Thalidomide | 2010 |
Novel agents in development for peripheral T-cell lymphoma.
Topics: Aminopterin; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Depsipeptides; Drug Design; Drugs, Investigational; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Lenalidomide; Lymphoma, T-Cell, Peripheral; Purine Nucleosides; Pyrazines; Pyrimidinones; Salvage Therapy; Thalidomide | 2010 |
[Molecular-targeted therapy of multiple myeloma].
Topics: Boronic Acids; Bortezomib; Drug Delivery Systems; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide | 2010 |
[Treatment of AL-amyloidosis--results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis].
Topics: Adult; Aged; Amyloidosis; Boronic Acids; Bortezomib; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Middle Aged; Pyrazines; Thalidomide | 2010 |
Role of autologous stem cell transplantation in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Humans; Lenalidomide; Multicenter Studies as Topic; Multiple Myeloma; Patient Selection; Pyrazines; Randomized Controlled Trials as Topic; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2007 |
Treatment of relapsed and refractory myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2009 |
Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations.
Topics: Aged; Antineoplastic Agents; Biopsy, Needle; Bone Marrow; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Evidence-Based Medicine; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Plasma Cells; Pyrazines; Retreatment; Switzerland; Thalidomide | 2010 |
Management of treatment-related adverse events in patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disorders of Excessive Somnolence; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Venous Thromboembolism | 2010 |
Multiple myeloma - current issues and controversies.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Management; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2010 |
Optimising patient outcomes in myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Management; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Risk Assessment; Thalidomide; Treatment Outcome | 2010 |
Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Recurrence; Thalidomide; Transcription, Genetic | 2010 |
Intracranial multifocal dural involvement in multiple myeloma: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Dura Mater; Fatal Outcome; Humans; Lenalidomide; Male; Meningeal Neoplasms; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide | 2010 |
Drug-mediated and cellular immunotherapy in multiple myeloma.
Topics: Antibody-Dependent Cell Cytotoxicity; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cancer Vaccines; Combined Modality Therapy; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Immunologic Memory; Immunotherapy; Immunotherapy, Active; Immunotherapy, Adoptive; Killer Cells, Natural; Lenalidomide; Multiple Myeloma; Pyrazines; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Thalidomide; Tumor Escape | 2010 |
Plasma cell leukaemia and other aggressive plasma cell malignancies.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide | 2010 |
The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Costs and Cost Analysis; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Survival Rate; Sweden; Thalidomide | 2010 |
Reassessing the standard of care in indolent lymphoma: a clinical update to improve clinical practice.
Topics: Antibodies, Monoclonal, Murine-Derived; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Pyrazines; Radioimmunotherapy; Rituximab; Thalidomide | 2010 |
[Current treatment strategies for multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Diphosphonates; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Pyrazines; Thalidomide | 2010 |
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Incidence; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Risk Assessment; Risk Factors; Thalidomide; Treatment Outcome | 2010 |
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
Topics: Boronic Acids; Bortezomib; Glomerular Filtration Rate; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Melphalan; Multiple Myeloma; Prognosis; Pyrazines; Renal Insufficiency; Thalidomide; Transplantation, Autologous | 2010 |
Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Plasma cell leukemia: concepts and management.
Topics: Aged; Antigens, CD20; Antineoplastic Agents; Boronic Acids; Bortezomib; CD56 Antigen; Humans; Lenalidomide; Leukemia, Plasma Cell; Multiple Myeloma; Neoplasms, Second Primary; Palliative Care; Paraproteinemias; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2010 |
Multiple myeloma.
Topics: Anemia; Bone Diseases; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Proteinase Inhibitors; Humans; Hypercalcemia; Immunologic Factors; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Recurrence; Renal Insufficiency; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2011 |
Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2011 |
Ten years of improvement in the management of multiple myeloma: 2000-2010.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Clinical impact of chromosomal aberrations in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide; Treatment Outcome | 2011 |
Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Graft vs Host Disease; Humans; Immunomodulation; Models, Animal; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous | 2011 |
Chemotherapy-induced neuropathic pain.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Neuralgia; Pyrazines; Thalidomide | 2011 |
Management of older patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2011 |
Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2011 |
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Primary Myelofibrosis; Protease Inhibitors; Pyrazines; Thalidomide | 2011 |
Treatment of newly diagnosed myeloma in patients not eligible for transplantation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Treatment Outcome | 2011 |
Treatment of newly diagnosed multiple myeloma in transplant-eligible patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2011 |
The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2011 |
Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Female; Humans; Male; Medical Oncology; Multiple Myeloma; Neoplasm Staging; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2011 |
Treatment options for relapsed and refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Medical Oncology; Models, Biological; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Thalidomide | 2011 |
Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comorbidity; Congresses as Topic; Disease-Free Survival; Europe; Evidence-Based Practice; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2011 |
[Current treatment of AL amyloidosis].
Topics: Amyloid; Amyloidosis; Biomarkers; Boronic Acids; Bortezomib; Cardiomyopathies; Consensus Development Conferences as Topic; Dexamethasone; Drug Therapy, Combination; Heart Transplantation; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Kidney Failure, Chronic; Kidney Transplantation; Lenalidomide; Melphalan; Natriuretic Peptide, Brain; Paraproteinemias; Paraproteins; Peptide Fragments; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Renal Dialysis; Thalidomide | 2011 |
Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2011 |
Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Standard of Care; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2011 |
Therapy of relapsed and refractory multiple myeloma.
Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lactones; Lenalidomide; Middle Aged; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Secondary Prevention; Thalidomide | 2011 |
[New insights in the treatment of myeloma with renal failure].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Contraindications; Cyclophosphamide; Dexamethasone; Fluid Therapy; Humans; Hypercalcemia; Immunoglobulin Light Chains; Kidney Failure, Chronic; Lenalidomide; Melphalan; Multicenter Studies as Topic; Multiple Myeloma; Myeloma Proteins; Prospective Studies; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Renal Dialysis; Thalidomide | 2011 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Multiple Myeloma; Pyrazines; Risk; Thalidomide; Venous Thromboembolism | 2011 |
New agents in follicular lymphoma.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Humans; Immunoconjugates; Lenalidomide; Lymphoma, Follicular; Mice; Nitrogen Mustard Compounds; Phosphotransferases; Protein Kinase Inhibitors; Pyrazines; Recurrence; Remission Induction; Rituximab; Signal Transduction; Thalidomide; Tumor Microenvironment | 2011 |
Novel agents-based regimens as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Topics: Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Transplantation, Autologous | 2012 |
Genomic stratification of multiple myeloma treated with novel agents.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Genomics; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide | 2012 |
[Current treatment strategies with novel agents for multiple myeloma].
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Drug Design; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous | 2011 |
[Present status and perspective of targeted therapy for B-cell lymphoma].
Topics: Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Drug Discovery; Flavonoids; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lenalidomide; Lymphoma, B-Cell; Molecular Targeted Therapy; Piperidines; Protease Inhibitors; Protein Kinase C; Protein Kinase C beta; Protein-Tyrosine Kinases; Pyrazines; Rituximab; Thalidomide; Vorinostat | 2011 |
[New treatment strategy for Crow-Fukase (POEMS) syndrome].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Boronic Acids; Bortezomib; Combined Modality Therapy; Demyelinating Diseases; Humans; Lenalidomide; Melphalan; Peripheral Blood Stem Cell Transplantation; POEMS Syndrome; Pyrazines; Thalidomide; Transplantation, Autologous; Vascular Endothelial Growth Factor A | 2010 |
Renal crescentic alpha heavy chain deposition disease: a report of 3 cases and review of the literature.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cutis Laxa; Dexamethasone; Diabetic Nephropathies; Erythropoietin; Fatal Outcome; Female; Heavy Chain Disease; Hematuria; Humans; Hypertension, Renal; Immunoglobulin alpha-Chains; Immunoglobulin gamma-Chains; Immunoglobulin mu-Chains; Kidney Glomerulus; Male; Multiple Myeloma; Paraproteinemias; Proteinuria; Pyrazines; Thalidomide; Urticaria; Vasculitis, Leukocytoclastic, Cutaneous | 2011 |
Advances in the autologous and allogeneic transplantation strategies for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous | 2011 |
The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Cyclophosphamide; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Pyrazines; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide | 2011 |
Management of treatment-emergent peripheral neuropathy in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Early Diagnosis; Humans; Immunologic Factors; Incidence; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Thalidomide | 2012 |
[Thrombotic complications following the treatment of multiple myeloma with new agents].
Topics: Anthracyclines; Anticoagulants; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Thrombosis | 2011 |
Management of myeloma-associated renal dysfunction in the era of novel therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Prednisone; Pyrazines; Renal Insufficiency; Thalidomide | 2012 |
Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide; Treatment Outcome | 2012 |
Latest advances and current challenges in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Prognosis; Protease Inhibitors; Protein Kinase Inhibitors; Pyrazines; Thalidomide | 2012 |
Advances in the treatment of relapsed or refractory Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Brentuximab Vedotin; Drug Therapy; Everolimus; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Immunoconjugates; Immunotherapy; Lenalidomide; Protease Inhibitors; Pyrazines; Recurrence; Rituximab; Secondary Prevention; Sirolimus; Thalidomide | 2012 |
[Multiple myeloma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Denosumab; Diphosphonates; Humans; Imidazoles; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Zoledronic Acid | 2012 |
[AL amyloidosis].
Topics: Algorithms; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Heart Failure; Humans; Lenalidomide; Melphalan; Myocardium; Palliative Care; Patient Selection; Prognosis; Pyrazines; Quality of Life; Risk Assessment; Risk Factors; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2012 |
SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Evidence-Based Practice; Hematology; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Grading; Practice Guidelines as Topic; Pyrazines; Societies, Medical; Thalidomide | 2012 |
Immunoglobulin light-chain amyloidosis: growing recognition, new approaches to therapy, active clinical trials.
Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Middle Aged; Prognosis; Pyrazines; Thalidomide | 2012 |
European perspective on multiple myeloma treatment strategies: update following recent congresses.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Congresses as Topic; Europe; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2012 |
(Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Induction Chemotherapy; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide | 2012 |
Waldenström macroglobulinemia: my way.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Pyrazines; Rituximab; Survival Analysis; Thalidomide; Waldenstrom Macroglobulinemia | 2013 |
Multiple myeloma: improved outcomes with new therapeutic approaches.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide; Treatment Outcome | 2012 |
Biological therapy doublets: pairing rituximab with interferon, lenalidomide, and other biological agents in patients with follicular lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Biological Products; Boronic Acids; Bortezomib; Drug Therapy, Combination; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon-alpha; Lenalidomide; Lymphoma, Follicular; Pyrazines; Rituximab; Thalidomide; Tumor Microenvironment | 2012 |
Achieving an early myeloma response in patients with kidney impairment.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Glomerular Filtration Rate; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Time Factors | 2012 |
Evolving chemotherapy options for the treatment of myeloma kidney: a 40-year perspective.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Pyrazines; Thalidomide | 2012 |
Fifty years of melphalan use in hematopoietic stem cell transplantation.
Topics: Adenine Nucleotides; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Boronic Acids; Bortezomib; Clofarabine; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous | 2013 |
Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion.
Topics: Aged; Amyloidosis; Bence Jones Protein; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light-chain Amyloidosis; Kidney; Lenalidomide; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Renal Insufficiency; Thalidomide | 2012 |
[Update on treatment of multiple myeloma: including myeloma kidney and molecular targeting drugs].
Topics: Boronic Acids; Bortezomib; Drug Design; Humans; Immunologic Factors; Kidney Neoplasms; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Plasmacytoma; Pyrazines; Thalidomide | 2012 |
Light-chain amyloidosis: SCT, novel agents and beyond.
Topics: Amyloidosis; Animals; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Immunologic Factors; Immunosuppressive Agents; Immunotherapy; Lenalidomide; Melphalan; Pyrazines; Survival Analysis; Thalidomide | 2013 |
Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Calibration; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Time Factors | 2012 |
How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comprehension; Drug-Related Side Effects and Adverse Reactions; Humans; Kinetics; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Thalidomide; Time Factors | 2012 |
What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?
Topics: Bone Diseases; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Fractures, Bone; Humans; Imidazoles; In Situ Hybridization, Fluorescence; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Proteinuria; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Time Factors; Translocation, Genetic; Treatment Outcome; Zoledronic Acid | 2012 |
Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy; Humans; Lenalidomide; Medical Oncology; Melphalan; Models, Biological; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Risk; Thalidomide; Treatment Outcome | 2012 |
Current therapeutic strategy for multiple myeloma.
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Creatinine; Cyclophosphamide; Denosumab; Dexamethasone; Diphosphonates; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulins; Kidney; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Neoplasms, Second Primary; Precision Medicine; Prednisolone; Pyrazines; Quality of Life; Recurrence; Remission Induction; Survival Rate; Thalidomide; Zoledronic Acid | 2013 |
Induction therapy for newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2013 |
Part I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Diphosphonates; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous; Zoledronic Acid | 2013 |
Part II: role of maintenance therapy in transplant-ineligible patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Vincristine | 2013 |
New advances in the diagnosis and treatment of POEMS syndrome.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Boronic Acids; Bortezomib; Castleman Disease; Chromosome Aberrations; Combined Modality Therapy; Dexamethasone; Disease Management; Drug Therapy, Combination; Genes, Immunoglobulin; Humans; Hypertension, Pulmonary; Lenalidomide; Melphalan; Osteosclerosis; Peripheral Blood Stem Cell Transplantation; Plasma Cells; POEMS Syndrome; Prognosis; Pyrazines; Severity of Illness Index; Symptom Assessment; Thalidomide; Transplantation, Autologous; Vascular Endothelial Growth Factor A | 2013 |
[Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials].
Topics: Amyloidosis; Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Humans; Immunoglobulin Light-chain Amyloidosis; Immunosuppressive Agents; Lenalidomide; Pyrazines; Thalidomide | 2013 |
Continuous treatment with new agents for newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Induction Chemotherapy; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2013 |
Therapeutic strategies for the treatment of multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytokines; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Homeostasis; Humans; Immune System; Immunotherapy; Lenalidomide; Multiple Myeloma; Oligopeptides; Prognosis; Protease Inhibitors; Pyrazines; Recurrence; Syndecan-1; Thalidomide | 2013 |
Diagnosis and therapy of multiple myeloma.
Topics: Age Factors; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide | 2013 |
Safety and effectiveness of low-dose lenalidomide therapy for multiple myeloma complicated with bortezomib-associated interstitial pneumonia.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Immunologic Factors; Lenalidomide; Lung Diseases, Interstitial; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2013 |
Stringent complete remission of primary plasma cell leukemia with reduced-dose bortezomib, lenalidomide and dexamethasone: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Pyrazines; Remission Induction; Thalidomide | 2013 |
[Thalidomide in the treatment of multiple myeloma: focus on combination with bortezomib].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Multiple Myeloma; Polyneuropathies; Pyrazines; Thalidomide; Treatment Outcome | 2013 |
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Double-Blind Method; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous | 2013 |
[Multiple myeloma].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Oligopeptides; Prognosis; Pyrazines; Thalidomide | 2013 |
Management of double-refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Retreatment; Thalidomide | 2013 |
Bortezomib in combination with thalidomide or lenalidomide or doxorubicin regimens for the treatment of multiple myeloma: a meta-analysis of 14 randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Doxorubicin; Humans; Lenalidomide; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2014 |
Bortezomib and lenalidomide as front-line therapy for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Odds Ratio; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2014 |
Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2013 |
Second autologous transplant as salvage therapy in multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Humans; Interferon-alpha; Maintenance Chemotherapy; Multicenter Studies as Topic; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Recurrence; Reoperation; Retrospective Studies; Salvage Therapy; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2013 |
Initial treatment of transplant candidates with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Evidence-Based Medicine; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2013 |
New developments in post-transplant maintenance treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Glucocorticoids; Humans; Lenalidomide; Multiple Myeloma; Postoperative Period; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Role of consolidation therapy in transplant eligible multiple myeloma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Consolidation Chemotherapy; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Multiple myeloma: Defining the high-risk patient and determining the optimal treatment strategy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Oligopeptides; Pyrazines; Randomized Controlled Trials as Topic; Risk Factors; Thalidomide | 2013 |
Role of consolidation/maintenance therapy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2013 |
Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients.
Topics: Angiogenesis Inhibitors; Autografts; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Remission Induction; Thalidomide; Time Factors; Transplantation Conditioning | 2013 |
The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients.
Topics: Boronic Acids; Bortezomib; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2014 |
Ibrutinib in B-cell Lymphomas.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Thalidomide; Treatment Outcome | 2014 |
New approaches to management of multiple myeloma.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Depsipeptides; Frail Elderly; Glycine; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Oligopeptides; Phosphorylcholine; Proteasome Inhibitors; Pyrazines; Quality of Life; Recurrence; Thalidomide; Treatment Outcome | 2014 |
Monoclonal antibodies currently in Phase II and III trials for multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Tumor Microenvironment | 2014 |
Current and future therapeutic approach for Waldenström's macroglobulinemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comorbidity; Disease Progression; Everolimus; Forecasting; Guillain-Barre Syndrome; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Immunotherapy; Incidence; Lenalidomide; Myelin-Associated Glycoprotein; Protein Kinase Inhibitors; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Thalidomide; Transplantation, Autologous; Treatment Outcome; Waldenstrom Macroglobulinemia; Watchful Waiting | 2014 |
Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Cyclophosphamide; Dexamethasone; Humans; Induction Chemotherapy; Middle Aged; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide | 2014 |
Advanced thyroid cancers: new era of treatment.
Topics: Anilides; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; ErbB Receptors; Genetic Therapy; Histone Deacetylase Inhibitors; Humans; Immunotherapy; Lithium; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyridines; Quinazolines; Stilbenes; Thalidomide; Thyroid Neoplasms | 2014 |
The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Hematopoietic Stem Cell Transplantation; Humans; Maintenance Chemotherapy; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2015 |
Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Induction Chemotherapy; Multiple Myeloma; Neoadjuvant Therapy; Neutropenia; Peripheral Nervous System Diseases; Pyrazines; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide; Treatment Outcome | 2014 |
Novel agents in CNS myeloma treatment.
Topics: Animals; Blood-Brain Barrier; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
Current challenges in the management of patients with relapsed/refractory multiple myeloma.
Topics: Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2011 |
Treatment-related adverse events in patients with relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Kidney; Multiple Myeloma; Nervous System Diseases; Oligopeptides; Pyrazines; Recurrence; Thalidomide; Venous Thromboembolism | 2011 |
Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2014 |
Scleromyxedema.
Topics: Boronic Acids; Bortezomib; Humans; Immunoglobulins, Intravenous; Pyrazines; Scleromyxedema; Thalidomide; Treatment Outcome | 2014 |
Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human; Cyclophosphamide; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Practice Guidelines as Topic; Pyrazines; Risk Assessment; Thalidomide; Translocation, Genetic | 2014 |
Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Duodenum; Epirubicin; Fatal Outcome; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Prednisone; Pyrazines; Remission Induction; Stomach; Thalidomide; Tomography, X-Ray Computed; Vincristine | 2014 |
Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review.
Topics: Amitriptyline; Anticonvulsants; Antidepressive Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Carbamazepine; Central Nervous System; Cyclohexanols; Duloxetine Hydrochloride; Epothilones; Humans; Neoplasms; Neuralgia; Oxcarbazepine; Peripheral Nervous System Diseases; Pyrazines; Taxoids; Thalidomide; Thiophenes; Venlafaxine Hydrochloride; Vinca Alkaloids | 2015 |
Pomalidomide for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Pyrazines; Thalidomide | 2014 |
[Supportive care in multiple myeloma for continuing anti-myeloma therapies].
Topics: Anemia; Bone Density Conservation Agents; Bone Diseases, Metabolic; Boronic Acids; Bortezomib; Diphosphonates; Humans; Hypercalcemia; Kidney Diseases; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide | 2014 |
[Treatment of transplant-eligible symptomatic multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Combined Modality Therapy; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasm, Residual; Nitrogen Mustard Compounds; Pyrazines; Remission Induction; Thalidomide; Transplantation Conditioning | 2014 |
[Treatment of untreated multiple myeloma patients ineligible for autologous stem cell transplantation].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Clinical Trials as Topic; Contraindications; Cyclophosphamide; Dexamethasone; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Japan; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Practice Guidelines as Topic; Prednisone; Pyrazines; Risk Factors; Thalidomide | 2014 |
[Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
Topics: Administration, Oral; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thalidomide | 2014 |
[Plasma cell leukemia].
Topics: Aged; Antineoplastic Agents; Biomedical Research; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Prognosis; Pyrazines; Rare Diseases; Thalidomide | 2014 |
Current treatment landscape for relapsed and/or refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Treatment Outcome | 2015 |
Targeting the bone marrow microenvironment in multiple myeloma.
Topics: Angiogenesis Inhibitors; Animals; Bone Marrow; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Plasma Cells; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome; Tumor Microenvironment | 2015 |
Managing multiple myeloma in the over 70s: a review.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autografts; Bone Density Conservation Agents; Bortezomib; Comorbidity; Cyclophosphamide; Dexamethasone; Diphosphonates; Fractures, Compression; Geriatric Assessment; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Palliative Care; Stem Cell Transplantation; Thalidomide; Vertebroplasty | 2015 |
Maintenance Therapy in Multiple Myeloma: Novel Concepts in Clinical Practice from Recent Clinical Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Humans; Maintenance Chemotherapy; Multiple Myeloma; Thalidomide | 2016 |
Pooled analysis of the reports of pomalidomide after failure of lenalidomide and (or) bortezomib for multiple myeloma.
Topics: Age Factors; Aged; Aged, 80 and over; Bortezomib; Clinical Trials as Topic; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide | 2016 |
Treatment-related symptom management in patients with multiple myeloma: a review.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug-Related Side Effects and Adverse Reactions; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Multiple Myeloma; Oligopeptides; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Quality of Life; Thalidomide | 2015 |
The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Europe; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Survival Rate; Thalidomide | 2015 |
Waldenstrom macroglobulinemia: prognosis and management.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunoglobulin M; Lenalidomide; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Thalidomide; Waldenstrom Macroglobulinemia | 2015 |
Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.
Topics: Allografts; Bortezomib; Chemoradiotherapy; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Transplantation Conditioning | 2015 |
Treatment for patients with newly diagnosed multiple myeloma in 2015.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Precision Medicine; Survival Analysis; Thalidomide; Transplantation Conditioning; Transplantation, Autologous | 2015 |
Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bortezomib; Cytokines; Dendritic Cells; Dexamethasone; Drug Resistance, Neoplasm; Drug Synergism; Hematopoiesis; Humans; Killer Cells, Natural; Lenalidomide; Lymphoma, B-Cell; Molecular Targeted Therapy; Peptide Hydrolases; Rituximab; T-Lymphocytes; Thalidomide; Tumor Microenvironment; Ubiquitin-Protein Ligases | 2015 |
Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
Topics: Bone and Bones; Bone Marrow; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Humans; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Thalidomide; Tumor Microenvironment | 2016 |
Bone formation following lenalidomide-dexamethasone combination therapy in cases of multiple myeloma refractory to high-dose chemotherapy with bortezomib and autologous peripheral blood stem cell transplantation: report of a case and review of the literat
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Osteogenesis; Peripheral Blood Stem Cell Transplantation; Salvage Therapy; Thalidomide | 2015 |
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Proteasome Inhibitors; Salvage Therapy; Thalidomide | 2016 |
First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Germany; Humans; Melphalan; Multiple Myeloma; Prednisone; Randomized Controlled Trials as Topic; Thalidomide | 2016 |
Mantle Cell Lymphoma.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cytarabine; Drug Administration Schedule; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Molecular Targeted Therapy; Neoplasm Staging; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Risk Factors; Rituximab; Thalidomide; Transplantation, Autologous | 2016 |
Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis.
Topics: Bortezomib; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2016 |
Sorafenib for the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Proliferation; Humans; Lenalidomide; Multiple Myeloma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thalidomide | 2016 |
Are maintenance and continuous therapies indicated for every patient with multiple myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Neoplasm, Residual; Retreatment; Thalidomide; Treatment Outcome | 2016 |
[Multiple myeloma and other plasma cell dyscrasias].
Topics: Bortezomib; Female; Humans; Immunologic Factors; Male; Multiple Myeloma; Proteasome Inhibitors; Thalidomide | 2016 |
Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulins; Immunosuppressive Agents; Kidney Diseases; Lenalidomide; Melphalan; Oligopeptides; Paraproteinemias; Pentostatin; Rituximab; Thalidomide; Vidarabine | 2016 |
Concise review - Treatment of multiple myeloma in the very elderly: How do novel agents fit in?
Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Frailty; Geriatric Assessment; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Myeloma; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide | 2016 |
Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis.
Topics: Antineoplastic Agents; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Induction Chemotherapy; Infections; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Proteasome Inhibitors; Randomized Controlled Trials as Topic; Risk; Thalidomide | 2016 |
Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice.
Topics: Bortezomib; Consolidation Chemotherapy; Humans; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Proteasome Inhibitors; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2016 |
Current treatments for renal failure due to multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Renal Insufficiency; Thalidomide | 2016 |
Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Everolimus; Humans; Imidazoles; Immunologic Factors; Indoles; Kidney Diseases; Lenalidomide; Multiple Myeloma; Nivolumab; Oligopeptides; Oximes; Proteasome Inhibitors; Protein Kinase Inhibitors; Sulfonamides; Thalidomide; Vemurafenib | 2017 |
Stem Cell Transplantation in Multiple Myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Bortezomib; Clinical Trials as Topic; Consolidation Chemotherapy; Humans; Lenalidomide; Multiple Myeloma; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2017 |
The role of maintenance therapy in multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide; Transplantation, Autologous | 2016 |
Practical Considerations in Managing Relapsed Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Recurrence; Thalidomide | 2017 |
Efficacy and safety of elotuzumab for the treatment of multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Immunotherapy; Lenalidomide; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome | 2017 |
An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of Elotuzumab.
Topics: Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Models, Biological; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide | 2017 |
Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Disease Progression; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Proteasome Inhibitors; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2017 |
Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Humans; Multiple Myeloma; Randomized Controlled Trials as Topic; Recurrence; Thalidomide; Treatment Outcome | 2017 |
Posttransplant maintenance therapy in multiple myeloma: the changing landscape.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Molecular Targeted Therapy; Multiple Myeloma; Postoperative Care; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2017 |
Two cases of permanent indwelling catheter for long-term administration of intrapleural chemotherapy.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Catheters, Indwelling; Dexamethasone; Drainage; Fatal Outcome; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Pleural Effusion, Malignant; Rituximab; Thalidomide; Thoracentesis | 2017 |
Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses.
Topics: Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Thalidomide | 2017 |
Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Dexamethasone; Glycine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Multiple Myeloma; Oligopeptides; Panobinostat; Proteasome Inhibitors; Recurrence; Thalidomide | 2017 |
Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recurrence; Technology Assessment, Biomedical; Thalidomide | 2018 |
Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Neutropenia; Recurrence; Thalidomide; Thrombocytopenia | 2017 |
Fixed duration vs continuous therapy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Consolidation Chemotherapy; Disease-Free Survival; Humans; Melphalan; Multiple Myeloma; Prednisone; Survival Rate; Thalidomide; Time Factors | 2017 |
Gastrointestinal perforation in light chain amyloidosis in the era of novel agent therapy - a case series and review of the literature.
Topics: Adult; Aged; Bortezomib; Humans; Immunoglobulin Light-chain Amyloidosis; Intestinal Perforation; Lenalidomide; Male; Middle Aged; Thalidomide | 2018 |
[Research Advance in Light Chain Escape of Multiple Myeloma -Review].
Topics: Bortezomib; Humans; Immunoglobulin G; Immunoglobulin Light Chains; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2017 |
Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Thalidomide; Treatment Outcome | 2018 |
Optimizing therapy in bortezomib-exposed patients with multiple myeloma.
Topics: Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2018 |
Pathophysiology of drug-induce peripheral neuropathy in patients with multiple myeloma.
Topics: Animals; Antineoplastic Agents; Bortezomib; Humans; MicroRNAs; Multiple Myeloma; Nerve Growth Factors; Peripheral Nervous System Diseases; Protease Inhibitors; Thalidomide | 2018 |
Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trial
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2018 |
Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Infusions, Intravenous; Membrane Glycoproteins; Molecular Targeted Therapy; Multiple Myeloma; Thalidomide; Treatment Outcome | 2018 |
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Survival Rate; Thalidomide; Treatment Outcome | 2018 |
[Chemotherapy-induced peripheral neuropathy: Symptomatology and epidemiology].
Topics: Antineoplastic Agents; Bortezomib; Humans; Immunosuppressive Agents; Neoplasms; Peripheral Nervous System Diseases; Platinum Compounds; Quality of Life; Symptom Assessment; Taxoids; Thalidomide; Vinca Alkaloids | 2018 |
[Daratumumab for multiple myeloma].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2018 |
[First-line treatment of multiple myeloma].
Topics: Antineoplastic Agents; Bortezomib; Germany; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2019 |
Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Network Meta-Analysis; Prednisone; Thalidomide; Treatment Outcome | 2019 |
Risk adapted post-transplant maintenance in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2019 |
POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management.
Topics: Adrenal Cortex Hormones; Allografts; Bortezomib; Castleman Disease; Diagnosis, Differential; Humans; POEMS Syndrome; Risk Assessment; Risk Factors; Stem Cell Transplantation; Thalidomide; Vascular Endothelial Growth Factor A | 2019 |
Primary extramedullary plasmacytoma with diffuse lymph node involvement: a case report and review of the literature.
Topics: Aged; Bortezomib; Dexamethasone; Fatigue; Humans; Lymph Nodes; Lymphadenopathy; Male; Plasma Cells; Plasmacytoma; Prednisone; Remission Induction; Thalidomide | 2019 |
Treatment Outcomes in Patients With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem-Cell Transplantation: Systematic Review and Network Meta-analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2019 |
Cost-effectiveness of lenalidomide plus low-dose dexamethasone for newly diagnosed multiple myeloma patients ineligible for stem cell transplantation in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; China; Combined Modality Therapy; Cost-Benefit Analysis; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Observational Studies as Topic; Quality-Adjusted Life Years; Stem Cell Transplantation; Thalidomide | 2019 |
Upfront treatment for newly diagnosed transplant-ineligible multiple myeloma patients: A systematic review and network meta-analysis of 14,533 patients over 29 randomized clinical trials.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bortezomib; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Network Meta-Analysis; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2019 |
Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Network Meta-Analysis; Thalidomide; Treatment Outcome | 2020 |
Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Network Meta-Analysis; Randomized Controlled Trials as Topic; Thalidomide | 2019 |
Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future.
Topics: Adaptive Clinical Trials as Topic; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Thalidomide; Transplantation, Autologous; Withholding Treatment | 2020 |
Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.
Topics: Antibodies, Bispecific; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Humans; Immunoconjugates; Lenalidomide; Multiple Myeloma; Neoplasm, Residual; Recurrence; Survival Analysis; Thalidomide | 2020 |
Second malignancies in multiple myeloma; emerging patterns and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasm, Residual; Neoplasms, Second Primary; Risk Factors; Thalidomide; Transplantation, Autologous | 2020 |
Modern treatments and future directions for newly diagnosed multiple myeloma patients.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bortezomib; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Plasma Cells; Survival Analysis; Thalidomide; Transplantation, Autologous | 2020 |
Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Costs; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Progression-Free Survival; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2020 |
Scleromyxedema treatment: a systematic review and update.
Topics: Bortezomib; Humans; Prospective Studies; Retrospective Studies; Scleromyxedema; Thalidomide | 2020 |
Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma.
Topics: Antibodies, Monoclonal; Bortezomib; Dexamethasone; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2020 |
The role of novel agents for consolidation after autologous transplantation in newly diagnosed multiple myeloma: a systematic review.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Consolidation Chemotherapy; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Risk Assessment; Thalidomide; Transplantation, Autologous | 2021 |
Sequencing multiple myeloma therapies with and after antibody therapies.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; High-Throughput Nucleotide Sequencing; Humans; Immunotherapy; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2020 |
Should all newly diagnosed MM patients receive CD38 antibody-based treatment?
Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Male; Melphalan; Membrane Glycoproteins; Multiple Myeloma; Neoplasm Proteins; Thalidomide | 2020 |
Consensus statement on the treatment of transplant-eligible patients with newly diagnosed multiple myeloma in New Zealand.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bortezomib; Consensus; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; New Zealand; Practice Guidelines as Topic; Thalidomide | 2020 |
New regimens and directions in the management of newly diagnosed multiple myeloma.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bortezomib; Clinical Trials as Topic; Disease Management; Drugs, Investigational; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Protease Inhibitors; Randomized Controlled Trials as Topic; Risk; Thalidomide; Therapies, Investigational | 2021 |
Lessons Learned Treating Patients with Multiple Myeloma in Resource-Constrained Settings.
Topics: Antineoplastic Agents; Bortezomib; Developing Countries; Dexamethasone; Humans; Immunosuppressive Agents; Multiple Myeloma; Poverty; Stem Cell Transplantation; Thalidomide | 2021 |
Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Multiple Myeloma; Proteasome Inhibitors; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2022 |
Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML.
Topics: Bortezomib; Deubiquitinating Enzymes; Drug Discovery; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Proteasome Endopeptidase Complex; Thalidomide; Ubiquitin | 2022 |
Efficacy of maintenance treatment in patients with multiple myeloma: a systematic review and network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Glycine; Humans; Lenalidomide; Multiple Myeloma; Network Meta-Analysis; Prednisone; Thalidomide | 2022 |
143 trial(s) available for thalidomide and bortezomib
| Article | Year |
|---|---|
Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma.
Topics: Boronic Acids; Bortezomib; Cost-Benefit Analysis; Delphi Technique; Economics, Pharmaceutical; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2004 |
Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Leukopenia; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Thrombocytopenia; Transplantation, Homologous | 2006 |
Low dose Velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Treatment Outcome | 2006 |
Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Pyrazines; Recurrence; Salvage Therapy; Survival Analysis; Thalidomide | 2006 |
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Tolerance; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Recurrence; Safety; Salvage Therapy; Thalidomide | 2007 |
Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2006 |
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Proteins; Bone Marrow; Boronic Acids; Bortezomib; Cisplatin; Creatinine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous | 2007 |
Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Hypercalcemia; Kidney Failure, Chronic; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Proteinuria; Pyrazines; Thalidomide; Treatment Outcome; Vincristine | 2007 |
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cell Differentiation; Cell Proliferation; Cell Survival; Cytotoxins; Dexamethasone; Dose-Response Relationship, Drug; Interleukin-6; Lenalidomide; Ligands; Macrophage Colony-Stimulating Factor; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, SCID; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Myeloma; Neoplasm Transplantation; Osteoclasts; Phosphorylcholine; Pyrazines; RANK Ligand; Stromal Cells; Thalidomide; Transplantation, Heterologous; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2007 |
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2007 |
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2007 |
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2007 |
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Polyethylene Glycols; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide | 2008 |
The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Female; Humans; Liposomes; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome | 2008 |
VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide | 2008 |
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.
Topics: Antineoplastic Agents; B-Cell Activating Factor; Bone Remodeling; Bone Resorption; Boronic Acids; Bortezomib; Cathepsin K; Cathepsins; Cells, Cultured; Chemokine CCL3; Humans; Integrin alphaVbeta3; Lenalidomide; Multiple Myeloma; Osteoclasts; Osteoprotegerin; Proto-Oncogene Proteins; Pyrazines; RANK Ligand; Thalidomide; Trans-Activators; Transcription Factor AP-1; Tumor Necrosis Factor Ligand Superfamily Member 13 | 2008 |
[Bortezomib-based combination therapy for relapsed or refractory multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Constipation; Cyclophosphamide; Dexamethasone; Dizziness; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fatigue; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide; Treatment Outcome | 2008 |
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone and Bones; Bone Remodeling; Boronic Acids; Bortezomib; Cytokines; Dexamethasone; Female; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Neovascularization, Physiologic; Pyrazines; Recurrence; Survival Rate; Thalidomide | 2008 |
Update on recent developments for patients with newly diagnosed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Treatment Outcome | 2008 |
Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Interactions; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome; Young Adult | 2008 |
Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Boronic Acids; Bortezomib; Dexamethasone; Epirubicin; Female; Hematopoietic Stem Cell Mobilization; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Survival Analysis; Thalidomide; Treatment Outcome | 2009 |
[Bortezomib combined with other drugs for treating 60 cases of multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2009 |
Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Remission Induction; Salvage Therapy; Steroids; Thalidomide; Treatment Outcome | 2009 |
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Stem Cell Transplantation; Survival Analysis; Thalidomide; Treatment Outcome | 2009 |
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Glucocorticoids; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2009 |
Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome | 2010 |
Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Secondary Prevention; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multip
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Korea; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Prednisolone; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Italy; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Polyethylene Glycols; Prednisone; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome | 2010 |
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Pyrazines; Risk Factors; Thalidomide | 2010 |
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Chi-Square Distribution; Dexamethasone; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Gene Rearrangement; Genes, Immunoglobulin Heavy Chain; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Polymerase Chain Reaction; Pyrazines; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome; Tumor Burden | 2010 |
Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Fatigue; Hematologic Diseases; Humans; Lenalidomide; Multiple Myeloma; Pain; Pyrazines; Remission Induction; Sensation Disorders; Stem Cell Transplantation; Survival Analysis; Thalidomide; Treatment Outcome | 2010 |
A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome; Vincristine | 2010 |
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
Bortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: a Chinese experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; China; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Multiple Myeloma; Pyrazines; Remission Induction; Thalidomide; Treatment Outcome | 2010 |
Bortezomib plus thalidomide for newly diagnosed multiple myeloma in China.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Thalidomide; Treatment Outcome; Young Adult | 2010 |
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Prednisone; Proportional Hazards Models; Protease Inhibitors; Pyrazines; Risk Assessment; Risk Factors; Spain; Thalidomide; Time Factors; Treatment Outcome | 2010 |
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Incidence; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Melphalan; Multiple Myeloma; Prednisone; Proportional Hazards Models; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Cell-Derived Microparticles; Dexamethasone; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Thromboplastin; Venous Thrombosis; Vincristine | 2011 |
Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Calcium-Calmodulin-Dependent Protein Kinases; Death-Associated Protein Kinases; Dexamethasone; Disease-Free Survival; Factor Analysis, Statistical; Humans; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Thalidomide; Transplantation, Autologous | 2010 |
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Pyrazines; Remission Induction; Reoperation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2010 |
Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Treatment Outcome | 2011 |
Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Retrospective Studies; Thalidomide; Transplantation, Autologous | 2012 |
Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Thalidomide; Treatment Outcome | 2011 |
A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Female; Glucocorticoids; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Thalidomide; Treatment Outcome | 2011 |
Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Survival Rate; Thalidomide | 2011 |
[The efficacy and safety of bortezomib plus thalidomide in treatment of newly diagnosed multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2011 |
Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antineoplastic Agents; Benzylamines; Boronic Acids; Bortezomib; Child; Cyclams; Europe; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myeloablative Agonists; Prognosis; Pyrazines; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2011 |
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide; Treatment Failure; Treatment Outcome | 2011 |
Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine | 2012 |
Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Sarcoma, Myeloid; Survival Rate; Thalidomide | 2012 |
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Dose-Response Relationship, Drug; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Survival Analysis; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome | 2011 |
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Glomerular Filtration Rate; Humans; Induction Chemotherapy; Kidney Diseases; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Neoadjuvant Therapy; Prednisone; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome | 2011 |
Bortezomib-dexamethasone or vincristine-doxorubicin-dexamethasone as induction therapy followed by thalidomide as maintenance therapy in untreated multiple myeloma patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome; Vincristine | 2011 |
Emergence of central nervous system myeloma in the era of novel agents.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Central Nervous System Neoplasms; Combined Modality Therapy; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous | 2012 |
Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome | 2012 |
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Male; Metabolic Clearance Rate; Middle Aged; Multiple Myeloma; Nausea; Neutropenia; Panobinostat; Pyrazines; Recurrence; Remission Induction; Thalidomide; Thrombocytopenia; Treatment Outcome | 2012 |
A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Polyethylene Glycols; Prognosis; Prospective Studies; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide | 2012 |
Two cycles of the PS-341/bortezomib, adriamycin, and dexamethasone combination followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cross-Over Studies; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Quality of Life; Recurrence; Thalidomide | 2012 |
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Pyrazines; Thalidomide; Treatment Outcome | 2012 |
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide; Transplantation, Autologous | 2012 |
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomi
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Incidence; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Thalidomide | 2012 |
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cells; Thalidomide; Transplantation, Autologous | 2012 |
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Thalidomide; Vincristine | 2012 |
Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Boronic Acids; Bortezomib; Dexamethasone; DNA Methylation; Doxorubicin; Drug Administration Schedule; Epigenesis, Genetic; Female; Humans; Immunity, Cellular; Lenalidomide; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Plasma Cells; Prospective Studies; Pyrazines; T-Cell Antigen Receptor Specificity; Thalidomide; Transplantation, Autologous | 2012 |
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Maintenance Chemotherapy; Male; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Remission Induction; Survival Rate; Thalidomide | 2012 |
Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Pyrazines; Risk Assessment; Thalidomide | 2013 |
[Current development of new drugs in malignant lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Brentuximab Vedotin; Diphtheria Toxin; Drug Discovery; Everolimus; Humans; Hydroxamic Acids; Immunoconjugates; Indoles; Inotuzumab Ozogamicin; Interleukin-2; Lenalidomide; Lymphoma; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Purine Nucleosides; Pyrazines; Pyrimidinones; Recombinant Fusion Proteins; Sirolimus; Thalidomide; Vorinostat | 2012 |
Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Rate; Thalidomide | 2013 |
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Failure; Treatment Outcome | 2013 |
A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Europe; Female; Gastrointestinal Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Prospective Studies; Protease Inhibitors; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Thrombocytopenia; Treatment Outcome | 2013 |
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; France; Humans; Lenalidomide; Medical Oncology; Middle Aged; Multiple Myeloma; Pyrazines; Societies, Medical; Thalidomide; Treatment Failure; Treatment Outcome | 2013 |
Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Thalidomide; Treatment Outcome | 2013 |
Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Survival Rate; Thalidomide | 2013 |
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Recurrence; Thalidomide | 2013 |
Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2013 |
Value of novel agents and intensive therapy for patients with multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Middle Aged; Multiple Myeloma; Multivariate Analysis; Proportional Hazards Models; Pyrazines; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2014 |
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Recurrence; Thalidomide; Treatment Outcome | 2014 |
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide; Thrombocytopenia; Treatment Outcome | 2014 |
Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Patient Selection; Pyrazines; Remission Induction; Thalidomide; Transplantation, Autologous; Young Adult | 2014 |
Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Monitoring; Female; Half-Life; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Prospective Studies; Pyrazines; Sensitivity and Specificity; Thalidomide; Treatment Outcome | 2014 |
Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Electroacupuncture; Feasibility Studies; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pain Measurement; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Time Factors; Treatment Outcome | 2014 |
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Pyrazines; Risk Factors; Thalidomide; Treatment Outcome | 2014 |
Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Lymphopenia; Male; Middle Aged; Nausea; Nervous System Diseases; Recurrence; Remission Induction; Thalidomide; Treatment Outcome | 2015 |
Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélo
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Female; France; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2014 |
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Gene Expression; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Heavy Chains; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Polymerase Chain Reaction; Pyrazines; Recurrence; Survival Analysis; Thalidomide; Transplantation, Autologous | 2015 |
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2014 |
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study.
Topics: Actin Cytoskeleton; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axons; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Dexamethasone; Drug Monitoring; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neurogenesis; Peripheral Nervous System Diseases; Plasma Cells; Pyrazines; Survival Analysis; Syndecan-1; Thalidomide; Transplantation, Autologous | 2014 |
Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Humans; L-Lactate Dehydrogenase; Middle Aged; Multiple Myeloma; Multivariate Analysis; Mutation; Predictive Value of Tests; Pyrazines; Risk Factors; Survival Analysis; Thalidomide | 2015 |
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation.
Topics: Autografts; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Mobilization; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Thalidomide | 2015 |
The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Cyclophosphamide; Cytogenetic Analysis; Dexamethasone; Disease-Free Survival; Doxorubicin; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Thalidomide | 2015 |
Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Plasma Cells; Polyethylene Glycols; Precision Medicine; Proteomics; Pyrazines; Thalidomide | 2015 |
Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.
Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Community Health Services; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Prognosis; Proportional Hazards Models; Prospective Studies; Risk Assessment; Severity of Illness Index; Survival Analysis; Thalidomide; Treatment Outcome | 2015 |
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Quality of Life; Thalidomide | 2015 |
Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Bortezomib; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Stem Cell Transplantation; Survival Rate; Thalidomide | 2015 |
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide | 2015 |
Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome | 2016 |
Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Bortezomib; Dexamethasone; Electrophoresis; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Melphalan; Multiple Myeloma; Nephelometry and Turbidimetry; Practice Guidelines as Topic; Retrospective Studies; Thalidomide; Transplantation, Homologous | 2016 |
Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Administration Schedule; Drug Dosage Calculations; Female; Humans; Lenalidomide; Logistic Models; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Recurrence; Survival Analysis; Thalidomide; Treatment Outcome | 2016 |
Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cohort Studies; Dexamethasone; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome | 2016 |
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.
Topics: Aged; Bortezomib; Cell Adhesion Molecules; Dexamethasone; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; Humans; Immunophenotyping; Integrins; Lenalidomide; Male; Melphalan; Models, Genetic; Multiple Myeloma; Neoplasm, Residual; Phenotype; Plasma Cells; Prednisone; Prognosis; Thalidomide | 2016 |
Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Staging; Quality of Life; Thalidomide; Treatment Outcome | 2016 |
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neutropenia; Prospective Studies; Thalidomide; Thrombocytopenia | 2016 |
Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Consolidation Chemotherapy; Dexamethasone; Female; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Outcome | 2016 |
Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Thalidomide | 2016 |
The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Bortezomib; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation Conditioning; Vincristine | 2017 |
A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Thalidomide; Treatment Outcome | 2016 |
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hydroxamic Acids; Hyponatremia; Hypophosphatemia; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Nausea; Pain; Panobinostat; Peripheral Nervous System Diseases; Thalidomide; Therapeutic Index, Drug; Treatment Outcome; United Kingdom | 2016 |
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Female; Humans; Hydroxamic Acids; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Oligopeptides; Risk Factors; Thalidomide; Vorinostat | 2016 |
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Prospective Studies; Survival Rate; Thalidomide; Treatment Outcome; Tumor Burden | 2017 |
Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial.
Topics: Bortezomib; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Interferon-alpha; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Survival Rate; Thalidomide | 2017 |
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Immunoglobulin Light Chains; Immunologic Factors; Male; Middle Aged; Survival Rate; Thalidomide | 2017 |
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2017 |
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.
Topics: Adolescent; Adult; Aged; Bortezomib; Chromosome Aberrations; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prognosis; Progression-Free Survival; Thalidomide; Transplantation, Autologous; Young Adult | 2018 |
FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Approval; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide; United States | 2017 |
Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide | 2018 |
Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Feasibility Studies; Follow-Up Studies; Multiple Myeloma; Panobinostat; Recurrence; Survival Rate; Thalidomide | 2019 |
Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2019 |
Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Female; Humans; Japan; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Prognosis; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous | 2019 |
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cohort Studies; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Thalidomide; Treatment Outcome | 2019 |
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chemotherapy, Adjuvant; Combined Modality Therapy; Dexamethasone; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Survival Analysis; Thalidomide; Transplantation, Autologous; Treatment Outcome; Young Adult | 2019 |
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Depsipeptides; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Peptides, Cyclic; Survival Rate; Thalidomide | 2019 |
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Febrile Neutropenia; Female; Frail Elderly; Frailty; Hematologic Diseases; Humans; Incidence; Infections; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Progression-Free Survival; Recurrence; Republic of Korea; Thalidomide | 2020 |
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Prognosis; Prospective Studies; Remission Induction; Survival Rate; Thalidomide; Transplantation, Autologous | 2020 |
Pomalidomide-bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Japan; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Thalidomide; Treatment Outcome | 2020 |
Serum brain-derived neurotrophic factor (BDNF) concentration predicts polyneuropathy and overall survival in multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Bortezomib; Brain-Derived Neurotrophic Factor; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Polyneuropathies; Survival Rate; Thalidomide | 2020 |
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Female; Humans; Immunologic Factors; Immunomodulation; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Remission Induction; Thalidomide; Treatment Outcome | 2021 |
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Rate; Thalidomide | 2021 |
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2020 |
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Male; Multiple Myeloma; Quality of Life; Thalidomide | 2020 |
Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-1
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Dexamethasone; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2020 |
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Multiple Myeloma; Stem Cell Transplantation; Stem Cells; Thalidomide; Transplantation, Autologous | 2021 |
Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Frail Elderly; Hematologic Diseases; Humans; Hyponatremia; Japan; Kaplan-Meier Estimate; Male; Multiple Myeloma; Peripheral Nervous System Diseases; Precision Medicine; Progression-Free Survival; Prospective Studies; Thalidomide; Treatment Outcome | 2021 |
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2022 |
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label,
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Administration Schedule; Europe; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Young Adult | 2021 |
Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Dexamethasone; Humans; Multiple Myeloma; Renal Insufficiency; Thalidomide | 2022 |
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide; Thrombocytopenia | 2023 |
493 other study(ies) available for thalidomide and bortezomib
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Moving disease biology from the lab to the clinic.
Topics: Bone Marrow; Boronic Acids; Bortezomib; Cell Division; Drug Delivery Systems; Heterocyclic Compounds, 3-Ring; Humans; Lenalidomide; Models, Biological; Multiple Myeloma; Protease Inhibitors; Pyrazines; Pyridines; Thalidomide | 2003 |
Innovative strategies in lymphoma therapy.
Topics: Alemtuzumab; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cancer Vaccines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Forecasting; Genetic Therapy; Humans; Immunoconjugates; Immunotherapy; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Prednisone; Protease Inhibitors; Proteomics; Pyrazines; Radioimmunotherapy; Randomized Controlled Trials as Topic; Rituximab; Signal Transduction; Survival Analysis; Thalidomide; Time Factors; Vincristine | 2003 |
[Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide | 2004 |
[Targeted in therapies multiple myeloma].
Topics: Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2004 |
[Multiple myeloma -- therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Radiotherapy, Adjuvant; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2005 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide | 2005 |
Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide.
Topics: Antineoplastic Agents; Asthenia; Biopsy; Bone Marrow Cells; Boronic Acids; Bortezomib; Female; Humans; Immunosuppressive Agents; Liver; Liver Neoplasms; Middle Aged; Multiple Myeloma; Plasma Cells; Plasmacytoma; Pyrazines; Recurrence; Thalidomide | 2005 |
NF-kappaB and not the MAPK signaling pathway regulates GADD45beta expression during acute inflammation.
Topics: Animals; Antigens, Differentiation; Apoptosis; Arsenites; Blotting, Northern; Blotting, Western; Boronic Acids; Bortezomib; Dexamethasone; DNA Damage; Extracellular Signal-Regulated MAP Kinases; Female; Gene Library; Genetic Vectors; I-kappa B Proteins; Inflammation; Lipopolysaccharides; Luciferases; Male; MAP Kinase Signaling System; Mice; Mice, Transgenic; NF-kappa B; NF-KappaB Inhibitor alpha; Oxidative Stress; Promoter Regions, Genetic; Proteasome Inhibitors; Protein Binding; Pyrazines; RNA, Messenger; Signal Transduction; Sodium Compounds; Thalidomide; Time Factors; Tissue Distribution; Tumor Necrosis Factor-alpha | 2005 |
Bortezomib treatment followed by a second non-myeloablative allogeneic stem cell transplant in two previously autografted patients with multiple myeloma relapse.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Pyrazines; Recurrence; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous | 2005 |
[Therapeutic outcomes in systemic lymphatic diseases and plasmacytoma. New hope for palliative patients].
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lymphoma; Multiple Myeloma; Prognosis; Pyrazines; Radioimmunotherapy; Thalidomide | 2005 |
Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Fatal Outcome; Humans; Immunoglobulin D; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Salvage Therapy; Thalidomide | 2005 |
Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Remission Induction; Salvage Therapy; Thalidomide | 2005 |
New therapies for the treatment of multiple myeloma.
Topics: Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Platelet Aggregation Inhibitors; Polydeoxyribonucleotides; Protease Inhibitors; Pyrazines; Thalidomide | 2005 |
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.
Topics: Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Differentiation; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Parathyroid Hormone; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Retrospective Studies; Thalidomide; Treatment Outcome | 2005 |
Multiple myeloma: the present and the future.
Topics: Antineoplastic Agents, Alkylating; Bone Diseases; Boronic Acids; Bortezomib; Diphosphonates; Humans; Immunosuppressive Agents; Medical Oncology; Melphalan; Multiple Myeloma; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2005 |
New agents and approaches in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2003 |
New treatment approaches in multiple myeloma.
Topics: Aged; Boronic Acids; Bortezomib; Congresses as Topic; Female; Humans; Incidence; Israel; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide | 2005 |
Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2005 |
Hematologic malignancies: from clinical science to clinical practice - 2nd European Congress.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematologic Neoplasms; Humans; Ki-1 Antigen; Molecular Structure; Multiple Myeloma; Pyrazines; Thalidomide | 2006 |
Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous | 2006 |
A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Korea; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2006 |
[Molecular-targeted therapy for hormone-refractory prostate cancer].
Topics: Angiotensin Receptor Antagonists; Antineoplastic Agents; Atrasentan; Benzamides; Boronic Acids; Bortezomib; Calcitriol; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelin A Receptor Antagonists; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sulfonamides; Thalidomide; Vitamin D | 2006 |
[A cure for multiple myeloma?].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2006 |
Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2006 |
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Clarithromycin; Dexamethasone; Diphosphonates; Glomerulonephritis; Humans; Idarubicin; Imidazoles; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Nephrotic Syndrome; Pamidronate; Protein Synthesis Inhibitors; Pyrazines; Skin Neoplasms; Thalidomide; Zoledronic Acid | 2006 |
New drugs for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Design; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Survival Rate; Thalidomide; Treatment Outcome | 2006 |
Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells.
Topics: Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Caspase 3; Cell Proliferation; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Multiple Myeloma; NF-kappa B; Proto-Oncogene Proteins c-akt; Pyrazines; Resveratrol; STAT3 Transcription Factor; Stilbenes; Syndecan-1; Thalidomide; Tumor Cells, Cultured | 2007 |
Novel agents for multiple myeloma treatment.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Design; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2006 |
Medical management update: multiple myeloma.
Topics: Adrenal Cortex Hormones; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Dental Care for Chronically Ill; Diphosphonates; Hematopoietic Stem Cell Transplantation; Humans; Jaw Diseases; Jaw Neoplasms; Multiple Myeloma; Oral Hemorrhage; Osteonecrosis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Thalidomide | 2007 |
Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Multiple Myeloma; Pyrazines; Recurrence; Reproducibility of Results; Thalidomide | 2007 |
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous | 2007 |
Multiple myeloma therapies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Clinical Trials as Topic; HSP90 Heat-Shock Proteins; Humans; Immunosuppressive Agents; Lactams, Macrocyclic; Melphalan; Multiple Myeloma; Pyrazines; Thalidomide | 2007 |
Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Capsaicin; Caspase 3; Caspase Inhibitors; Cell Line, Tumor; Cell Proliferation; Cyclin D1; DNA; Extracellular Signal-Regulated MAP Kinases; G1 Phase; Humans; Inhibitor of Apoptosis Proteins; Interleukin-6; Janus Kinase 1; Microtubule-Associated Proteins; Multiple Myeloma; Neoplasm Proteins; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins c-bcl-2; Pyrazines; STAT3 Transcription Factor; Survivin; Thalidomide; Vascular Endothelial Growth Factor A | 2007 |
Bortezomib and lenalidomide effective in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2007 |
Advances in the treatment of MDS, multiple myeloma, and CLL.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Multiple Myeloma; Myelodysplastic Syndromes; Nurse's Role; Oncology Nursing; Prognosis; Pyrazines; Risk Assessment; Thalidomide | 2007 |
Managing patients with multiple myeloma and mantle cell lymphoma: where are we now?
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Multiple Myeloma; Nurse's Role; Nursing Assessment; Oncology Nursing; Pyrazines; Thalidomide | 2007 |
Multiple myeloma patient care: treatment options and nursing considerations.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Nurse's Role; Oncology Nursing; Pyrazines; Thalidomide | 2007 |
Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; L-Lactate Dehydrogenase; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Tumor Lysis Syndrome | 2008 |
Bortezomib in combination with thalidomide and dexamethasone--a successful treatment regimen in refractory extramedullary multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Plasmacytoma; Pyrazines; Radiography; Remission Induction; Spinal Neoplasms; Thalidomide; Transplantation, Autologous | 2008 |
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
Topics: Animals; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Boronic Acids; Bortezomib; Clone Cells; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Mice; Mice, Inbred Strains; Multiple Myeloma; Neoplastic Stem Cells; Plasma Cells; Pyrazines; Syndecan-1; Thalidomide; Tumor Necrosis Factor Receptor Superfamily, Member 7; Tumor Stem Cell Assay | 2008 |
Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
Topics: Aged; Angiogenic Proteins; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Capillaries; Cytokines; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Prognosis; Pyrazines; Thalidomide | 2008 |
Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease.
Topics: Amyloidosis; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Immunosuppressive Agents; Male; Protease Inhibitors; Pyrazines; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide | 2008 |
Controversies regarding the use of dexamethasone in patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Doxorubicin; Glucocorticoids; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide; Vincristine | 2008 |
Treatment for elderly patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide | 2008 |
Multiple myeloma presenting with advanced renal failure: a case report and new treatment options.
Topics: Adult; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Male; Multiple Myeloma; Pyrazines; Renal Dialysis; Renal Insufficiency; Thalidomide | 2008 |
[Treatment of myeloma in the elderly].
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Diphosphonates; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Thalidomide | 2008 |
Transient efficacy of double high-dose chemotherapy and autologous peripheral stem cell transplantation, immunoglobulin, thalidomide, and bortezomib in the treatment of scleromyxedema.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Immunoglobulins; Male; Peripheral Blood Stem Cell Transplantation; Pyrazines; Recurrence; Scleromyxedema; Thalidomide | 2008 |
Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.
Topics: Alkaline Phosphatase; Apoptosis; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Osteoblasts; Osteoclasts; Pyrazines; Thalidomide; Transforming Growth Factor beta | 2008 |
New treatments in multiple myeloma: beyond optimal treatment.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide | 2008 |
Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Risk Factors; Salvage Therapy; Survival Rate; Thalidomide | 2008 |
Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Dental Prophylaxis; Diphosphonates; Female; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pyrazines; Retrospective Studies; Thalidomide; Young Adult; Zoledronic Acid | 2009 |
Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.
Topics: Aged; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin D2; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Dexamethasone; Female; Humans; Intracellular Signaling Peptides and Proteins; Male; Melphalan; Middle Aged; Multiple Myeloma; Phosphorylation; Pyrazines; Retinoblastoma Protein; Thalidomide; Time Factors; Transfection; Up-Regulation; Vincristine | 2008 |
Novel agents in myeloma: an exciting saga.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide; Thrombosis | 2009 |
[Outcome of bortezomib plus chemotherapy with or without stem cell transplantation for treatment of multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2008 |
Bortezomib plus melphalan and prednisone for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2008 |
Induction therapy in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Humans; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous | 2008 |
Bortezomib plus melphalan and prednisone for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Disease Progression; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis; Thalidomide | 2008 |
Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Electrophysiology; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Prevalence; Pyrazines; Thalidomide | 2008 |
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).
Topics: Age Factors; Aged; Analysis of Variance; Boronic Acids; Bortezomib; Drug Evaluation; Female; Greece; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Staging; Pyrazines; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Cutaneous involvement in multiple myeloma and bortezomib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin A; Melphalan; Multiple Myeloma; Myeloma Proteins; Paresthesia; Peripheral Nervous System Diseases; Plasma Cells; Prednisone; Pyrazines; Remission Induction; Skin; Thalidomide; Xerophthalmia | 2009 |
[Therapeutic news in multiple myeloma. Congress of the French National Society of Internal Medicine, December 2008, Bordeaux].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; France; Humans; Internal Medicine; Melphalan; Multiple Myeloma; Prognosis; Pyrazines; Societies, Medical; Thalidomide | 2009 |
Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Curcumin; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Nude; Multiple Myeloma; NF-kappa B; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; Thalidomide; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2009 |
Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Meta-Analysis as Topic; Multiple Myeloma; Pyrazines; Research Design; Salvage Therapy; Survival Analysis; Thalidomide; Transplantation, Autologous | 2009 |
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Consensus Development Conferences as Topic; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Medical Oncology; Multiple Myeloma; Pyrazines; Thalidomide | 2009 |
[A clinical analysis of 25 cases of multiple myeloma complicated by extramedullary plasmacytomas].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Plasmacytoma; Prognosis; Pyrazines; Thalidomide | 2009 |
Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Separation; Cyclophosphamide; Dexamethasone; Female; Flow Cytometry; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Plasma Cells; Prognosis; Prospective Studies; Pyrazines; Thalidomide; Treatment Outcome | 2009 |
Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide.
Topics: Antineoplastic Agents; Bone Morphogenetic Protein 2; Boronic Acids; Bortezomib; Case-Control Studies; Cell Differentiation; Core Binding Factor Alpha 1 Subunit; Down-Regulation; Humans; Lenalidomide; Multiple Myeloma; Osteoblasts; Pyrazines; RNA, Messenger; Sp7 Transcription Factor; Thalidomide; Transcription Factors; Tumor Cells, Cultured | 2010 |
Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Male; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Pyrazines; Recurrence; Renal Insufficiency; Risk Factors; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide | 2009 |
Relapse/Refractory myeloma patient: potential treatment guidelines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2009 |
DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Intercellular Signaling Peptides and Proteins; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Peripheral Blood Stem Cell Transplantation; Prognosis; Pyrazines; Recurrence; Thalidomide; Transplantation, Autologous; Vincristine | 2010 |
Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Female; Humans; Male; Middle Aged; Multiple Myeloma; Plasma Cells; Prognosis; Pyrazines; Thalidomide | 2010 |
Lenalidomide-induced acute acneiform folliculitis of the head and neck: not only the anti-EGF receptor agents.
Topics: Acneiform Eruptions; Aged; Boronic Acids; Bortezomib; Candida albicans; Candidiasis; Desonide; Dexamethasone; Doxycycline; ErbB Receptors; Fluconazole; Folliculitis; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Pyrazines; Thalidomide | 2010 |
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiovascular Diseases; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Gastrointestinal Diseases; Glomerular Filtration Rate; Hematologic Diseases; Humans; Italy; Kidney Diseases; Male; Melphalan; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Proteins; Peripheral Nervous System Diseases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Survival Analysis; Thalidomide | 2010 |
Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Betulinic Acid; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Drug Therapy, Combination; Electrophoretic Mobility Shift Assay; Enzyme Activation; Flow Cytometry; Humans; Immunoenzyme Techniques; Immunosuppressive Agents; Interleukin-6; Janus Kinase 1; Janus Kinase 2; Luciferases; Multiple Myeloma; Pentacyclic Triterpenes; Protease Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyrazines; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor; Thalidomide; Triterpenes; Tumor Cells, Cultured | 2010 |
Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2009 |
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Cells, Cultured; Dexamethasone; Disease Models, Animal; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Panobinostat; Pyrazines; Random Allocation; Thalidomide; Xenograft Model Antitumor Assays | 2010 |
Treatment of multiple myeloma: 2009 update.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine | 2009 |
Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma.
Topics: Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Outcome Assessment, Health Care; Pyrazines; Thalidomide; Transplantation, Autologous; Vincristine | 2010 |
[IgA multiple myeloma with adverse prognostic factors--a case report].
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Drug Resistance, Neoplasm; Humans; Immunoglobulin A; Male; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide | 2009 |
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Proportional Hazards Models; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2010 |
Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclin D1; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppression Therapy; Lenalidomide; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Second Primary; Pyrazines; Rituximab; Thalidomide; Transplantation, Autologous | 2010 |
Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Clone Cells; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Karyotyping; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplastic Stem Cells; Peripheral Blood Stem Cell Transplantation; Polyploidy; Protease Inhibitors; Pyrazines; Thalidomide; Translocation, Genetic; Transplantation, Autologous | 2010 |
Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Asthenia; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Prognosis; Pyrazines; Risk Management; Risk Reduction Behavior; Thalidomide | 2010 |
Multiple myeloma patients experience high response rate with new three-drug combination.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Humans; Lenalidomide; Leukocytes; Multicenter Studies as Topic; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2009 |
High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Doxorubicin; Female; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Outcome Assessment, Health Care; Proportional Hazards Models; Prospective Studies; Pyrazines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thalidomide; Thrombosis; Vincristine | 2010 |
Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kidney; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Renal Insufficiency; Thalidomide; Time Factors; Treatment Outcome; X-Rays | 2010 |
Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Clinical Trials as Topic; Compassionate Use Trials; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Research; Stem Cell Transplantation; Thalidomide | 2010 |
Nonspecific interstitial pneumonitis after bortezomib and thalidomide treatment in a multiple myeloma patient.
Topics: Aged; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lung Diseases, Interstitial; Male; Multiple Myeloma; Pyrazines; Thalidomide | 2010 |
[Analysis of high-risk multiple myeloma patients treated with high-dose chemotherapy].
Topics: Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Humans; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prognosis; Pulse Therapy, Drug; Pyrazines; Risk; Survival Rate; Thalidomide; Transplantation, Autologous | 2010 |
The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Feasibility Studies; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Multiple Myeloma; Panobinostat; Pyrazines; Thalidomide; Treatment Failure; Treatment Outcome | 2010 |
Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Evaluation; Female; Hematologic Diseases; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Nervous System Diseases; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Retrospective Studies; Thalidomide; Time Factors; Transplantation, Autologous | 2010 |
Treatment of newly diagnosed multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2008 |
Clinical management of myeloma--state of the art.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Pyrazines; Receptors, Glucocorticoid; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide | 2010 |
Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytogenetic Analysis; Female; Humans; Immunomodulation; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk Factors; Salvage Therapy; Thalidomide | 2010 |
Frontline regimens for multiple myeloma patients.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Design; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2010 |
Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Pyrazines; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Thalidomide; Time Factors | 2010 |
Early response assessment in patients with multiple myeloma during anti-angiogenic therapy using arterial spin labelling: first clinical results.
Topics: Aged; Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Pilot Projects; Pyrazines; Reproducibility of Results; Sensitivity and Specificity; Spin Labels; Thalidomide; Treatment Outcome | 2010 |
No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Boronic Acids; Bortezomib; Cyclophosphamide; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; DNA, Neoplasm; Female; Follow-Up Studies; Genotype; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Phenotype; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Pyrazines; Retrospective Studies; Survival Rate; Thalidomide | 2010 |
γ-Tocotrienol but not γ-tocopherol blocks STAT3 cell signaling pathway through induction of protein-tyrosine phosphatase SHP-1 and sensitizes tumor cells to chemotherapeutic agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Boronic Acids; Bortezomib; Chromans; Enzyme Induction; G1 Phase; gamma-Tocopherol; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Inhibitor of Apoptosis Proteins; Janus Kinase 1; Janus Kinase 2; Mice; Neoplasm Proteins; Neoplasms; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyrazines; RNA, Small Interfering; src-Family Kinases; STAT3 Transcription Factor; Thalidomide; Vitamin E | 2010 |
Optimising bortezomib in newly diagnosed multiple myeloma.
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thalidomide; Time Factors; Treatment Outcome | 2010 |
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Pyrazines; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Boronic Acids; Bortezomib; Cytarabine; Deoxycytidine; Dexamethasone; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; HIV Infections; Humans; Lenalidomide; Lymphoma, Large-Cell, Immunoblastic; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polyethylene Glycols; Pyrazines; Recombinant Proteins; Thalidomide; Young Adult | 2010 |
Lenalidomide for bortezomib-resistant multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Health Status Indicators; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Thalidomide; Treatment Failure | 2010 |
Lenalidomide efficacy in bortezomib-resistant myeloma.
Topics: Acute Kidney Injury; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Gene Deletion; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Risk Factors; Thalidomide; Treatment Failure | 2010 |
Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Thromboembolism | 2011 |
Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway.
Topics: Antineoplastic Agents; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Humans; Inositol Polyphosphate 5-Phosphatases; Interleukin-6; Janus Kinase 2; Multiple Myeloma; Phosphoric Monoester Hydrolases; Phosphorylation; Pyrazines; Signal Transduction; STAT3 Transcription Factor; Thalidomide; Vanadates | 2010 |
First-line treatment of elderly multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2010 |
In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; HL-60 Cells; Humans; Immunohistochemistry; Inhibitory Concentration 50; K562 Cells; Ki-67 Antigen; Lenalidomide; Leukemia, Myeloid; Lymphoma; Multiple Myeloma; Phosphorylcholine; Pyrazines; Thalidomide; Time Factors | 2012 |
Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Drug Discovery; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Risk Factors; Survival Rate; Thalidomide; Transplantation, Autologous; Young Adult | 2011 |
A new standard of care in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoadjuvant Therapy; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Standard of Care; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2010 |
Successful treatment with bortezomib and thalidomide for POEMS syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Middle Aged; POEMS Syndrome; Pyrazines; Radionuclide Imaging; Remission Induction; Thalidomide; Treatment Outcome | 2011 |
Janus activated kinase 2/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Flavonoids; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 2; Multiple Myeloma; Pyrazines; Signal Transduction; STAT3 Transcription Factor; Thalidomide | 2011 |
Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Doxorubicin; Female; Humans; Lenalidomide; Male; Middle Aged; Mitoxantrone; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome; Vincristine | 2011 |
Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Drug Costs; Drug Resistance, Neoplasm; Drug Utilization; Female; France; Health Care Costs; Hospitals, University; Humans; Lenalidomide; Male; Medical Records; Middle Aged; Multiple Myeloma; Practice Patterns, Physicians'; Pyrazines; Recurrence; Retrospective Studies; Thalidomide | 2011 |
Primary plasma cell leukemia: a retrospective multicenter study of 73 patients.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Retrospective Studies; Survival Rate; Thalidomide; Transplantation, Autologous; Treatment Outcome; Young Adult | 2011 |
Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Denmark; Female; Genetic Association Studies; Humans; Interferon-alpha; Interleukin-1beta; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; NF-kappa B p50 Subunit; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Prognosis; Promoter Regions, Genetic; Pyrazines; Recombinant Proteins; Survival Analysis; Thalidomide | 2011 |
Recent advances in myeloma treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Quality of Life; Salvage Therapy; Stem Cell Transplantation; Thalidomide | 2011 |
Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2011 |
Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Biomarkers; Boronic Acids; Bortezomib; Case-Control Studies; Cytokine Receptor gp130; Female; GATA2 Transcription Factor; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Receptors, CXCR4; T-Lymphocyte Subsets; Thalidomide; Transplantation, Autologous | 2011 |
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
Topics: Activated Protein C Resistance; Aged; Anticoagulants; Aspirin; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunologic Factors; International Normalized Ratio; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Risk Factors; Thalidomide; Thrombosis; Venous Thromboembolism; Warfarin | 2011 |
Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Female; Humans; Japan; Leukopenia; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Retrospective Studies; Survival; Thalidomide; Thrombocytopenia; Time Factors | 2011 |
History of multiple myeloma.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Bence Jones Protein; Boronic Acids; Bortezomib; History, 19th Century; History, Ancient; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Paraproteinemias; Prednisone; Proteinuria; Pyrazines; Stem Cell Transplantation; Thalidomide; Urethane | 2011 |
Allogeneic transplantation in multiple myeloma.
Topics: Animals; Boronic Acids; Bortezomib; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Mice; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Thalidomide; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2011 |
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide.
Topics: Adult; Aged; Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Immunosuppressive Agents; Lenalidomide; Male; Melphalan; Middle Aged; Pyrazines; Recurrence; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome | 2012 |
[Effect of different regimens on bone disease of multiple myeloma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Resorption; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Multiple Myeloma; Pyrazines; RANK Ligand; Thalidomide | 2011 |
Cost effectiveness of treatments for relapsed/refractory multiple myeloma: response to a methodology. RE: Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, Löthgren M. The cost effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swed
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Humans; Kaplan-Meier Estimate; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Sweden; Thalidomide | 2011 |
In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Biological Availability; Blotting, Western; Boron Compounds; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dexamethasone; Drug Synergism; Enzyme Activation; Glycine; Humans; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Thalidomide; Xenograft Model Antitumor Assays | 2011 |
In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors.
Topics: Annexin A5; Antigens, CD34; Boronic Acids; Bortezomib; Caspases; Colony-Forming Units Assay; Doxorubicin; Flow Cytometry; Health; Hematopoietic Stem Cells; Humans; Immunohistochemistry; Lenalidomide; Phosphorylcholine; Pyrazines; Staining and Labeling; Thalidomide; Tissue Donors; Trypan Blue | 2012 |
Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Thalidomide; Tissue Donors; Transplantation Conditioning; Transplantation, Autologous | 2012 |
Multiple myeloma associated IgA pemphigus: treatment with bortezomib- and lenalidomide-based regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin A; Lenalidomide; Middle Aged; Multiple Myeloma; Pemphigus; Pyrazines; Remission Induction; Thalidomide | 2011 |
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; Chromosome Aberrations; Comparative Genomic Hybridization; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Lenalidomide; Models, Biological; Multiple Myeloma; Peptide Hydrolases; Pyrazines; RNA, Small Interfering; Thalidomide; Ubiquitin-Protein Ligases | 2011 |
Cardiac amyloidosis: a treatable disease, often overlooked.
Topics: Adrenergic beta-Antagonists; Amyloidosis; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Boronic Acids; Bortezomib; Calcium Channel Blockers; Dexamethasone; Diuretics; Drug Therapy, Combination; Female; Heart Failure; Humans; Lenalidomide; Melphalan; Middle Aged; Myocardium; Prealbumin; Pyrazines; Severity of Illness Index; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2011 |
Successful treatment with bortezomib and thalidomide for POEMS syndrome associated with multicentric mixed-type Castleman's disease.
Topics: Adult; Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Castleman Disease; Drug Therapy, Combination; Humans; Male; POEMS Syndrome; Pyrazines; Thalidomide; Vascular Endothelial Growth Factor A | 2011 |
Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Computer Simulation; Cost-Benefit Analysis; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Models, Economic; Multiple Myeloma; Norway; Pyrazines; Quality of Life; Quality-Adjusted Life Years; Thalidomide | 2011 |
Sudden significant total protein concentration change: not an analytical problem.
Topics: Aged; Antineoplastic Agents; Blood Proteins; Boronic Acids; Bortezomib; Humans; Lenalidomide; Male; Multiple Myeloma; Pyrazines; Serum Albumin; Serum Globulins; Thalidomide | 2011 |
Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Epirubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Proteasome Endopeptidase Complex; Pyrazines; Thalidomide; Up-Regulation | 2011 |
A third-generation IMiD for MM.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Pyrazines; Thalidomide | 2011 |
NICE guidance on bortezomib and thalidomide for first-line treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Drug Costs; Evidence-Based Medicine; Humans; Multiple Myeloma; Practice Guidelines as Topic; Pyrazines; Quality-Adjusted Life Years; State Medicine; Thalidomide; Treatment Outcome; United Kingdom | 2011 |
Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Monitoring; Drugs, Investigational; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin G; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Immunoglobulin M; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Neoplasm, Residual; Prognosis; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Thalidomide | 2012 |
Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Leukemia, Plasma Cell; Male; Melphalan; Middle Aged; Prednisone; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome; Vincristine | 2012 |
Amyloidosis.
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Marrow; Boronic Acids; Bortezomib; Cyclophosphamide; Delayed Diagnosis; Dexamethasone; Dyspnea; Heart Diseases; Humans; Kidney; Kidney Diseases; Male; Narration; Pyrazines; Quality of Life; Serum Amyloid A Protein; Thalidomide | 2011 |
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2012 |
Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Renal Insufficiency; Survival Analysis; Thalidomide; Treatment Outcome | 2011 |
What is the benefit of maintenance therapy with lenalidomide or bortezomib after autologous stem cell transplantation in multiple myeloma and what is the risk of developing a secondary primary malignancy?
Topics: Boronic Acids; Bortezomib; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Risk Factors; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2011 |
Drugs: More shots on target.
Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Glycine; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide; Threonine | 2011 |
Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.
Topics: Acute Kidney Injury; Aged; Boronic Acids; Bortezomib; Combined Modality Therapy; Databases, Factual; Dexamethasone; Female; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Dialysis; Thalidomide | 2012 |
Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Fatal Outcome; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Neoplasms, Second Primary; Pyrazines; Recurrence; Remission Induction; Thalidomide | 2012 |
The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide | 2012 |
Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Growth Differentiation Factor 15; Humans; Lenalidomide; Male; Melphalan; Mesenchymal Stem Cells; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Signal Transduction; Thalidomide | 2012 |
A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Thalidomide | 2012 |
Timing of the high-dose therapy in the area of new drugs.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Melphalan; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2011 |
Scleromyxoedema due to a plasma cell neoplasm: rapid remission with bortezomib, thalidomide and dexamethasone.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Middle Aged; Neoplasms, Plasma Cell; Pyrazines; Scleromyxedema; Thalidomide | 2012 |
Multiple myeloma: treatment evolution.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Young Adult | 2012 |
Frontline treatment of multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide | 2012 |
Stem cell transplantation for multiple myeloma: current and future status.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Developing Countries; History, 20th Century; History, 21st Century; Humans; Lenalidomide; Multiple Myeloma; Patient Care; Pyrazines; Stem Cell Transplantation; Thalidomide | 2012 |
Targeted therapy of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Pyrazines; Secondary Prevention; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2012 |
[Prognostic significance of morphology in multiple myeloma].
Topics: Aged; Antineoplastic Agents; Bone Marrow; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Plasma Cells; Prognosis; Pyrazines; Thalidomide; Transplantation, Autologous | 2012 |
Bortezomib combined with thalidomide and dexamethasone is effective for patient with crystal-storing histiocytosis associated with monoclonal gammopathy of undermined significance.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Female; Histiocytosis; Humans; Paraproteinemias; Pyrazines; Thalidomide | 2012 |
Light chain deposition disease affecting the gastrointestinal tract in the setting of post-living donor kidney transplantation.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Gastrointestinal Tract; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Immunoglobulin Light Chains; Kidney Transplantation; Lenalidomide; Male; Middle Aged; Paraproteinemias; Pyrazines; Thalidomide; Treatment Outcome | 2012 |
Bortezomib induces heme oxygenase-1 expression in multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Heme Oxygenase-1; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Tumor Cells, Cultured | 2012 |
Reduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Humans; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Stem Cells; Thalidomide; Vincristine | 2012 |
Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; International Agencies; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome; Vincristine | 2012 |
Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Female; Humans; Lenalidomide; Liver Neoplasms; Middle Aged; Multimodal Imaging; Multiple Myeloma; Positron-Emission Tomography; Pyrazines; Recurrence; Thalidomide; Tomography, X-Ray Computed; Treatment Failure | 2012 |
[Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].
Topics: Amyloidosis; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Combinations; Drug Therapy, Combination; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Immunologic Factors; Lenalidomide; Melphalan; Prednisone; Pyrazines; Thalidomide | 2012 |
Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation.
Topics: Aged; Antiviral Agents; Boronic Acids; Bortezomib; Cytomegalovirus; Cytomegalovirus Infections; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Pyrazines; Retrospective Studies; Risk Factors; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Viral Load; Viremia; Virus Activation | 2012 |
The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Renal Insufficiency; Survival Rate; Thalidomide; Vincristine | 2013 |
Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.
Topics: Aged; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA Methylation; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Interferon Regulatory Factors; Lenalidomide; Multiple Myeloma; PAX5 Transcription Factor; Phenotype; Positive Regulatory Domain I-Binding Factor 1; Prognosis; Proto-Oncogene Proteins c-bcl-6; Pyrazines; Regulatory Factor X Transcription Factors; Repressor Proteins; Syndecan-1; Thalidomide; Transcription Factors; X-Box Binding Protein 1 | 2012 |
[It is not necessary to use novel agents to all patients with newly diagnosed myeloma as an initial therapy].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide | 2012 |
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Muscle Weakness; Neutropenia; Pneumonia; Pyrazines; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome | 2013 |
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dexamethasone; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Lenalidomide; Mice; Mice, SCID; Molecular Sequence Data; Multiple Myeloma; Neovascularization, Pathologic; Protease Inhibitors; Proto-Oncogene Proteins c-mdm2; Pyrazines; Random Allocation; Thalidomide; Thiophenes; Ubiquitin Thiolesterase; Ubiquitin-Specific Peptidase 7; Xenograft Model Antitumor Assays | 2012 |
BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amides; Antineoplastic Agents; Boronic Acids; Bortezomib; Caspases; Cell Survival; Humans; I-kappa B Proteins; Lenalidomide; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Nitriles; Phosphorylation; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; RNA, Messenger; Signal Transduction; Thalidomide; Tumor Cells, Cultured | 2013 |
Chemotherapeutic agents increase the risk for pulmonary function test abnormalities in patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lung Diseases; Male; Middle Aged; Multiple Myeloma; Pyrazines; Respiratory Function Tests; Risk Factors; Thalidomide | 2012 |
How to select among available options for the treatment of multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Radiation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |
Role of carfilzomib in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Multiple Myeloma; Oligopeptides; Peptide Hydrolases; Proteasome Inhibitors; Pyrazines; Thalidomide | 2012 |
Safety and efficacy of triplet regimens in newly diagnosed light chain amyloidosis.
Topics: Adult; Aged; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Pyrazines; Retrospective Studies; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2013 |
Lenalidomide is effective for the treatment of bortezomib-resistant extramedullary disease in patients with multiple myeloma: report of 2 cases.
Topics: Aged; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide | 2013 |
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus doxorubicin and dexamethasone as induction therapy in previously untreated multiple myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Immunophenotyping; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Drug Costs; Health Care Costs; Hospitalization; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Multivariate Analysis; Netherlands; Prognosis; Pyrazines; Recurrence; Regression Analysis; Retrospective Studies; Thalidomide; Young Adult | 2013 |
[Diagnosis and treatment for plasma cell leukemia].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Glucocorticoids; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Plasma Cell; Melphalan; Pyrazines; Rituximab; Thalidomide | 2012 |
Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Thalidomide; Treatment Outcome | 2013 |
Hodgkin's lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Boronic Acids; Bortezomib; Combined Modality Therapy; Dacarbazine; Dexamethasone; Doxorubicin; Epstein-Barr Virus Infections; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Salvage Therapy; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Vinblastine; Vincristine | 2013 |
Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy.
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Melphalan; Myeloablative Agonists; Myocardium; Pyrazines; Steroids; Survival Analysis; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |
Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone.
Topics: Amines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Combined Modality Therapy; Creatine Kinase, MM Form; Cyclohexanecarboxylic Acids; Dexamethasone; Drug Synergism; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunologic Factors; Kidney Diseases; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Polyneuropathies; Pravastatin; Pyrazines; Rhabdomyolysis; Thalidomide | 2012 |
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Recurrence; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
High frequencies of response after limited primary therapy for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Thalidomide; Treatment Outcome | 2013 |
Total cost comparison in relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Fees, Pharmaceutical; Health Expenditures; Humans; Lenalidomide; Models, Economic; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2013 |
Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosomes, Human, Pair 1; Female; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Recurrence; Thalidomide; Treatment Outcome; Trisomy | 2013 |
Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Health Care Costs; Health Resources; Hospitalization; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide | 2013 |
The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenan
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Controlled Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Lenalidomide; Male; Markov Chains; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Thalidomide; United States | 2013 |
Multiple myeloma, version 1.2013.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Humans; Hydroxamic Acids; Lenalidomide; Multiple Myeloma; Nitrogen Mustard Compounds; Oligopeptides; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Vorinostat | 2013 |
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; CD11b Antigen; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Coculture Techniques; Cytokines; Flow Cytometry; HLA-DR Antigens; Humans; Immunologic Factors; Lenalidomide; Lewis X Antigen; Lipopolysaccharides; Multiple Myeloma; Myeloid Cells; Pyrazines; Reactive Oxygen Species; Sialic Acid Binding Ig-like Lectin 3; T-Lymphocytes; Thalidomide; Tumor Burden; Tumor Microenvironment | 2013 |
Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease Management; Drug Administration Routes; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Plasma Cells; Prognosis; Pyrazines; Recurrence; Risk; Thalidomide; Translocation, Genetic; Transplantation, Autologous | 2013 |
"IM iD"eally treating multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Pyrazines; Thalidomide | 2013 |
[Molecular targeting agents for multiple myeloma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Glycine; Histone Deacetylases; Humans; Immunologic Factors; Lactones; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrazines; Pyrroles; Thalidomide | 2012 |
Potent antimyeloma activity of a novel ERK5/CDK inhibitor.
Topics: Animals; Blotting, Western; Boronic Acids; Bortezomib; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 9; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 4 or More Rings; Humans; Lenalidomide; Mice, SCID; Mitogen-Activated Protein Kinase 7; Multiple Myeloma; Protein Kinase Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Xenograft Model Antitumor Assays | 2013 |
Multiple myeloma: so much progress, but so many unsolved questions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Outcome Assessment, Health Care; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2013 |
Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide; Transplantation, Autologous | 2013 |
Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplasm Staging; Prognosis; Proportional Hazards Models; Pyrazines; Recurrence; Retrospective Studies; Risk Factors; Salvage Therapy; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.
Topics: Aged; Antineoplastic Agents; Blood Component Removal; Boronic Acids; Bortezomib; Dexamethasone; Female; Filgrastim; Glucocorticoids; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recombinant Proteins; Retrospective Studies; Thalidomide; Transplantation, Autologous | 2013 |
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Incidence; Lenalidomide; Leukemia; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Risk Factors; Thalidomide; Young Adult | 2013 |
Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Discovery; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Male; Medical Records; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Pyrazines; Retrospective Studies; Skin; Thalidomide | 2014 |
The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Drug Tolerance; Female; Humans; Lenalidomide; Logistic Models; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Oligopeptides; Outcome Assessment, Health Care; Prognosis; Pyrazines; Retrospective Studies; Risk Factors; Survival Analysis; Thalidomide | 2014 |
[The appearance of t(9;22)(q34;q11.2) in BJP-λ type multiple myeloma during maintenance therapy including lenalidomide].
Topics: Bence Jones Protein; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Translocation, Genetic | 2013 |
Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis.
Topics: Aged; Amyloid; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Diseases; Boronic Acids; Bortezomib; Carpal Tunnel Syndrome; Dexamethasone; Disease Progression; Doxorubicin; Duodenal Diseases; Female; Femur Head; Fractures, Spontaneous; Gastrointestinal Hemorrhage; Hip Fractures; Humans; Jejunal Diseases; Lenalidomide; Melphalan; Multiple Myeloma; Osteolysis; Prednisolone; Pyrazines; Thalidomide; Vincristine | 2013 |
Very long-lasting remission of refractory T-large granular lymphocytes leukemia and myeloma by lenalidomide treatment.
Topics: Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Thalidomide; Treatment Outcome | 2013 |
Activation of coagulation by lenalidomide-based regimens for the treatment of multiple myeloma.
Topics: Blood Coagulation; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Phosphatidylserines; Pyrazines; Thalidomide; Thromboplastin | 2013 |
Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Dexamethasone; Disease Progression; Female; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Plasma Cell; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Sequence Deletion; Thalidomide; Treatment Outcome; Trisomy | 2013 |
Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
Topics: Adult; Aged; Anti-Bacterial Agents; Antigens, CD34; Antineoplastic Agents; Benzylamines; Boronic Acids; Bortezomib; Cohort Studies; Cyclams; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Health Care Costs; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lenalidomide; Leukocytes, Mononuclear; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Thalidomide; Time Factors; Transplantation Conditioning; Treatment Outcome | 2013 |
Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Central Nervous System; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Injections, Spinal; Kaplan-Meier Estimate; Lenalidomide; Male; Meninges; Middle Aged; Multiple Myeloma; Orbit; Proportional Hazards Models; Pyrazines; Radiotherapy, Adjuvant; Retrospective Studies; Salvage Therapy; Spine; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine | 2013 |
Clinical profile and treatment outcomes of immunoglobulin D associated AL amyloidosis.
Topics: Aged; Aged, 80 and over; Amyloidosis; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Immunoglobulin D; Male; Middle Aged; Pyrazines; Thalidomide; Treatment Outcome; Vincristine | 2013 |
Sequence of novel agents in multiple myeloma: an instrumental variable analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide | 2013 |
The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Republic of Korea; Singapore; Survival Rate; Tertiary Care Centers; Thalidomide | 2013 |
Testicular invading refractory multiple myeloma during bortezomib treatment successfully treated with lenalidomide: a case report.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Genital Neoplasms, Male; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Invasiveness; Orchiectomy; Proteasome Inhibitors; Pyrazines; Secondary Prevention; Spermatic Cord; Stem Cell Transplantation; Testicular Neoplasms; Thalidomide; Vincristine | 2014 |
Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
Pomalidomide in the treatment of relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2013 |
10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide; Time Factors; Young Adult | 2013 |
CXCR4 is a good survival prognostic indicator in multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Chemokine CXCL12; Chromosome Aberrations; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazines; Receptors, CXCR4; Survival Rate; Thalidomide | 2013 |
Multiple myeloma: a descriptive study of 217 Egyptian patients.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Cytarabine; Dexamethasone; Egypt; Female; Hospitals, Urban; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pyrazines; Retrospective Studies; Severity of Illness Index; Thalidomide; Vincristine | 2014 |
Brain abscess caused by Nocardia cyriacigeorgica in two patients with multiple myeloma: novel agents, new spectrum of infections.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Abscess; Female; Host-Pathogen Interactions; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Nocardia; Nocardia Infections; Pyrazines; Thalidomide | 2014 |
Meningeal myelomatosis developed after treatment with novel agents.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cerebrospinal Fluid; Dexamethasone; Fatal Outcome; Female; Humans; Magnetic Resonance Imaging; Meningeal Neoplasms; Multiple Myeloma; Plasma Cells; Pyrazines; Thalidomide | 2013 |
Transplants for the elderly in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide | 2013 |
Myeloma presenting during pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Contraindications; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypercalcemia; Idarubicin; Infant, Newborn; Lenalidomide; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Myeloma Proteins; Osteolysis; Plasmacytoma; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrazines; Remission Induction; Spinal Cord Compression; Thalidomide; Thoracic Vertebrae; Transplantation, Autologous | 2014 |
[Myeloma therapy(2) Treatment of transplant-ineligible patients].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2013 |
Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Fatigue; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Korea; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2014 |
VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Remodeling; Bone Resorption; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Serum Response Element; Thalidomide; Transplantation, Autologous | 2014 |
Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Injections, Subcutaneous; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2013 |
Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Rate; Thalidomide; Transplantation, Autologous; Treatment Failure | 2014 |
[Attainment of complete hematological remission is crucial for extended survival of AL amyloidosis patients with cardiac involvement].
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Heart Neoplasms; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Melphalan; Middle Aged; Pyrazines; Remission Induction; Thalidomide; Treatment Outcome | 2013 |
Initial treatment of nontransplant patients with multiple myeloma.
Topics: Age Factors; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide; Treatment Outcome | 2013 |
Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma.
Topics: Adult; Aged; Antibodies, Neoplasm; Antibody Specificity; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Autoantigens; Boronic Acids; Bortezomib; Chaperonin 60; Combined Modality Therapy; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Female; Glucocorticoids; Hematopoietic Stem Cell Transplantation; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Male; Melphalan; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Neoplasm Proteins; Oligoclonal Bands; Pyrazines; Remission Induction; Thalidomide; Transplantation, Autologous | 2014 |
Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide | 2014 |
AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dexamethasone; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Profiling; Gossypol; Humans; Lenalidomide; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Thalidomide; Waldenstrom Macroglobulinemia | 2014 |
Effectiveness of haemodiafiltration with ultrafiltrate regeneration in the reduction of light chains in multiple myeloma with renal failure.
Topics: Acute Kidney Injury; Adsorption; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Female; Hemodiafiltration; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Ion Exchange Resins; Male; Membranes, Artificial; Middle Aged; Multiple Myeloma; Myeloma Proteins; Polymers; Pyrazines; Serum Albumin; Thalidomide; Treatment Outcome | 2013 |
Myeloma kidney: the importance of assessing the response by monitoring free light chains in serum.
Topics: Acute Kidney Injury; Anemia; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Drug Monitoring; Drug Substitution; Flank Pain; Humans; Immunoglobulin kappa-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pyrazines; Renal Dialysis; Thalidomide | 2013 |
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Disease-Free Survival; Drug Evaluation; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Nervous System Diseases; Prednisone; Prognosis; Proportional Hazards Models; Pyrazines; Randomized Controlled Trials as Topic; Retrospective Studies; Thalidomide; Treatment Outcome | 2014 |
Establishment and characterization of bortezomib-resistant U266 cell line: constitutive activation of NF-κB-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; NF-kappa B; Pyrazines; Signal Transduction; Syndecan-1; Thalidomide; Ubiquitination | 2014 |
Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Prognosis; Pyrazines; Retrospective Studies; Survival Analysis; Thalidomide; Transplantation, Autologous | 2014 |
HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Endothelial Cells; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Panobinostat; Proteome; Pyrazines; Reactive Oxygen Species; Thalidomide; Transcription, Genetic | 2014 |
Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population.
Topics: Adult; Age Distribution; Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Registries; Survival Analysis; Sweden; Thalidomide; Treatment Outcome | 2014 |
Post-transplantation consolidation and maintenance therapy with lenalidomide for Japanese patients with multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Japan; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Positron-Emission Tomography; Pyrazines; Thalidomide; Transplantation Conditioning | 2013 |
Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Male; Multiple Myeloma; Multivariate Analysis; Proportional Hazards Models; Pyrazines; Renal Insufficiency; Risk; Thalidomide; Treatment Outcome | 2014 |
Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis.
Topics: Acute Kidney Injury; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Models, Theoretical; Multiple Myeloma; Pyrazines; Renal Dialysis; Thalidomide | 2014 |
Acquired Fanconi syndrome with proximal tubular cytoplasmic fibrillary inclusions of λ light chain restriction.
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Cytoplasm; Dexamethasone; Fanconi Syndrome; Humans; Immunoglobulin Light Chains; Kidney Tubules, Proximal; Male; Microscopy, Fluorescence; Microscopy, Immunoelectron; Multiple Myeloma; Myeloma Proteins; Phagosomes; Proteinuria; Pyrazines; Thalidomide | 2014 |
Bortezomib-induced lung toxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Substitution; Female; Humans; Lenalidomide; Lung Diseases; Multiple Myeloma; Pyrazines; Spirometry; Thalidomide | 2014 |
Comparative cost-effectiveness models for the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Disease Progression; Humans; Melphalan; Models, Economic; Multiple Myeloma; Prednisolone; Pyrazines; Survival Analysis; Thalidomide; United Kingdom | 2014 |
Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Diffusion Magnetic Resonance Imaging; Female; Granulocyte Colony-Stimulating Factor; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pilot Projects; Prospective Studies; Pyrazines; Reproducibility of Results; Thalidomide; Treatment Outcome; Whole Body Imaging | 2014 |
A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Cells, Cultured; Dendritic Cells; Humans; Lenalidomide; Lymphocyte Activation; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Oligodeoxyribonucleotides; Pyrazines; T-Lymphocytes; Thalidomide; Toll-Like Receptor 9 | 2014 |
Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Prospective Studies; Pyrazines; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2014 |
SNS01-T modulation of eIF5A inhibits B-cell cancer progression and synergizes with bortezomib and lenalidomide.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Eukaryotic Translation Initiation Factor 5A; Humans; Lenalidomide; Lymphoproliferative Disorders; Mice; Nanoparticles; Neoplasm Transplantation; Peptide Initiation Factors; Polyethyleneimine; Pyrazines; RNA-Binding Proteins; RNA, Small Interfering; Thalidomide; Xenograft Model Antitumor Assays | 2014 |
Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisolone; Prognosis; Pyrazines; Retreatment; Salvage Therapy; Thalidomide; Treatment Outcome | 2014 |
Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
Topics: Adult; Aged; Amyloidogenic Proteins; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiomyopathies; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Kidney Diseases; Lenalidomide; Male; Melphalan; Middle Aged; Myeloablative Agonists; Proteasome Inhibitors; Pyrazines; Remission Induction; Retrospective Studies; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2014 |
Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Drugs, Investigational; Europe; Female; Humans; Japan; Kaplan-Meier Estimate; Lenalidomide; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrazines; Retrospective Studies; Salvage Therapy; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2014 |
United Kingdom Myeloma Forum position statement on the use of consolidation and maintenance treatment in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Clinical Trials as Topic; Consolidation Chemotherapy; Disease Management; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Remission Induction; Survival Analysis; Thalidomide; United Kingdom | 2014 |
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplastic Stem Cells; Paraffin Embedding; Peptide Hydrolases; Prednisolone; Pyrazines; Salvage Therapy; Survival Analysis; Syndecan-1; Thalidomide; Treatment Outcome; Ubiquitin-Protein Ligases | 2014 |
Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression Profiling; Humans; Interferon Regulatory Factors; Lenalidomide; Lymphoma, Mantle-Cell; Mice; Mice, SCID; Neoplasm Transplantation; Proteasome Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-myc; Pyrazines; Signal Transduction; Thalidomide | 2014 |
The osteoblastogenesis potential of adipose mesenchymal stem cells in myeloma patients who had received intensive therapy.
Topics: Adipose Tissue; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; Cells, Cultured; Cycloheximide; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Mesenchymal Stem Cells; Middle Aged; Multiple Myeloma; Osteoblasts; Osteogenesis; Pyrazines; Remission Induction; Thalidomide; Transplantation, Autologous | 2014 |
Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Constipation; Cyclophosphamide; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Evaluation; Drug Substitution; Feasibility Studies; Female; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Humans; Immunologic Factors; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Retrospective Studies; Sensation Disorders; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2014 |
Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Humans; Immunosuppressive Agents; Lenalidomide; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pyrazines; Retrospective Studies; Thalidomide; Time Factors | 2014 |
Successful bortezomib/dexamethasone induction therapy with lenalidomide in an elderly patient with primary plasma cell leukemia complicated by renal failure and pulmonary hypertension.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Hypertension, Pulmonary; Induction Chemotherapy; Lenalidomide; Leukemia, Plasma Cell; Male; Pyrazines; Remission Induction; Renal Insufficiency; Thalidomide | 2014 |
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Leukemia, Plasma Cell; Neoplasms, Second Primary; Pyrazines; Thalidomide; Treatment Outcome | 2015 |
Best treatment strategies in high-risk multiple myeloma: navigating a gray area.
Topics: Antineoplastic Combined Chemotherapy Protocols; Back Pain; Biopsy; Bone Density Conservation Agents; Bone Marrow; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulin G; Immunoglobulin lambda-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Referral and Consultation; Thalidomide; Translocation, Genetic; Transplantation, Autologous; Zoledronic Acid | 2014 |
Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Dexamethasone; Drug Administration Schedule; Female; Humans; Japan; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2014 |
Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Cohort Studies; Dexamethasone; Drug Therapy, Combination; Female; Hematologic Agents; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Middle Aged; Paraproteinemias; Pyrazines; Recurrence; Thalidomide; Treatment Outcome | 2014 |
Extended high cut-off haemodialysis for myeloma cast nephropathy in Auckland, 2008-2012.
Topics: Aged; Antineoplastic Agents; Antineoplastic Protocols; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin Light Chains; Immunosuppressive Agents; Kidney; Kidney Failure, Chronic; Leukemia, Plasma Cell; Male; Middle Aged; Multiple Myeloma; New Zealand; Pyrazines; Remission Induction; Renal Dialysis; Thalidomide; Treatment Outcome | 2014 |
Inhibitory effects of bortezomib on platelet aggregation in patients with multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Platelet Aggregation; Platelet Function Tests; Prospective Studies; Pyrazines; Thalidomide; Venous Thromboembolism | 2014 |
Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Disease Progression; Drug Evaluation; Feasibility Studies; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Sensation Disorders; Thalidomide; Thromboembolism; Transplantation, Autologous | 2014 |
Clinical analysis of six cases of multiple myeloma first presenting with coagulopathy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Sedimentation; Boronic Acids; Bortezomib; Coagulants; Coagulation Protein Disorders; Dexamethasone; Doxorubicin; Female; Hematoma; Hematuria; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide | 2014 |
Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Combined Modality Therapy; Dexamethasone; Disease Progression; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lenalidomide; Male; Mediastinal Neoplasms; Middle Aged; Multiple Myeloma; Mutation, Missense; Neoplasm Proteins; Neoplasms, Second Primary; Osteolysis; Palliative Care; Plasmacytoma; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazines; Remission Induction; Salvage Therapy; Sulfonamides; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vemurafenib | 2014 |
Hepatic extramedullary disease in multiple myeloma with 17p deletion.
Topics: Aneuploidy; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Clone Cells; Dexamethasone; Fatal Outcome; Female; Gene Deletion; Genes, p53; Humans; Incidental Findings; Lenalidomide; Liver; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Multiple Primary; Osteolysis; Proteasome Inhibitors; Pyrazines; Recurrence; Thalidomide; Tumor Suppressor Protein p53; Uterine Neoplasms | 2014 |
A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Causality; Cladribine; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Neutropenia; Paraproteinemias; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Registries; Retrospective Studies; Thalidomide | 2014 |
Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Retrospective Studies; Survivin; Thalidomide; Vincristine | 2014 |
Bortezomib, lenalidomide and dexamethasone (VRD) combination as salvage therapy in refractory angioimmunoblastic T cell lymphoma.
Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; Immunoblastic Lymphadenopathy; Lenalidomide; Lymphoma, T-Cell; Pyrazines; Salvage Therapy; Thalidomide; Tomography, Emission-Computed | 2014 |
Effect of 13q deletion on IL-6 production in patients with multiple myeloma: a hypothesis may hold true.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Case-Control Studies; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 13; Female; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Interleukin-6; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density; Bone Diseases; Boronic Acids; Bortezomib; Case-Control Studies; Female; Humans; Lenalidomide; Male; Middle Aged; Multidetector Computed Tomography; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2014 |
Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Biopsy; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Diagnosis, Differential; Disease Progression; Doxorubicin; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Lactams, Macrocyclic; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Transplantation, Autologous | 2014 |
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Topics: Acute Kidney Injury; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease Progression; Edema; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Hypertension, Renal; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Podocytes; Proteasome Inhibitors; Proteinuria; Pyrazines; Recurrence; Shock, Septic; Teniposide; Thalidomide; Thrombotic Microangiopathies | 2014 |
Resident rounds part III: plasma cell leukemia with initial cutaneous presentation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Bortezomib; Dexamethasone; Doxorubicin; Erythema; Fatal Outcome; Female; Humans; Lenalidomide; Leukemia, Plasma Cell; Middle Aged; Renal Dialysis; Thalidomide; Vincristine | 2014 |
Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents.
Topics: Acute Disease; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Bortezomib; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2015 |
The importance of screening for serum free light chains in suspected cases of multiple myeloma and their impact on the kidney.
Topics: Aged; Antineoplastic Agents; Biopsy; Bone Marrow; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Electrophoresis; Humans; Immunoglobulin Light Chains; Kidney Diseases; Male; Middle Aged; Multiple Myeloma; Paraproteinemias; Pyrazines; Thalidomide | 2014 |
A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Examination; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Drug Substitution; Female; Humans; Immunohistochemistry; Lenalidomide; Leukemia, Plasma Cell; Leukocyte Common Antigens; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Plasma Cells; Pyrazines; Remission Induction; Thalidomide; Time Factors; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome; Vincristine | 2014 |
Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Failure | 2015 |
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.
Topics: Antineoplastic Agents; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Female; Humans; Indoles; Lenalidomide; Lymphoma, Mantle-Cell; Male; Signal Transduction; Thalidomide | 2015 |
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Animals; Antibody-Dependent Cell Cytotoxicity; Bortezomib; Cell Line, Tumor; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Synergism; Female; Humans; Immunotherapy; Killer Cells, Natural; Lenalidomide; Lymphocyte Activation; Male; Mice; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Thalidomide; Xenograft Model Antitumor Assays | 2015 |
Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital.
Topics: Aged; Antineoplastic Agents; Australia; Boronic Acids; Bortezomib; Cost of Illness; Female; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Pyrazines; Respiratory Tract Infections; Risk Factors; Thalidomide | 2015 |
Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Middle Aged; Prospective Studies; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome | 2015 |
Multiple myeloma: is a shift toward continuous therapy needed to move forward?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Stem Cell Transplantation; Thalidomide | 2015 |
[Treatment of multiple myeloma with lenalidomide and bortezomib combination therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2015 |
[Latest advances on the maintenance therapy of multiple myeloma].
Topics: Boronic Acids; Bortezomib; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2015 |
Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
Topics: Adult; Aged; Bortezomib; Costs and Cost Analysis; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Thalidomide | 2015 |
Efficacy of bortezomib and thalidomide in the recrudescent form of multicentric mixed-type Castleman's disease.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Castleman Disease; Humans; Male; Pyrazines; Thalidomide | 2015 |
Precipitation of ventricular bigeminy by DMSO during autologous haematopoietic stem cell transplantation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Atrioventricular Block; Bortezomib; Cryoprotective Agents; Dexamethasone; Dimethyl Sulfoxide; Electrocardiography; Humans; Isotonic Solutions; Lenalidomide; Male; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Ventricular Premature Complexes | 2015 |
Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
Topics: Animals; Antineoplastic Agents; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dexamethasone; Disease Models, Animal; Drug Resistance, Neoplasm; Humans; Lenalidomide; Melphalan; Mice; Multiple Myeloma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; Signal Transduction; Thalidomide; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2015 |
NICE guidance on pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib.
Topics: Boronic Acids; Bortezomib; Disease-Free Survival; Drug Approval; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2015 |
Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment.
Topics: Aged; Amyloidogenic Proteins; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Heart; Heart Failure; Humans; Kidney; Male; Middle Aged; Remission Induction; Retrospective Studies; Survival Analysis; Thalidomide; Treatment Outcome | 2016 |
[Complications and managements in treatment of melphalan, prednisone and new agents].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide | 2015 |
Risk stratification model in elderly patients with multiple myeloma: clinical role of magnetic resonance imaging combined with international staging system and cytogenetic abnormalities.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Humans; Magnetic Resonance Imaging; Male; Melphalan; Middle Aged; Models, Biological; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Radiography; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide | 2015 |
[Carfilzomib in multiple myeloma relapses].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Heart; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide | 2015 |
CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon.
Topics: ADP-ribosyl Cyclase 1; Animals; Bortezomib; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide | 2015 |
A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Computer Simulation; Cost-Benefit Analysis; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Netherlands; Quality-Adjusted Life Years; Survival Analysis; Thalidomide | 2016 |
Plasma cell leukemia mimicking hairy cell leukemia.
Topics: Adult; Antineoplastic Agents; Bone Marrow; Bone Marrow Transplantation; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Immunologic Factors; Lenalidomide; Leukemia, Hairy Cell; Leukemia, Plasma Cell; Plasma Cells; Thalidomide | 2015 |
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Incidence; Lenalidomide; Male; Multiple Myeloma; Neoplasm Staging; Neoplasms, Second Primary; Plasmacytoma; Pyrazines; Remission Induction; Risk; Thalidomide; Treatment Outcome | 2015 |
Adnectin-targeted inhibitors: rationale and results.
Topics: Adenine; Angiogenesis Inhibitors; Antineoplastic Agents; Bortezomib; Clinical Trials as Topic; Drug Evaluation, Preclinical; Fibronectins; Humans; Lenalidomide; Molecular Targeted Therapy; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Pyrazoles; Pyrimidines; Thalidomide; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
17P deleted multiple myeloma presenting with intracranial disease: durable remission after tailored management.
Topics: Autografts; Bortezomib; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 17; Consolidation Chemotherapy; Female; Humans; Middle Aged; Multiple Myeloma; Smith-Magenis Syndrome; Stem Cell Transplantation; Thalidomide | 2016 |
A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Outcome; Vincristine | 2015 |
Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Disease Progression; Female; Follow-Up Studies; Glomerular Basement Membrane; Glomerular Filtration Rate; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Light Chains; Kidney Diseases; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proteinuria; Retrospective Studies; Survival Rate; Thalidomide; Waldenstrom Macroglobulinemia | 2015 |
Dose-adjusted Lenalidomide Combined with Low-dose Dexamethasone Rescues Older Patients with Bortezomib-resistant Multiple Myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease Progression; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide; Treatment Outcome | 2015 |
Outcomes of primary refractory multiple myeloma and the impact of novel therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Immunologic Factors; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Proportional Hazards Models; Proteasome Inhibitors; Radiography; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Thalidomide; Treatment Outcome | 2015 |
Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase I as Topic; Dexamethasone; Humans; Induction Chemotherapy; Lenalidomide; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2015 |
Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Follow-Up Studies; Health Care Costs; Health Resources; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Prognosis; Survival Rate; Thalidomide | 2016 |
How I treat high-risk myeloma.
Topics: Aged; Antineoplastic Agents; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Thalidomide | 2015 |
Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myeloma patients aged 65 years or older: a retrospective single Institutional analysis.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Interferon-alpha; Male; Multiple Myeloma; Polyethylene Glycols; Proteasome Inhibitors; Recombinant Proteins; Remission Induction; Retrospective Studies; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2015 |
Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs.
Topics: Aged; Antineoplastic Agents; Bortezomib; Cost-Benefit Analysis; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; United Kingdom | 2015 |
Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Demography; Dexamethasone; Female; Humans; Injections, Subcutaneous; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Thalidomide; Treatment Outcome | 2015 |
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2015 |
Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 17; Cytogenetic Analysis; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Induction Chemotherapy; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prognosis; Remission Induction; Retrospective Studies; Survival Analysis; Thalidomide; Translocation, Genetic; Transplantation, Autologous; Treatment Outcome | 2016 |
Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Comorbidity; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide | 2016 |
Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Female; Humans; Lenalidomide; Male; Markov Chains; Melphalan; Multiple Myeloma; Prednisone; Quality-Adjusted Life Years; Thalidomide; Treatment Outcome; United States | 2016 |
Lenalidomide affect expression level of cereblon protein in multiple myeloma cell line RPMI8226.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Blotting, Western; Bortezomib; Cell Line, Tumor; Humans; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Thalidomide; Ubiquitin-Protein Ligases | 2015 |
Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Interferon-gamma; Male; Middle Aged; Multiple Myeloma; Thalidomide; Treatment Outcome | 2015 |
TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease Progression; DNA, Neoplasm; Female; Germ-Line Mutation; Humans; Lenalidomide; Male; Membrane Glycoproteins; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Polymorphism, Single Nucleotide; Prognosis; Receptors, Interleukin-1; Survival Analysis; Thalidomide; Toll-Like Receptor 4 | 2016 |
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Polymorphism, Single Nucleotide; Remission Induction; Thalidomide | 2016 |
New patterns of relapse in multiple myeloma: a case of "light chain escape" in which FLC predicted relapse earlier than urine and serum immunofixation.
Topics: Bence Jones Protein; Bendamustine Hydrochloride; Blood Protein Electrophoresis; Bortezomib; Dexamethasone; Humans; Immunoelectrophoresis; Immunoglobulin G; Immunoglobulin kappa-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Stem Cell Transplantation; Thalidomide | 2016 |
Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome.
Topics: Alemtuzumab; Aminopterin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Deoxycytidine; Depsipeptides; Diphtheria Toxin; Disease Progression; Doxorubicin; Electrons; Gemcitabine; Humans; Hydroxamic Acids; Immunotherapy; Incidence; Interleukin-2; Lenalidomide; Lymphoma, T-Cell; Mycosis Fungoides; Pentostatin; Photopheresis; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Retinoids; Sezary Syndrome; Stem Cell Transplantation; Thalidomide; United States; Vorinostat | 2015 |
The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis.
Topics: Antineoplastic Agents; Bortezomib; China; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Survival Analysis; Thalidomide | 2015 |
Uninvolved immunoglobulins predicting hematological response in newly diagnosed AL amyloidosis.
Topics: Aged; Aged, 80 and over; Amyloidosis; Bortezomib; Disease-Free Survival; Female; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Immunoglobulins; Immunologic Factors; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Retrospective Studies; Thalidomide; Treatment Outcome | 2016 |
Bone marrow infiltration by multiple myeloma causes anemia by reversible disruption of erythropoiesis.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Marrow; Bortezomib; Dexamethasone; Erythrocyte Indices; Erythroid Cells; Erythropoiesis; Female; Humans; Lenalidomide; Male; Middle Aged; Models, Theoretical; Multiple Myeloma; Thalidomide; Treatment Outcome | 2016 |
CD200 Expression on Plasma Cell Myeloma Cells is Associated with the Efficacies of Bortezomib, Lenalidomide and Thalidomide.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bortezomib; Female; Gene Expression; Humans; Immunohistochemistry; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Survival Analysis; Thalidomide; Treatment Outcome | 2015 |
Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2016 |
[Efficacy and prognostic factors of induction therapy combined with autologous stem cell transplantation in 201 patients with multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Humans; Multiple Myeloma; Neoadjuvant Therapy; Peripheral Blood Stem Cell Transplantation; Prognosis; Remission Induction; Survival Rate; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2016 |
Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Thalidomide; Vitamin D | 2016 |
Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Prognosis; Recurrence; Registries; Retrospective Studies; Survival Analysis; Thalidomide; Transplantation, Autologous | 2016 |
Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma?
Topics: Bortezomib; Humans; Lenalidomide; Leukemia, Plasma Cell; Multiple Myeloma; Prognosis; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Thalidomide; Treatment Outcome | 2016 |
Outcome of patients with multiple myeloma and renal failure on novel regimens.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Iran; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Renal Dialysis; Renal Insufficiency; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Thalidomide; Time Factors; Treatment Outcome | 2016 |
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Consensus; Cytogenetics; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Risk Factors; Thalidomide; Transplantation, Autologous | 2016 |
Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Topics: Aged; Animals; Antineoplastic Agents; Apoptosis; Boron Compounds; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Female; Glycine; Humans; Male; Mice; Middle Aged; Multiple Myeloma; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Thalidomide; Xenograft Model Antitumor Assays | 2016 |
Nonamyloidotic Light Chain Cardiomyopathy: The Arrhythmogenic Magnetic Resonance Pattern.
Topics: Bortezomib; Cardiomyopathies; Combined Modality Therapy; Defibrillators, Implantable; Dexamethasone; Edema; Emergencies; Heart; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin kappa-Chains; Kidney; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Nephrotic Syndrome; Paraproteinemias; Paraproteins; Recurrence; Syncope; Thalidomide; Torsades de Pointes; Transplantation, Autologous | 2016 |
Primary Plurifocal Extramedullary Plasmacytoma of Breast.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Breast Neoplasms; Dexamethasone; Female; Humans; Mammography; Plasmacytoma; Thalidomide | 2016 |
A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azetidines; Bortezomib; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Drug Synergism; Epigenomics; Heterografts; Humans; Hypoxia; Mice; Multiple Myeloma; Nitro Compounds; Thalidomide; Ubiquitin Thiolesterase; Ubiquitin-Specific Peptidase 7 | 2016 |
Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Health Care Costs; Humans; Lenalidomide; Life Expectancy; Male; Middle Aged; Models, Economic; Multiple Myeloma; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recurrence; Sweden; Thalidomide; Treatment Outcome | 2016 |
Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bortezomib; C-Reactive Protein; Chromosome Aberrations; Chromosomes, Human, Pair 1; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Exosomes; Female; Gene Amplification; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Microarray Analysis; MicroRNAs; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Risk Factors; Thalidomide; Tumor Microenvironment | 2016 |
Quadruple Cancers of Non-producing Multiple Myeloma, Cholangiocellular Carcinoma, and Two Different Thyroid Cancers.
Topics: Aged; Bile Duct Neoplasms; Bortezomib; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Cholangiocarcinoma; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2016 |
[Clinical Analysis of Multiple Myeloma Patients Aged over 80 Years].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide | 2016 |
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bortezomib; Female; Humans; L-Selectin; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Recurrence; Survival Analysis; Thalidomide; Vascular Cell Adhesion Molecule-1 | 2016 |
Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Diarrhea; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Nervous System Diseases; Pharmacovigilance; Prospective Studies; Risk Factors; Thalidomide; Treatment Outcome | 2016 |
Prolonged Response in Patient With Multiply Relapsed B-cell Acute Lymphoblastic Leukemia and Monosomy-7 to Bortezomib, Lenalidomide, and Dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Child; Chromosome Deletion; Chromosomes, Human, Pair 7; Dexamethasone; Female; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Thalidomide | 2016 |
LC-MS/MS method for simultaneous determination of thalidomide, lenalidomide, cyclophosphamide, bortezomib, dexamethasone and adriamycin in serum of multiple myeloma patients.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bortezomib; Chromatography, Liquid; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Monitoring; Humans; Immunosuppressive Agents; Lenalidomide; Limit of Detection; Multiple Myeloma; Tandem Mass Spectrometry; Thalidomide | 2016 |
Canadian cost analysis comparing maintenance therapy with bortezomib versus lenalidomide for patients with multiple myeloma post autologous stem cell transplant.
Topics: Antineoplastic Agents; Bortezomib; Canada; Combined Modality Therapy; Costs and Cost Analysis; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2016 |
Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression.
Topics: Adaptor Proteins, Signal Transducing; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Gene Expression; Humans; Immunologic Factors; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Neoplasm Proteins; Peptide Hydrolases; Prednisolone; Remission Induction; Survival Analysis; Thalidomide; Treatment Outcome; Ubiquitin-Protein Ligases | 2016 |
Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Case-Control Studies; Combined Modality Therapy; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Interleukin-10; Interleukin-10 Receptor beta Subunit; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Polymorphism, Single Nucleotide; Prognosis; Survival Analysis; Thalidomide | 2017 |
Multiple myeloma--translation of trial results into reality.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cyclic N-Oxides; Drug Approval; Drug Discovery; Glycine; Humans; Indolizines; Lactones; Lenalidomide; Multiple Myeloma; Oligopeptides; Practice Guidelines as Topic; Pyridinium Compounds; Pyrroles; Thalidomide | 2016 |
Pleural effusion as a manifestation of multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Diagnosis, Differential; Humans; Kidney Failure, Chronic; Lenalidomide; Lung Neoplasms; Male; Multiple Myeloma; Pleural Effusion; Thalidomide; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data.
Topics: Antineoplastic Agents; Bortezomib; Drug Therapy, Combination; Female; Humans; Hydroxamic Acids; Indoles; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Panobinostat; Proportional Hazards Models; Recurrence; Survival Analysis; Thalidomide; Treatment Outcome | 2017 |
Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array.
Topics: Bortezomib; Female; Genotype; Humans; Male; Multiple Myeloma; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Thalidomide | 2017 |
[A clinical analysis of 69 newly diagnosed multiple myeloma patients with renal insufficiency].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Renal Insufficiency; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2016 |
The possible role of burden of therapy on the risk of myeloma extramedullary spread.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Risk Factors; Sarcoma, Myeloid; Survival Rate; Thalidomide | 2017 |
Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cardiotoxicity; Heart Diseases; Humans; Kaplan-Meier Estimate; Lenalidomide; Multiple Myeloma; Propensity Score; Proportional Hazards Models; Risk; Thalidomide | 2017 |
Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Bone and Bones; Bone Marrow; Bortezomib; Female; Follow-Up Studies; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Osteolysis; Radiation Dosage; Retrospective Studies; Sensitivity and Specificity; Thalidomide; Tomography, X-Ray Computed; Treatment Outcome; Whole Body Imaging | 2016 |
Panobinostat in multiple myeloma.
Topics: Bortezomib; Dexamethasone; Humans; Hydroxamic Acids; Multiple Myeloma; Panobinostat; Thalidomide | 2016 |
Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Drug Evaluation; Female; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2017 |
Mobilization of human immature hematopoietic progenitors through combinatory use of bortezomib and immunomodulatory drugs.
Topics: Aged; Antigens, CD34; Blood Cells; Bone Marrow Cells; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Receptors, CXCR4; Thalidomide | 2017 |
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bortezomib; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide | 2017 |
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bortezomib; Disease Progression; Gene Expression; Humans; Immunoglobulin Light Chains; Immunoglobulin M; Immunoglobulins; Lenalidomide; Multiple Myeloma; Prognosis; Recurrence; Stem Cell Transplantation; Survival Analysis; Thalidomide | 2017 |
Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Outpatient Clinics, Hospital; Retrospective Studies; Survival Rate; Thalidomide | 2017 |
Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cohort Studies; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2017 |
Treatment of newly diagnosed myeloma: Bortezomib-based triplet.
Topics: Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Thalidomide | 2016 |
Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma: A case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bortezomib; Humans; Lenalidomide; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Male; Multiple Myeloma; Neoplasms, Multiple Primary; Positron Emission Tomography Computed Tomography; Thalidomide; Thoracic Vertebrae; Treatment Outcome | 2017 |
Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; beta Catenin; Bortezomib; Casein Kinase I; Cell Line; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p21; Female; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Thalidomide; Tumor Suppressor Protein p53 | 2017 |
Multiple myeloma associated with an Evan's syndrome.
Topics: Acidosis, Lactic; Adrenal Cortex Hormones; Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Bortezomib; Dexamethasone; Fatal Outcome; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomide; Thrombocytopenia | 2016 |
Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Comorbidity; Drug Resistance, Neoplasm; Europe; Female; Humans; Lenalidomide; Longitudinal Studies; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Quality of Life; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2017 |
Case of lymphadenopathy with lytic bone lesions.
Topics: Bortezomib; Dexamethasone; Diagnosis, Differential; Humans; Incidental Findings; Lenalidomide; Lymphadenopathy; Male; Middle Aged; Multiple Myeloma; Osteolysis; Thalidomide; Treatment Outcome | 2017 |
Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Female; Germany; Health Surveys; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Transplantation, Autologous | 2017 |
Crystalglobulinemia manifesting as chronic arthralgia and acute limb ischemia: A clinical case report.
Topics: Amputation, Surgical; Arterial Occlusive Diseases; Arthralgia; Bortezomib; Dexamethasone; Humans; Lenalidomide; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Thalidomide | 2017 |
[Clinical Effects of Different Chemotherapeutic Regimens on the Patients with Multiple Myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Doxorubicin; Humans; Multiple Myeloma; Thalidomide; Treatment Outcome; Vincristine | 2017 |
Bortezomib, Thalidomide, and Dexamethasone (VTD) Induction Results in Better Overall Survival than Adriamycin, Thalidomide, and Dexamethasone (ATD) Induction in Previously Untreated Myeloma Patients Eligible for Transplants.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Humans; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2017 |
Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.
Topics: Administration, Oral; Administrative Claims, Healthcare; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Databases, Factual; Drug Administration Schedule; Drug Costs; Eligibility Determination; Female; Health Expenditures; Health Services Accessibility; Healthcare Disparities; Humans; Immunologic Factors; Insurance Benefits; Lenalidomide; Male; Medicare Part D; Models, Economic; Multiple Myeloma; Process Assessment, Health Care; SEER Program; Thalidomide; Time Factors; Treatment Outcome; United States | 2017 |
Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bortezomib; Combined Modality Therapy; Disease Progression; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Pneumonia; Recombinant Fusion Proteins; Recurrence; Salvage Therapy; Syndecan-1; Thalidomide; Transplantation, Autologous | 2017 |
Bortezomib Does Not Prevent the Occurrence of Kaposi's Sarcoma in Patients with Haematological Malignancies: Two Case Reports.
Topics: Aged; Amyloidosis; Antineoplastic Agents; Bortezomib; Female; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasms, Multiple Primary; Sarcoma, Kaposi; Skin Neoplasms; Thalidomide | 2017 |
Lenalidomide as a treatment for relapsed AL amyloidosis in an HIV-positive patient.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; HIV Seropositivity; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Middle Aged; Paraproteinemias; Recurrence; Thalidomide; Treatment Outcome | 2017 |
Comparison of cyclophosphamide-thalidomide-dexamethasone to bortezomib-cyclophosphamide-dexamethasone as induction therapy for multiple myeloma patients in Brazil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide | 2017 |
Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bortezomib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Coculture Techniques; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 1; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nitriles; Pyrazoles; Pyrimidines; Signal Transduction; STAT Transcription Factors; Stromal Cells; Thalidomide; Time Factors | 2017 |
Causes of early death in multiple myeloma patients treated with high-dose therapy followed by autologous stem cell transplantation: A study based on the nationwide Danish Multiple Myeloma Registry.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Bortezomib; Cyclophosphamide; Denmark; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Registries; Stem Cell Transplantation; Survival Rate; Thalidomide | 2017 |
Improved survival in Medicare patients with multiple myeloma: findings from a large nationwide and population-based cohort.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Medicare; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Thalidomide; United States | 2017 |
Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy.
Topics: Adult; Aged; Aged, 80 and over; Bortezomib; Female; Humans; Lenalidomide; Male; Middle Aged; Models, Statistical; Multiple Myeloma; Neoplasm Staging; Retrospective Studies; Risk Assessment; ROC Curve; Survival Rate; Thalidomide | 2017 |
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Survival Analysis; Thalidomide; Treatment Outcome | 2018 |
Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asian; Black or African American; Bortezomib; Female; Health Services Accessibility; Healthcare Disparities; Hispanic or Latino; Humans; Lenalidomide; Male; Medicare; Multiple Myeloma; Process Assessment, Health Care; Proportional Hazards Models; Risk Factors; SEER Program; Stem Cell Transplantation; Thalidomide; Time Factors; Treatment Outcome; United States; White People | 2017 |
Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Myeloma Proteins; Survival Rate; Thalidomide; Treatment Outcome | 2018 |
[Digital ischemia revealing multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cryoglobulinemia; Dexamethasone; Fingers; Humans; Ischemia; Male; Multiple Myeloma; Necrosis; Osteolysis; Paraneoplastic Syndromes; Skin Ulcer; Thalidomide; Toes | 2018 |
Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Thalidomide | 2018 |
A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus - clinical significance and possible mechanisms: a case report.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clarithromycin; Diabetes Mellitus; Female; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide; Treatment Outcome | 2018 |
Impact of the affordability of novel agents in patients with multiple myeloma: Real-world data of current clinical practice in Mexico.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Drug Costs; Female; Follow-Up Studies; Health Services Accessibility; Healthcare Disparities; Hematopoietic Stem Cell Transplantation; Hospitals, Private; Hospitals, Public; Humans; Male; Mexico; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2018 |
[Treatment of systemic AL amyloidosis: about 25 cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Follow-Up Studies; Hospitals, Military; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Melphalan; Middle Aged; Prognosis; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2017 |
[Development of a standardized guide for optimizing drug adherence information to be dispensed during a pharmaceutical counseling with a multiple myeloma patient: Initial validation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Counseling; Dexamethasone; Female; Hospitals, University; Humans; Lenalidomide; Male; Medication Adherence; Melphalan; Multiple Myeloma; Patient Education as Topic; Practice Guidelines as Topic; Prednisone; Prospective Studies; Thalidomide | 2018 |
Microvesicles shed from bortezomib-treated or lenalidomide-treated human myeloma cells inhibit angiogenesis in vitro.
Topics: Bortezomib; Cell Line, Tumor; Cell Movement; Cell-Derived Microparticles; Coculture Techniques; Down-Regulation; Fibroblast Growth Factor 2; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; In Vitro Techniques; Interleukin-6; Lenalidomide; Multiple Myeloma; Neoplasm Invasiveness; Neovascularization, Pathologic; Thalidomide; Vascular Endothelial Growth Factor A | 2018 |
IgM k multiple myeloma with monoclonal surface immunoglobulin expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin kappa-Chains; Immunoglobulin M; Middle Aged; Multiple Myeloma; Paraproteinemias; Plasma Cells; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2018 |
Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Czech Republic; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Progression-Free Survival; Prospective Studies; Registries; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Thalidomide | 2018 |
[Cost-Effectiveness Analysis of Different Chemotherapy Regimens in the Treatment of Patients with Multiple Myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Cyclophosphamide; Dexamethasone; Humans; Multiple Myeloma; Retrospective Studies; Thalidomide; Treatment Outcome | 2018 |
[Clinical Efficacy and Safety of Different Doses of Dexamethasone Combined with Bortezomib and Thalidomide for Treating Patients with Multiple Myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Multiple Myeloma; Thalidomide; Treatment Outcome | 2018 |
Successful retreatment with lenalidomide for relapsed and refractory multiple myeloma previously treated with bortezomib, lenalidomide and pomalidomide.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Male; Multiple Myeloma; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2018 |
Active IgGκ Multiple Myeloma Presenting With Crystalline Keratopathy.
Topics: Aged; Antineoplastic Agents; Bortezomib; Corneal Diseases; Dexamethasone; Drug Therapy, Combination; Glucocorticoids; Humans; Immunoglobulin G; Immunoglobulins; Immunosuppressive Agents; Male; Microscopy, Electron, Transmission; Multiple Myeloma; Paraproteinemias; Thalidomide; Vision Disorders; Visual Acuity | 2018 |
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Practice Patterns, Physicians'; Prospective Studies; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome | 2018 |
Multiple myeloma: Updated approach to management in 2018.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; beta 2-Microglobulin; Bortezomib; Disease Management; Humans; Hypercalcemia; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oligopeptides; Pain; Prognosis; Renal Insufficiency; Serum Albumin; Thalidomide | 2018 |
Bortezomib Prescription Pattern for the Treatment of Multiple Myeloma by Hematologists in Nigeria.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Hematology; Humans; Male; Middle Aged; Multiple Myeloma; Nigeria; Practice Patterns, Physicians'; Specialization; Surveys and Questionnaires; Thalidomide; Young Adult | 2018 |
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chemotherapy, Adjuvant; Drugs, Investigational; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Analysis; Thalidomide; Therapies, Investigational; Transplantation, Autologous; Treatment Outcome | 2019 |
A unique case of rapidly progressive glomerulonephritis following dexamethasone/bortezomib/thalidomide treatment for myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease Progression; Female; Glomerulonephritis; Humans; Middle Aged; Multiple Myeloma; Thalidomide | 2018 |
Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Female; Finland; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Progression-Free Survival; Thalidomide; Treatment Outcome | 2018 |
Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centre.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bortezomib; Female; Health Services Accessibility; Hematopoietic Stem Cell Transplantation; Hospitalization; Humans; Immunosuppressive Agents; Induction Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; New Zealand; Progression-Free Survival; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2019 |
[Clinical Analysis of Maintenance Therapy with Thalidomine and Bortezomib for Multiple Myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2018 |
Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report.
Topics: Antineoplastic Agents; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light-chain Amyloidosis; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Psoriasis; Thalidomide; Transplantation, Autologous | 2018 |
[Successful Treatment with Pomalidomide, Bortezomib, and Dexamethasone in a Patient with Frail Refractory and Relapsed Multiple Myeloma with Extramedullary Disease].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2018 |
[Clinical Application of R-ISS Staging System in 412 Newly Diagnosed Patients with Multiple Myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Multiple Myeloma; Neoplasm Staging; Prognosis; Retrospective Studies; Thalidomide; Treatment Outcome | 2019 |
Real-world treatment patterns, resource use and cost burden of multiple myeloma in Portugal.
Topics: Age Factors; Aged; Antineoplastic Agents; Boron Compounds; Bortezomib; Drug Costs; Female; Glycine; Health Care Costs; Health Resources; Hospitalization; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Portugal; Practice Patterns, Physicians'; Progression-Free Survival; Proteasome Inhibitors; Stem Cell Transplantation; Survival Rate; Thalidomide | 2019 |
Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study.
Topics: Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Retrospective Studies; Survival Analysis; Thalidomide; Treatment Outcome | 2019 |
[Multiple myeloma treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Transplantation, Autologous | 2018 |
Epstein-Barr virus infection is associated with clinical characteristics and poor prognosis of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cells, Cultured; DNA, Viral; Epstein-Barr Virus Infections; Female; Gene Expression Regulation, Viral; Herpesvirus 4, Human; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Leukocytes, Mononuclear; Male; Middle Aged; Multiple Myeloma; Prognosis; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2019 |
Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells.
Topics: Antibodies, Monoclonal; Biomarkers, Tumor; Bortezomib; Cell Line, Tumor; Dexamethasone; Enzyme-Linked Immunosorbent Assay; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Interleukin-6; Metformin; Multiple Myeloma; Phenformin; Plasma Cells; Receptors, Interleukin-6; Sequence Analysis, RNA; Signal Transduction; Syndecan-1; Thalidomide | 2019 |
Redefining the treatment paradigm for multiple myeloma.
Topics: Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2019 |
Registering a CD38 antibody upfront for multiple myeloma.
Topics: Antibodies, Monoclonal; Bortezomib; Cell Transplantation; Dexamethasone; Humans; Multiple Myeloma; Thalidomide | 2019 |
New daratumumab quadruplets and triplets for newly diagnosed MM.
Topics: Antibodies, Monoclonal; Bortezomib; Cell Transplantation; Dexamethasone; Humans; Multiple Myeloma; Thalidomide | 2019 |
Frontline treatment of elderly non transplant-eligible multiple myeloma patients using CyBorD with or without thalidomide-based consolidation: a retrospective multi-centre analysis of real-world data.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Consolidation Chemotherapy; Dexamethasone; Female; Humans; Male; Multiple Myeloma; New Zealand; Retrospective Studies; Survival Analysis; Thalidomide | 2019 |
Bortezomib-Based Chemotherapy with Autologous Stem Cell Transplantation for Monoclonal Gammopathy of Renal Significance: A Case Report and Literature Review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Kidney Diseases; Male; Paraproteinemias; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2019 |
Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2019 |
Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) Observational Study, 2008-2016.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Comorbidity; Drug Utilization; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Latin America; Male; Middle Aged; Multiple Myeloma; Practice Patterns, Physicians'; Private Facilities; Public Facilities; Retrospective Studies; Thalidomide; Treatment Outcome | 2020 |
Editorial: Immunotherapy in Multiple Myeloma.
Topics: ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bortezomib; Humans; Immunotherapy; Melphalan; Multiple Myeloma; Signaling Lymphocytic Activation Molecule Family; Thalidomide | 2019 |
Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Female; Humans; Immunoglobulin D; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Risk Factors; Survival Analysis; Thalidomide; Treatment Outcome; Young Adult | 2019 |
Hematological, Biochemical and Renal Changes in Patients of Multiple Myeloma Treated with Bortezomib Based Triple Drug Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Multiple Myeloma; Thalidomide; Treatment Outcome | 2019 |
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomid
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome | 2020 |
In response to: Treatment of patients with multiple myeloma progressing on frontline therapy with lenalidomide, Moreau et al., 2019.
Topics: Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2019 |
Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; beta 2-Microglobulin; Biomarkers; Bone Marrow Cells; Bortezomib; China; Chromosome Deletion; Chromosomes, Human, Pair 1; Disease-Free Survival; Female; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Prognosis; Retrospective Studies; Thalidomide | 2020 |
Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Thalidomide; Treatment Outcome | 2020 |
Bortezomib and Thalidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Stem Cell Transplantation; Survival Analysis; Thalidomide; Treatment Outcome | 2019 |
Hemophagocytic relapsed intramedullary plasmacytoma.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Bortezomib; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Magnetic Resonance Imaging; Melphalan; Neoplasm Recurrence, Local; Oligopeptides; Plasmacytoma; Positron Emission Tomography Computed Tomography; Pubic Bone; Rare Diseases; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2020 |
Anti-rasburicase antibodies induce clinical refractoriness by inhibiting the enzyme catalytic activity.
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Bortezomib; Dexamethasone; Female; Humans; Multiple Myeloma; Prognosis; Thalidomide; Urate Oxidase; Uric Acid | 2020 |
Case report of coexistence of myeloproliferative neoplasms and multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Bortezomib; Dexamethasone; Fusion Proteins, bcr-abl; Humans; Janus Kinase 2; Leukocytosis; Male; Middle Aged; Multiple Myeloma; Myeloproliferative Disorders; Paraproteinemias; Splenomegaly; Thalidomide; Treatment Outcome | 2020 |
Treatment of Persons with Multiple Myeloma in Underprivileged Circumstances: Real-World Data from a Single Institution.
Topics: Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Survival Rate; Thalidomide | 2020 |
Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Multiple Myeloma; Quality of Life; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide; Time Factors; Treatment Outcome; United Kingdom | 2020 |
Population Pharmacokinetics and Exposure Response Analysis of Pomalidomide in Subjects With Relapsed or Refractory Multiple Myeloma From the Novel Combination Treatment of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bayes Theorem; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Dose-Response Relationship, Drug; Female; Humans; Immunologic Factors; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Thalidomide | 2020 |
[Proteinuria in multiple myeloma: Be careful to iatrogeny].
Topics: Aged; Antineoplastic Agents; Autografts; Biopsy; Bortezomib; Dexamethasone; Female; Glomerulosclerosis, Focal Segmental; Humans; Iatrogenic Disease; Kidney; Lenalidomide; Multiple Myeloma; Oligopeptides; Proteinuria; Thalidomide; Thrombotic Microangiopathies; Withholding Treatment | 2020 |
Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentin
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide | 2020 |
[Ultra high-risk refractory multiple myeloma with a complex karyotype including t(14;19)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 19; Dexamethasone; Humans; Karyotype; Male; Multiple Myeloma; Thalidomide | 2020 |
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Quality of Life; Thalidomide | 2020 |
Dialysis Independence Following Combination Daratumumab, Thalidomide, Bortezomib, Cyclophosphamide, and Dexamethasone in Multiple Myeloma With Severe Renal Failure.
Topics: Adult; Antibodies, Monoclonal; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Male; Multiple Myeloma; Renal Dialysis; Renal Insufficiency; Thalidomide | 2020 |
[Ⅰ.Current Treatment Strategies for Transplant-Eligible Newly Diagnosed Multiple Myeloma].
Topics: Bortezomib; Humans; Multiple Myeloma; Thalidomide | 2020 |
Efficacy of VRD(Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs(Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Contai
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Consolidation Chemotherapy; Dexamethasone; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Thalidomide; Transplantation, Autologous | 2020 |
Pleural plasmacytomas - the role of radiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Fatal Outcome; Female; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Pleural Neoplasms; Prednisolone; Thalidomide | 2020 |
Myasthenia gravis with anti-muscle-specific tyrosine kinase antibodies during therapy for multiple myeloma: a case report.
Topics: Antineoplastic Agents; Autoantibodies; Bortezomib; Humans; Male; Middle Aged; Multiple Myeloma; Myasthenia Gravis; Receptor Protein-Tyrosine Kinases; Receptors, Cholinergic; Thalidomide | 2020 |
Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Bortezomib; Cyclophosphamide; Dexamethasone; Glucocorticoids; Humans; Immunoglobulin M; Immunosuppressive Agents; Male; Multiple Myeloma; Mutation; Myeloid Differentiation Factor 88; Rituximab; Stem Cell Transplantation; Thalidomide; Waldenstrom Macroglobulinemia | 2020 |
Bortezomib-based Triplet Regimens for Remission Induction in Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Multiple Myeloma; Remission Induction; Thalidomide; Treatment Outcome | 2020 |
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Humans; Induction Chemotherapy; Leukopenia; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pneumonia; Progression-Free Survival; Retrospective Studies; Stem Cell Transplantation; Thalidomide; Thrombocytopenia; Treatment Outcome | 2020 |
Primary plasma cell leukaemia in a 39-year-old man.
Topics: Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Marrow; Bortezomib; Dexamethasone; Diagnosis, Differential; Drug Therapy, Combination; Humans; Immunoglobulin G; Immunoglobulin lambda-Chains; Immunosuppressive Agents; Leukemia, Plasma Cell; Male; Thalidomide; Zoledronic Acid | 2020 |
Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Induction Chemotherapy; Multiple Myeloma; Pharmaceutical Preparations; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2021 |
Is the risk of second primary malignancy increased in multiple myeloma in the novel therapy era? A population-based, retrospective cohort study in Taiwan.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; Follow-Up Studies; Hematologic Neoplasms; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Registries; Retrospective Studies; Risk Factors; Taiwan; Thalidomide; Treatment Outcome | 2020 |
Case Report: IgG multiple myeloma and chronic myeloid leukemia in a single patient.
Topics: Bortezomib; Dexamethasone; Humans; Imatinib Mesylate; Immunoglobulin G; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Thalidomide | 2020 |
Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Doxorubicin; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm, Residual; Nervous System Diseases; Progression-Free Survival; Proteasome Inhibitors; Thalidomide; Transplantation, Autologous; Vincristine | 2020 |
A comparative study of cyclophosphamide, thalidomide and dexamethasone (CTD) versus bortezomib and dexamethasone (BDex) in light-chain amyloidosis.
Topics: Adult; Aged; Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; China; Cohort Studies; Cyclophosphamide; Dexamethasone; Female; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Retrospective Studies; Survival Rate; Thalidomide | 2021 |
Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Diphosphonates; Drug Interactions; Female; Humans; Hypophosphatemia; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Retrospective Studies; Thalidomide | 2021 |
Induction therapy before autologous HSCT: a proper preparation pays off?
Topics: Bortezomib; Dexamethasone; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2020 |
Treatment pathways and disease journeys differ before and after introduction of novel agents in newly diagnosed multiple myeloma in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Retrospective Studies; Taiwan; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2021 |
Elotuzumab in the treatment of relapsed and refractory multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Clinical Trials as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Killer Cells, Natural; Lenalidomide; Mesenchymal Stem Cells; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Thalidomide | 2021 |
Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase II as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Myeloma Proteins; Oligopeptides; Progression-Free Survival; Thalidomide | 2021 |
Immunomodulators in newly diagnosed multiple myeloma: current and future concepts.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2021 |
Survival, health care resource utilization and expenditures of first-line treatments for multiple myeloma patients ineligible for transplant in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Bortezomib; Female; Health Expenditures; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide; Young Adult | 2021 |
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Canada; Dexamethasone; Female; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide; Transplantation, Autologous | 2021 |
Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Czech Republic; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Registries; Thalidomide; Treatment Outcome | 2021 |
Cyclophosphamide, Thalidomide, and Dexamethasone as Initial Therapy for Patients With Newly Diagnosed Multiple Myeloma in a Middle-Income Country: 7-Year Follow-Up.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide | 2021 |
Improvement of erythema elevatum diutinum refractory to dapsone following treatment for underlying multiple myeloma.
Topics: Antineoplastic Agents; Bortezomib; Dapsone; Dermatologic Agents; Dexamethasone; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomide; Vasculitis, Leukocytoclastic, Cutaneous | 2021 |
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.
Topics: Biomarkers; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2022 |
Effect of therapeutic regimens and polypharmacy on health-related quality of life of people with multiple myeloma: a cross-sectional study in Belo Horizonte, Brazil.
Topics: Bortezomib; Brazil; Cross-Sectional Studies; Humans; Multiple Myeloma; Polypharmacy; Quality of Life; Surveys and Questionnaires; Thalidomide | 2022 |
Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a Salvage and Bridging Regimen before Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2022 |
Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Humans; Multiple Myeloma; Thalidomide | 2022 |
Successful Treatment of the TEMPI Syndrome with Pomalidomide Plus Dexamethasone Followed by Autologous Stem Cell Transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Proteasome Inhibitors; Thalidomide; Transplantation, Autologous | 2022 |
Response and Survival Estimates of Patients With Plasma Cell Myeloma in a Resource-Constrained Setting Using Protocols From High-Income Countries: A Single-Center Experience From Sri Lanka.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Developed Countries; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Sri Lanka; Thalidomide | 2022 |
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Standard of Care; Thalidomide | 2022 |
Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2022 |
Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Thalidomide | 2022 |
VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Salvage Therapy; Thalidomide; Treatment Outcome | 2023 |
Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2023 |
Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy.
Topics: Bortezomib; Chemokine CXCL10; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2023 |
Real-world effectiveness and safety of multiple myeloma treatments based on thalidomide and bortezomib: A retrospective cohort study from 2009 to 2020 in a Brazilian metropolis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Brazil; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2023 |
[Access and safety of dexamethasone in multiple myeloma patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2023 |
Survival outcomes among patients with multiple myeloma in the era of novel agents: exploratory assessment using an electronic medical record database in Japan.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Electronic Health Records; Humans; Japan; Multiple Myeloma; Prognosis; Retrospective Studies; Thalidomide | 2023 |
Response adaptive salvage with KTd and ASCT for functional high-risk multiple myeloma-The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Lymphoma; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2023 |
Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction.
Topics: Black or African American; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Thalidomide | 2023 |
The age-dependent changes in risk weights of the prognostic factors for multiple myeloma.
Topics: Aged; Bortezomib; Humans; Multiple Myeloma; Prognosis; Retrospective Studies; Thalidomide | 2023 |
[The efficacy and safety of bortezomib, pomalidomide and dexamethasone regimen in the treatment of relapsed/refractory multiple myeloma].
Topics: Bortezomib; Dexamethasone; Humans; Multiple Myeloma; Thalidomide | 2023 |